

0001493152-24-03214310-Q GT Biopharma, Inc. 2024081420240814160040160040160040 0 0001493152-24-032143 10-Q 114 20240630 20240814 20240814 GT Biopharma, Inc. 0000109657 2834 941620407 DE 1231 10-Q 34 001-40023 241207215 315 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94104 (800) 304-9888 315 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94104 OXIS INTERNATIONAL INC 19940916 DDI PHARMACEUTICALS INC 19920703 DIAGNOSTIC DATA INC /DE/ 19850312 10-Q 1 form10-q.htm false --12-31 Q2 0000109657 0000109657 2024-01-01 2024-06-30 0000109657 2024-08-10 0000109657 2024-06-30 0000109657 2023-12-31 0000109657 us-gaap:SeriesCPreferredStockMember 2024-06-30 0000109657 us-gaap:SeriesCPreferredStockMember 2023-12-31 0000109657 2024-04-01 2024-06-30 0000109657 2023-04-01 2023-06-30 0000109657 2023-01-01 2023-06-30 0000109657 us-gaap:SellingGeneralAndAdministrativeExpensesMember GTBP:OfficersEmployeesAndDirectorsMember 2024-04-01 2024-06-30 0000109657 us-gaap:SellingGeneralAndAdministrativeExpensesMember GTBP:OfficersEmployeesAndDirectorsMember 2023-04-01 2023-06-30 0000109657 us-gaap:SellingGeneralAndAdministrativeExpensesMember GTBP:OfficersEmployeesAndDirectorsMember 2024-01-01 2024-06-30 0000109657 us-gaap:SellingGeneralAndAdministrativeExpensesMember GTBP:OfficersEmployeesAndDirectorsMember 2023-01-01 2023-06-30 0000109657 us-gaap:PreferredStockMember 2024-03-31 0000109657 us-gaap:CommonStockMember 2024-03-31 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000109657 us-gaap:RetainedEarningsMember 2024-03-31 0000109657 2024-03-31 0000109657 us-gaap:PreferredStockMember 2023-12-31 0000109657 us-gaap:CommonStockMember 2023-12-31 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000109657 us-gaap:RetainedEarningsMember 2023-12-31 0000109657 us-gaap:PreferredStockMember 2023-03-31 0000109657 us-gaap:CommonStockMember 2023-03-31 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000109657 us-gaap:RetainedEarningsMember 2023-03-31 0000109657 2023-03-31 0000109657 us-gaap:PreferredStockMember 2022-12-31 0000109657 us-gaap:CommonStockMember 2022-12-31 0000109657 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000109657 us-gaap:RetainedEarningsMember 2022-12-31 0000109657 2022-12-31 0000109657 us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0000109657 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000109657 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000109657 us-gaap:PreferredStockMember 2024-01-01 2024-06-30 0000109657 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0000109657 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0000109657 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000109657 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000109657 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000109657 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0000109657 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0000109657 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0000109657 us-gaap:PreferredStockMember 2024-06-30 0000109657 us-gaap:CommonStockMember 2024-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000109657 us-gaap:RetainedEarningsMember 2024-06-30 0000109657 us-gaap:PreferredStockMember 2023-06-30 0000109657 us-gaap:CommonStockMember 2023-06-30 0000109657 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000109657 us-gaap:RetainedEarningsMember 2023-06-30 0000109657 2023-06-30 0000109657 us-gaap:CommonStockMember 2024-02-02 0000109657 us-gaap:CommonStockMember 2024-02-05 0000109657 srt:MaximumMember 2024-06-30 0000109657 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0000109657 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0000109657 us-gaap:WarrantMember 2024-01-01 2024-06-30 0000109657 us-gaap:WarrantMember 2023-01-01 2023-06-30 0000109657 us-gaap:ShortTermInvestmentsMember 2024-06-30 0000109657 us-gaap:ShortTermInvestmentsMember 2024-01-01 2024-06-30 0000109657 us-gaap:ShortTermInvestmentsMember 2023-12-31 0000109657 us-gaap:ShortTermInvestmentsMember 2023-01-01 2023-12-31 0000109657 2023-01-01 2023-12-31 0000109657 us-gaap:MoneyMarketFundsMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2024-06-30 0000109657 us-gaap:USTreasurySecuritiesMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasurySecuritiesMember 2024-06-30 0000109657 GTBP:USTreasuriesMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel1Member GTBP:USTreasuriesMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel2Member GTBP:USTreasuriesMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel3Member GTBP:USTreasuriesMember 2024-06-30 0000109657 us-gaap:FairValueInputsLevel1Member 2024-06-30 0000109657 us-gaap:FairValueInputsLevel2Member 2024-06-30 0000109657 us-gaap:FairValueInputsLevel3Member 2024-06-30 0000109657 us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000109657 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000109657 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000109657 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000109657 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000109657 GTBP:CytovanceBiologicsIncMember 2023-12-31 0000109657 GTBP:CytovanceBiologicsIncMember 2022-12-31 0000109657 GTBP:CytovanceBiologicsIncMember 2024-01-01 2024-06-30 0000109657 GTBP:CytovanceBiologicsIncMember 2023-01-01 2023-06-30 0000109657 GTBP:CytovanceBiologicsIncMember 2024-06-30 0000109657 GTBP:CytovanceBiologicsIncMember 2023-06-30 0000109657 GTBP:CommonWarrantsMember srt:MaximumMember 2023-01-04 0000109657 GTBP:PlacementAgentWarrantMember srt:MaximumMember 2023-01-04 0000109657 GTBP:PurchaseWarrantMember 2024-01-01 2024-06-30 0000109657 GTBP:PurchaseWarrantMember 2024-06-30 0000109657 GTBP:TwentyTwentyWarrantsMember 2020-01-01 2020-12-31 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2024-01-01 2024-06-30 0000109657 GTBP:TwoThousandTwentyWarrantsMember 2024-01-01 2024-06-30 0000109657 us-gaap:MeasurementInputSharePriceMember GTBP:TwoThousandTwentyThreeWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputSharePriceMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputRiskFreeInterestRateMember GTBP:TwoThousandTwentyThreeWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputRiskFreeInterestRateMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputPriceVolatilityMember GTBP:TwoThousandTwentyThreeWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputPriceVolatilityMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwoThousandTwentyThreeWarrantsMember srt:MinimumMember 2024-06-30 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwoThousandTwentyThreeWarrantsMember srt:MaximumMember 2024-06-30 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputExpectedDividendRateMember GTBP:TwoThousandTwentyThreeWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputExpectedDividendRateMember GTBP:TwoThousandTwentyThreeWarrantsMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyThreeWarrantsMember 2023-01-01 2023-12-31 0000109657 us-gaap:MeasurementInputSharePriceMember GTBP:TwoThousandTwentyWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputSharePriceMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputRiskFreeInterestRateMember GTBP:TwoThousandTwentyWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputRiskFreeInterestRateMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputPriceVolatilityMember GTBP:TwoThousandTwentyWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputPriceVolatilityMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 GTBP:TwentyTwentyWarrantsMember GTBP:TwoThousandTwentyWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputExpectedTermMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 us-gaap:MeasurementInputExpectedDividendRateMember GTBP:TwoThousandTwentyWarrantsMember 2024-06-30 0000109657 us-gaap:MeasurementInputExpectedDividendRateMember GTBP:TwoThousandTwentyWarrantsMember 2023-12-31 0000109657 GTBP:TwoThousandTwentyWarrantsMember 2023-01-01 2023-12-31 0000109657 GTBP:PurchaseAgreementMember 2024-05-23 2024-05-23 0000109657 us-gaap:CommonStockMember GTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:TwentyTwentyFourCommonWarrantsMember GTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:TwentyTwentyFourPlacementAgentWarrantMember GTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:TwentyTwentyFourCommonSharesAndTwentyTwentyFourCommonWarrantsMember GTBP:PurchaseAgreementMember 2024-05-23 0000109657 GTBP:PurchaseAgreementMember 2023-01-04 2023-01-04 0000109657 us-gaap:CommonStockMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:PrefundedWarrantMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:TwentyTwentyThreeCommonWarrantsMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:TwentyTwentyThreePlacementAgentWarrantMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:PurchaseAgreementMember GTBP:PreFundedWarrantsMember 2023-01-04 0000109657 GTBP:PlacementAgentWarrantMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:TwentyTwentyThreeCommonSharesAndTwentyTwentyThreeCommonWarrantsMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:PreFundedWarrantsAndTwentyTwentyThreeCommonWarrantsMember GTBP:PurchaseAgreementMember 2023-01-04 0000109657 GTBP:CommonWarrantAndPlacementAgentWarrantMember 2023-01-04 2023-01-04 0000109657 GTBP:BoardOfDirectorsEmployeesAndConsultantsMember 2024-01-01 2024-06-30 0000109657 GTBP:SeriesKPreferredStocksMember 2021-02-15 2021-02-16 0000109657 GTBP:SeriesKPreferredStocksMember 2021-02-16 0000109657 GTBP:SeriesKPreferredStockMember 2024-06-30 0000109657 GTBP:SeriesKPreferredStockMember 2023-12-31 0000109657 GTBP:WarrantsMember 2024-01-01 2024-06-30 0000109657 GTBP:OmnibusIncentivePlanMember 2022-04-01 2022-04-01 0000109657 GTBP:OmnibusIncentivePlanMember 2024-01-01 2024-06-30 0000109657 2023-05-15 2023-05-15 0000109657 2023-05-15 0000109657 2023-01-27 2023-01-27 0000109657 2023-01-27 0000109657 GTBP:WarrantsMember GTBP:RangeOneMember 2024-01-01 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeOneMember 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeTwoMember 2024-01-01 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeTwoMember 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeThreeMember 2024-01-01 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeThreeMember 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeFourMember 2024-01-01 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeFourMember 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeFiveMember 2024-01-01 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeFiveMember 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeSixMember 2024-01-01 2024-06-30 0000109657 GTBP:WarrantsMember GTBP:RangeSixMember 2024-06-30 0000109657 GTBP:WarrantsMember 2024-06-30 0000109657 GTBP:RangeOneMember 2024-01-01 2024-06-30 0000109657 GTBP:RangeOneMember 2024-06-30 0000109657 GTBP:RangeTwoMember 2024-01-01 2024-06-30 0000109657 GTBP:RangeTwoMember 2024-06-30 0000109657 GTBP:RangeThreeMember 2024-01-01 2024-06-30 0000109657 GTBP:RangeThreeMember 2024-06-30 0000109657 2022-05-13 2022-05-13 0000109657 2022-05-13 0000109657 2024-05-01 2024-05-31 0000109657 GTBP:CytovanceBiologicsIncMember 2022-08-24 0000109657 GTBP:CytovanceBiologicsIncMember 2024-04-25 0000109657 GTBP:ScientificResearchAgreementMember 2021-06-16 2021-06-16 0000109657 GTBP:ScientificResearchAgreementMember 2024-01-01 2024-06-30 0000109657 GTBP:ScientificResearchAgreementMember 2023-01-01 2023-06-30 0000109657 GTBP:ScientificResearchAgreementMember 2024-06-30 0000109657 GTBP:SponsoredResearchAgreementMember 2024-05-20 2024-05-20 0000109657 GTBP:SponsoredResearchAgreementMember 2024-01-01 2024-06-30 0000109657 GTBP:SponsoredResearchAgreementMember 2023-01-01 2023-06-30 0000109657 GTBP:SponsoredResearchAgreementMember 2024-06-30 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandSeventeenThroughTwoThousandTwentyMember 2016-07-18 2016-07-18 0000109657

GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember srt:MinimumMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember srt:MaximumMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandTwentyTwoMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandTwentyFiveMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandTwentySevenMember 2016-07-18 2016-07-18 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember GTBP:TwoThousandTwentyFiveMember 2024-05-13 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-05-13 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember srt:MinimumMember 2024-05-13 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember srt:MaximumMember 2024-05-13 2024-05-13 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2024-01-01 2024-06-30 0000109657 GTBP:TwoThousandSixteenPatentLicenseAgreementMember 2023-01-01 2023-06-30 0000109657 GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 2021-03-26 0000109657 GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 0000109657 srt:MinimumMember GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 2021-03-26 0000109657 srt:MaximumMember GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2021-03-26 2021-03-26 0000109657 GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2024-01-01 2024-06-30 0000109657 GTBP:TwoThousandAndTwentyOnePatentLicenseAgreementMember 2023-01-01 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft Â  Â  Â  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â  FORM 10-Q Â  â˜' Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Â  For the quarterly period ended June 30, 2024. Â  â˜ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Â  For the transition period from __________ to ____________. Â  Commission File Number 001-40023 Â  GT BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Â  Delaware Â  94-1620407 (State or other jurisdiction of incorporation or organization) Â  (I.R.S. Employer Identification Number) Â  (Address not applicable1) Â  415-919-4040 (Registrantâ€™s telephone number, including area code) Â  Securities registered pursuant to Section 12(b) of the Act: Â  Title of Each Class Â  Trading Symbol Â  Name of exchange on which registered Common Stock, $0.001 par value per share Â  GTBP Â  Nasdaq Capital Market Â  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜' No â˜ Â  Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜' No â˜ Â  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â  Large accelerated filer â˜ Accelerated filer â˜ Non-accelerated filer â˜' Smaller reporting company â˜' Emerging growth company â˜ Â  Â  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜' Â  As of August 10, 2024, the registrant had 2,234,328 shares of common stock outstanding. Â  1 Effective as of July 1, 2024, the Company became a fully remote company. We do not maintain a principal executive office. For purposes of compliance with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to the Companyâ€™s principal executive offices may be directed to 315 Montgomery Street, 10th Floor, San Francisco, California 94104, or by email to auditcommittee@gtbiopharma.com. Â  Â  Â  Â  Â  Â  GT Biopharma, Inc. and Subsidiaries FORM 10-Q For the Six Months Ended June 30, 2024 Table of Contents Â  Â  Â  Page PART I FINANCIAL INFORMATION Â  Item 1. Financial Statements Â  Â  Condensed Consolidated Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023 3 Â  Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 (Unaudited) 4 Â  Condensed Consolidated Statements of Stockholdersâ€™ Equity for the three and six months ended June 30, 2024 and 2023 (Unaudited) 5 Â  Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 (Unaudited) 7 Â  Condensed Notes to Consolidated Financial Statements (Unaudited) 8 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3. Quantitative and Qualitative Disclosures About Market Risk 28 Item 4. Controls and Procedures 28 Â  Â  Â  PART II OTHER INFORMATION Item 1. Legal Proceedings 29 Item 6. Exhibits 30 Â  Â  Â  SIGNATURES 31 Â  2 Â  Â  GT BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets Â  Â Â  June 30, 2024Â Â  December 31, 2023Â  Â Â  Â (Unaudited)Â Â  Â Â Â  ASSETSÂ  Â Â Â Â  Â Â Â  Current assetsÂ  Â Â Â Â  Â Â Â  Cash and cash equivalentsÂ  $9,249,000Â Â  $1,079,000Â  Short-term investmentsÂ  Â â€"Â Â  Â 12,893,000Â  Prepaid expenses and other current assetsÂ  Â 18,000Â Â  Â 84,000Â  Total Current AssetsÂ  Â 9,267,000Â Â  Â 14,056,000Â  Â Â  Â Â Â Â  Â Â Â  Operating lease right-of-use assetÂ  Â -Â Â  Â 53,000Â  TOTAL ASSETSÂ  $9,267,000Â Â  $14,109,000Â  Â Â  Â Â Â Â  Â Â Â  LIABILITIES AND STOCKHOLDERSâ€™ EQUITYÂ  Â Â Â Â  Â Â Â  Current liabilitiesÂ  Â Â Â Â  Â Â Â  Accounts payableÂ  $1,717,000Â Â  $4,328,000Â  Accrued expensesÂ  Â 1,765,000Â Â  Â 1,195,000Â  Current operating lease liabilityÂ  Â â€"Â Â  Â 58,000Â  Warrant liabilityÂ  Â 277,000Â Â  Â 1,052,000Â  Total Current LiabilitiesÂ  Â 3,759,000Â Â  Â 6,633,000Â  Â Â  Â Â Â Â  Â Â Â  Stockholdersâ€™ EquityÂ  Â Â Â Â  Â Â Â  Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectivelyÂ  Â 1,000Â Â  Â 1,000Â  Common stock, par value $0.001, 250,000,000 shares authorized, 2,234,328 and 1,380,633 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectivelyÂ  Â 2,000Â Â  Â 1,000Â  Additional paid in capitalÂ  Â 693,546,000Â Â  Â 689,539,000Â  Accumulated deficitÂ  Â (688,041,000)Â  Â (682,065,000) Total Stockholdersâ€™ EquityÂ  Â 5,508,000Â Â  Â 7,476,000Â  TOTAL LIABILITIES AND STOCKHOLDERSâ€™ EQUITYÂ  $9,267,000Â Â  $14,109,000Â  Â  The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â  3 Â  Â  GT BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Operations Â  Â Â  2024Â Â  2023Â Â  2024Â Â  2023Â  Â Â  For The Three Months EndedÂ Â  For the Six Months EndedÂ  Â Â  June 30,Â Â  June 30,Â  Â Â  2024Â Â  2023Â Â  2024Â Â  2023Â  Â Â  (Unaudited)Â Â  (Unaudited)Â Â  (Unaudited)Â Â  (Unaudited)Â  Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â  Operating Expenses:Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Research and developmentÂ  $1,784,000Â Â  $2,095,000Â Â  $2,561,000Â Â  $3,745,000Â  Â Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Selling, general and administrative (including $120,000 and $398,000 from stock compensation granted to officers, directors, and employees during the three months ended June 30, 2024 and 2023, respectively, and $222,000 and $905,000 for the six months ended June 30, 2024 and 2023, respectively)Â  Â 2,122,000Â Â  Â 1,526,000Â Â  Â 4,436,000Â Â  Â 3,541,000Â  Â Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Loss from OperationsÂ  Â (3,906,000)Â  Â (3,621,000)Â  Â (6,997,000)Â  Â (7,286,000) Â Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Other Income (Expense)Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Interest incomeÂ  Â 105,000Â Â  Â 220,000Â Â  Â 247,000Â Â  Â 384,000Â  Interest expenseÂ  Â â€"Â Â  Â (1,000)Â  Â â€"Â Â  Â (213,000) Change in fair value of warrant liabilityÂ  Â 117,000Â Â  Â 1,387,000Â Â  Â 775,000Â Â  Â 4,311,000Â  Gain on extinguishment of debtÂ  Â â€"Â Â  Â 14,000Â Â  Â â€"Â Â  Â 547,000Â  Unrealized gain (loss) on marketable securitiesÂ  Â 1,000Â Â  Â 9,000Â Â  Â (1,000)Â  Â 38,000Â  OtherÂ  Â (27,000)Â  Â â€"Â Â  Â â€"Â Â  Â â€"Â  Total Other IncomeÂ  Â 196,000Â Â  Â 1,629,000Â Â  Â 1,021,000Â Â  Â 5,067,000Â  Â Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Net LossÂ  $(3,710,000)Â  $(1,992,000)Â  $(5,976,000)Â  $(2,219,000) Â Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Net Loss Per Share - Basic and DilutedÂ  $(2.17)Â  $(1.49)Â  $(3.86)Â  $(1.68) Â Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Weighted average common shares outstanding - basic and dilutedÂ  Â 1,711,955Â Â  Â 1,339,087Â Â  Â 1,546,294Â Â  Â 1,321,069Â  Â  The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â  4 Â  Â  GT BIOPHARMA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY For The Three and Six Months Ended June 30, 2024 (Unaudited): Â  Â Â  SharesÂ Â  AmountÂ Â  SharesÂ Â  AmountÂ Â  CapitalÂ Â  DeficitÂ Â  TotalÂ  Â Â  Preferred SharesÂ Â  Common SharesÂ Â  Additional Paid inÂ Â  AccumulatedÂ Â  Â Â  Â Â  SharesÂ Â  AmountÂ Â  SharesÂ Â  AmountÂ Â  CapitalÂ Â  DeficitÂ Â  TotalÂ  Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â  Balance, March 31, 2024Â  Â 96,230Â Â  $1,000Â Â  Â 1,380,633Â Â  $1,000Â Â  $689,641,000Â Â  $(684,331,000)Â  $5,312,000Â  Issuance of common stock and warrants for cashÂ  Â -Â Â  Â -Â Â  Â 740,000Â Â  Â 1,000Â Â  Â 2,975,000Â Â  Â -Â Â  Â 2,976,000Â  Cancellation of common stock issued to prior CFOÂ  Â -Â Â  Â -Â Â  Â (13,902)Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â  Issuance of common shares to settle vendor payableÂ  Â -Â Â  Â -Â Â  Â 127,597Â Â  Â -Â Â  Â 810,000Â Â  Â -Â Â  Â 810,000Â  Fair value of vested stock optionsÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â 120,000Â Â  Â -Â Â  Â 120,000Â  Net lossÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â (3,710,000)Â  Â (3,710,000) Balance, June 30, 2024Â  Â 96,230Â Â  $1,000Â Â  Â 2,234,328Â Â  $2,000Â Â  $693,546,000Â Â  $(688,041,000)Â  $5,508,000Â  Â  Â Â  Preferred SharesÂ Â  Common SharesÂ Â  Additional Paid inÂ Â  AccumulatedÂ Â  Â Â  Â Â  SharesÂ Â  AmountÂ Â  SharesÂ Â  AmountÂ Â  CapitalÂ Â  DeficitÂ Â  TotalÂ  Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â  Balance, December 31, 2023Â  Â 96,230Â Â  $1,000Â Â  Â 1,380,633Â Â  $1,000Â Â  $689,539,000Â Â  $(682,065,000)Â  $7,476,000Â  Issuance of common stock and warrants for cashÂ  Â -Â Â  Â -Â Â  Â 740,000Â Â  Â 1,000Â Â  Â 2,975,000Â Â  Â -Â Â  Â 2,976,000Â  Cancellation of common stock issued to prior CFOÂ  Â -Â Â  Â -Â Â  Â (13,902)Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â  Issuance of common shares to settle vendor payableÂ  Â -Â Â  Â -Â Â  Â 127,597Â Â  Â -Â Â  Â 810,000Â Â  Â -Â Â  Â 810,000Â  Fair value of vested stock optionsÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â 222,000Â Â  Â -Â Â  Â 222,000Â  Net lossÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â (5,976,000)Â  Â (5,976,000) Balance, June 30, 2024Â  Â 96,230Â Â  $1,000Â Â  Â 2,234,328Â Â  $2,000Â Â  $693,546,000Â Â  $(688,041,000)Â  $5,508,000Â  Â  The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â  5 Â  Â  GT BIOPHARMA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY For The Three and Six Months Ended June 30, 2023 (Unaudited): Â  Â Â  SharesÂ Â  AmountÂ Â  SharesÂ Â  AmountÂ Â  CapitalÂ Â  DeficitÂ Â  TotalÂ  Â Â  Preferred SharesÂ Â  Common SharesÂ Â  Additional Paid inÂ Â  AccumulatedÂ Â  Â Â  Â Â  SharesÂ Â  AmountÂ Â  SharesÂ Â  AmountÂ Â  CapitalÂ Â  DeficitÂ Â  TotalÂ  Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â  Balance, March 31, 2023Â  Â 96,230Â Â  $1,000Â Â  Â 1,229,424Â Â  $1,000Â Â  $687,746,000Â Â  $(682,065,000)Â  $13,053,000Â  Private placement of common stockÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â  Issuance of common stock for exercise of prefunded warrantsÂ  Â -Â Â  Â -Â Â  Â 96,666Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â  Initial recognition of fair value of warrant liabilityÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â  Issuance of common shares for servicesÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â  Issuance of common shares to settle vendor payableÂ  Â -Â Â  Â -Â Â  Â 28,566Â Â  Â -Â Â  Â 304,000Â Â  Â -Â Â  Â 304,000Â  Fair value of vested stock optionsÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â 398,000Â Â  Â -Â Â  Â 398,000Â  Net lossÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â (1,992,000)Â  Â (1,992,000) Balance, June 30, 2023Â  Â 96,230Â Â  $1,000Â Â  Â 1,354,656Â Â  $1,000Â Â  $688,448,000Â Â  $(676,687,000)Â  $11,763,000Â  Â  Â Â  Preferred SharesÂ Â  Common SharesÂ Â  Additional Paid inÂ Â  AccumulatedÂ Â  Â Â  Â Â  SharesÂ Â  AmountÂ Â  SharesÂ Â  AmountÂ Â  CapitalÂ Â  DeficitÂ Â  TotalÂ  Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â  Balance, December 31, 2022Â  Â 96,230Â Â  $1,000Â Â  Â 1,090,748Â Â  $1,000Â Â  $686,200,000Â Â  $(674,467,000)Â  $11,734,000Â  BalanceÂ  Â 96,230Â Â  $1,000Â Â  Â 1,090,748Â Â  $1,000Â Â  $686,200,000Â Â  $(674,467,000)Â  $11,734,000Â  Private placement of common stockÂ  Â -Â Â  Â -Â Â  Â 120,000Â Â  Â -Â Â  Â 6,268,000Â Â  Â -Â Â  Â 6,268,000Â  Issuance of common stock for exercise of prefunded warrantsÂ  Â -Â Â  Â -Â Â  Â 96,666Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â  Initial recognition of fair value of warrant liabilityÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â (5,831,000)Â  Â -Â Â  Â (5,831,000) Issuance of common shares for servicesÂ  Â -Â Â  Â -Â Â  Â 2,449Â Â  Â -Â Â  Â 315,000Â Â  Â -Â Â  Â 315,000Â  Issuance of common shares to settle vendor payableÂ  Â -Â Â  Â -Â Â  Â 44,793Â Â  Â -Â Â  Â 591,000Â Â  Â -Â Â  Â 591,000Â  Fair value of vested stock optionsÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â 905,000Â Â  Â -Â Â  Â 905,000Â  Net lossÂ  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â -Â Â  Â (2,219,000)Â  Â (2,219,000) Balance, June 30, 2023Â  Â 96,230Â Â  $1,000Â Â  Â 1,354,656Â Â  $1,000Â Â  $688,448,000Â Â  $(676,687,000)Â  $11,763,000Â  BalanceÂ  Â 96,230Â Â  $1,000Â Â  Â 1,354,656Â Â  $1,000Â Â  $688,448,000Â Â  $(676,687,000)Â  $11,763,000Â  Â  The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â  6 Â  Â  GT BIOPHARMA, INC. AND SUBSIDIARIES Condensed Consolidated Statements of Cash Flows Â  Â Â  2024Â Â  2023Â  Â Â  For The Six Months EndedÂ  Â Â  June 30,Â  Â Â  2024Â Â  2023Â  Â Â  (Unaudited)Â Â  (Unaudited)Â  CASH FLOWS FROM OPERATING ACTIVITIESÂ  Â Â Â Â  Â Â Â  Net lossÂ  $(5,976,000)Â  $(2,219,000) Adjustments to reconcile net loss to net cash used in operating activities:Â  Â Â Â Â  Â Â Â  Stock based compensation - servicesÂ  Â -Â Â  Â 315,000Â  Stock based compensation - officers, directors, and employeesÂ  Â 222,000Â Â  Â 905,000Â  Change in fair value of warrant liabilityÂ

Â (775,000)Â  Â (4,311,000) Gain on extinguishment of share settled debtÂ  Â -Â Â  Â (547,000) Change in operating lease right-of-use assetsÂ  Â 53,000Â Â  Â 51,000Â  Unrealized loss (gain) on marketable securitiesÂ  Â (1,000)Â  Â (38,000) Changes in operating assets and liabilities:Â  Â Â Â Â  Â Â Â  Decrease in prepaid expensesÂ  Â 67,000Â Â  Â 5,000Â  Increase (Decrease) in accounts payable and accrued expensesÂ  Â (1,231,000)Â  Â 1,052,000Â  (Decrease) in operating lease liabilityÂ  Â (58,000)Â  Â (54,000) Net Cash Used in Operating ActivitiesÂ  Â (7,699,000)Â  Â (4,841,000) Â Â  Â Â Â Â  Â Â Â  CASH FLOWS FROM INVESTING ACTIVITIESÂ  Â Â Â Â  Â Â Â  Sale (purchase) of investmentsÂ  Â 12,893,000Â Â  Â (4,332,000) Net Cash Provided by (Used in) Investing ActivitiesÂ  Â 12,893,000Â Â  Â (4,332,000) Â Â  Â Â Â Â  Â Â Â  CASH FLOWS FROM FINANCING ACTIVITIESÂ  Â Â Â Â  Â Â Â  Proceeds from issuance of common stock and warrants, netÂ  Â 2,976,000Â Â  Â 6,268,000Â  Net Cash Provided by Financing ActivitiesÂ  Â 2,976,000Â Â  Â 6,268,000Â  Â Â  Â Â Â Â  Â Â Â  Net Increase (Decrease) in Cash and Cash EquivalentsÂ  Â 8,170,000Â Â  Â (2,905,000) Cash at Beginning of PeriodÂ  Â 1,079,000Â Â  Â 5,672,000Â  Cash at End of PeriodÂ  $9,249,000Â Â  $2,767,000Â  Â Â  Â Â Â Â  Â Â Â  SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:Â  Â Â Â Â  Â Â Â  Cash paid during the year for:Â  Â Â Â Â  Â Â Â  InterestÂ  $-Â Â  $-Â  Income taxesÂ  $-Â Â  $-Â  Â Â  Â Â Â Â  Â Â Â  SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIESÂ  Â Â Â Â  Â Â Â  Initial recognition of fair value of warrant liabilityÂ  $-Â Â  $5,831,000Â  Fair value of common stock issued to a vendor to settle accounts payableÂ  $810,000Â Â  $591,000Â  Â  The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â  7 Â  Â  GT BIOPHARMA, INC. AND SUBSIDIARIES NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Six Months Ended June 30, 2024 and 2023 (Unaudited) Â  Note 1 â€“ Organization and Going Concern Analysis Â  Organization Â  The corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data, Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March 11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc. Â  Throughout this Quarterly Report on Form 10-Q, the terms â€œGTBP,â€ â€œwe,â€ â€œus,â€ â€œour,â€ â€œthe Companyâ€ and â€œour Companyâ€ refer to GT Biopharma, Inc. Â  The GT Biopharma logo, TriKEÂ®, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders. Â  The Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKEÂ®), and Tetra-specific Killer Engager (Dual Targeting TriKEÂ®) platforms. The Companyâ€™s TriKEÂ® and Dual Targeting TriKEÂ® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patientâ€™s own natural killer cells (NK cells). Â  Going Concern Analysis Â  The Company does not have any product candidates approved for sale and have not generated any revenue from its product sales. The Company has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. For the six months ended June 30, 2024, the Company recorded a net loss of approximately $6.0 million and used cash in operations of $7.7 million. As of June 30, 2024, the Company had a cash and cash equivalents and short-term investments balance of $9.2 million, working capital of $5.8 million, and stockholdersâ€™ equity of $5.5 million. Â  The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Â  The Company has evaluated the significance of the uncertainty regarding the Companyâ€™s financial condition in relation to its ability to meet its obligations, which has raised doubts about the Companyâ€™s ability to continue as a going concern. While it is very difficult to estimate the Companyâ€™s future liquidity requirements, the Company believes if it is unable to obtain additional financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed consolidated financial statements are issued. There can be no assurances that the Company will be able to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Companyâ€™s business prospects, ability to meet long-term liquidity needs and the ability to continue operations. Â  Note 2 â€“ Summary of Significant Accounting Policies Â  Basis of Presentation and Principles of Consolidation Â  The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation. Â  The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€) and applicable rules and regulations of the Securities and Exchange Commission (â€œSECâ€) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the â€œ2023 Annual Reportâ€). The consolidated balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date. Â  8 Â  Â  In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Companyâ€™s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results. Â  Accounting Estimates Â  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include managementâ€™s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets. Â  Cash Equivalents and Short-Term Investments Â  The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed consolidated financial statements. At June 30, 2024 total cash equivalents which consist of money market funds and US treasuries, amounted to approximately $7.6 million. At December 31, 2023 total cash equivalents which consist of money market funds, amounted to approximately $443,000. Â  Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying unaudited condensed consolidated statements of operations. At June 30, 2024 and December 31, 2023, total short-term investments which consist of US treasuries and US government agencies, amounted to approximately $0 and $12.9 million, respectively. Â  Fair Value of Financial Instruments Â  Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (â€œASCâ€) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. Â  The three levels of the fair value hierarchy are as follows: Â  Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access. Â  Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities. Â  Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Â  The carrying amounts of the Companyâ€™s other financial assets and liabilities, such as cash and cash equivalents, short term investments, prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity of these instruments. Â  The carrying amount of the Companyâ€™s warrant liability of $277,000 and $1.1 million at June 30, 2024 and December 31, 2023, respectively, was based on Level 3 measurements. Â  9 Â  Â  Warrant Liability Â  The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, â€œDerivatives and Hedgingâ€ (â€œASC 815â€). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Â  The Companyâ€™s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes. Â  Common Stock (February 2024 Reverse Stock Split) Â  On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Companyâ€™s common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol â€œGTBP.â€ Â  As a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the reverse stock-split from 41,419,000 shares to 1,380,633 shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock remains unchanged at 250,000,000 shares. Â  Proportionate adjustments have been made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options and warrants for the Companyâ€™s common stock, and to the number of shares of common stock reserved for future issuance pursuant to the Companyâ€™s 2022 Omnibus Incentive Plan. Â  All share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented. Â  Stock-Based Compensation Â  The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Â  Stock-based payments to officers, directors, employees, and consultants in exchange for goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. Â  Research and Development Expenses Â  Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Companyâ€™s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed. Â  Leases Â  The Company accounts for its lease in accordance with the guidance of ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Companyâ€™s right to use an underlying asset during the lease term, and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. Â  In June 2024, the Companyâ€™s lease expired and was not renewed. Â  10 Â  Â  Net Loss Per Share Â  Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period.

Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Â  The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive: Â Schedule of Anti-dilutive Securities Â Â  June 30, 2024 (Unaudited)â€¯â€¯Â Â  June 30, 2023 (Unaudited)â€¯â€¯Â  Options to purchase common stockÂ  Â 126,265Â Â  Â 124,599Â  Warrants to purchase common stockÂ  Â 1,133,762Â Â  Â 304,962Â  Total anti-dilutive securitiesÂ Â 1,260,027Â Â  Â 429,561Â  Â  Concentration Â  Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (â€œFDICâ€) insurance limits of up to $250,000. Management believes that the financial institutions that hold the Companyâ€™s cash are financially sound and, accordingly, minimal credit risk exists. Â  The Company has a significant concentration of expenses incurred from and accounts payable and accrued expenses to Cytovance, a related party, and the University of Minnesota, see Note 4 â€“ Accounts Payable and Related Party. Â Segments Â  The Company determined its reporting units in accordance with â€œSegment Reportingâ€ (â€œASC 280â€). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated. Â  Management has determined that the Company has one consolidated operating segment. The Companyâ€™s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Companyâ€™s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments. Â  Recent Accounting Pronouncements Â  In November 2023, the FASB issued ASU No. 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosuresâ€ (â€œASU 2023-07â€), which introduces new reportable segment disclosure requirements related to significant segment expenses and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable segmentâ€™s profits and losses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are in the process of evaluating the impact that ASU 2023-07 will have on our segment related disclosures. Â  The Companyâ€™s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Companyâ€™s financial position and results of operations. Â  Note 3 â€“ Fair Value of Financial Instruments Â  Financial Assets Â  The following table represents the estimated fair values of the Companyâ€™s financial instruments: Schedule of Estimated Fair Value of Financial Instrument Â  Â  June 30, 2024 (Unaudited) Â  Â  Â  Â  Â  Â  Unrealized Â  Â  Unrealized Â  Â  Fair Â  Â  Â  Cost Â  Â  Gains Â  Â  Losses Â  Â  Value Â  Short-term investments Â  $ â€” Â  Â  $ Â â€” Â  Â  $ â€” Â  Â  $ â€” Â  Total Â  $ â€” Â  Â  $ Â â€” Â  Â  $ â€” Â  Â  $ â€” Â  Â  11 Â  Â  Â Â  December 31, 2023Â  Â Â  Â Â Â  UnrealizedÂ Â  UnrealizedÂ Â  FairÂ  Â Â  CostÂ Â  GainsÂ Â  LossesÂ Â  ValueÂ  Short-term investmentsÂ  $12,845,000Â Â  $48,000Â Â  $â€”Â Â  $12,893,000Â  TotalÂ  $12,845,000Â Â  $48,000Â Â  $â€”Â Â  $12,893,000Â  Â  The following table represents the Companyâ€™s fair value hierarchy for its financial assets (cash equivalents and investments): Â Schedule of Fair Value Hierarchy Financial Assets Â Â  Fair ValueÂ Â  Level 1Â Â  Level 2Â Â  Level 3Â  Â Â  June 30, 2024 (Unaudited)Â  Â Â  Fair ValueÂ Â  Level 1Â Â  Level 2Â Â  Level 3Â  Â Â  Â Â Â  Â Â Â  Â Â Â  Â Â  Cash equivalents:Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Money market fundsÂ  $1,037,000Â Â  $1,037,000Â Â  $â€”Â Â  $â€”Â  US treasuriesÂ  Â 6,570,000Â Â  Â â€”Â Â Â 6,570,000Â Â  Â â€”Â  Short-term investments:Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  US treasuriesÂ  Â â€”Â Â  Â â€”Â Â  Â â€”Â Â  Â â€”Â  Total financial assetsÂ $7,607,000Â Â  $1,037,000Â Â  $6,570,000Â Â  $â€”Â  Â  Â Â  Fair ValueÂ Â  Level 1Â Â  Level 2Â Â  Level 3Â  Â Â  December 31, 2023Â  Â Â  Fair ValueÂ Â  Level 1Â Â  Level 2Â Â  Level 3Â  Cash equivalents:Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Money market fundsÂ  $443,000Â Â  $443,000Â Â  $â€”Â Â  $â€”Â  Short-term investments:Â  Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  US treasuries and US govâ€™t. agenciesÂ  Â 12,893,000Â Â  Â â€”Â Â  Â 12,893,000Â Â  Â â€”Â  Total financial assetsÂ  $13,336,000Â Â  $443,000Â Â  $12,893,000Â Â  $â€”Â  Â  Warrant Liability Â  For the details of warrant liability transactions see Note 5 â€“ Warrant Liability. Â  Note 4 â€“ Accounts Payable and Accrued Expenses, and Related Party Â  Accounts payable consists of the following: Â Schedule of Accounts Payable Â Â  As of June 30, 2024Â Â  As of December 31, 2023Â  Â Â  Â (Unaudited)Â Â  Â Â Â  Accounts payable to Cytovance, a related party 1Â  $842,000Â Â  $3,515,000Â  Other accounts payableÂ  Â 875,000Â Â  Â 813,000Â  Total accounts payableÂ  $1,717,000Â Â  $4,328,000Â  Â  Â  1 Accounts Payable to Cytovance Biologics, Inc., a Related Party Â Â Accrued Expenses consists of the following: Â Schedule of Accrued Expenses Â Â  As of June 30, 2024Â Â  As of December 31, 2023Â  Â Â  Â (Unaudited)Â Â  Â Â Â  Accrued expenses, University of MinnesotaÂ  $862,000Â Â  $192,000Â  Other accrued expensesÂ  Â 903,000Â Â  Â 1,003,000Â  Total accrued expensesÂ $1,765,000Â Â  $1,195,000Â  Â  1 Accounts Payable to Cytovance Biologics, Inc. (â€œCytovanceâ€), a Related Party, since Cytovance owns greater than 5% of the Companyâ€™s issued and outstanding common stock Â  See Note 8 â€“ Commitments and Contingencies, Significant Agreements. Â  12 Â  Â  The details of the Companyâ€™s accounts payable to Cytovance Biologics, Inc., were as follows: Â Schedule of Accounts Payable to Related Party Â Â  June 30, 2024Â Â  June 30, 2023Â Â Â  Six Months EndingÂ  Â Â  June 30, 2024Â Â  June 30, 2023Â  Â Â  (Unaudited)Â Â  (Unaudited)Â  Beginning balanceÂ  $3,515,000Â Â  $2,283,000Â  Invoices, netÂ Â 778,000Â Â  Â 2,877,000Â  Payments in cashÂ  Â (2,641,000)Â  Â (1,130,000) Payments in common stock, at fair valueÂ  Â (810,000)Â  Â (1,120,000) Ending balanceÂ $842,000Â Â  $2,910,000Â  Â  University of Minnesota Â  See Note 8 â€“ Commitments and Contingencies, Significant Agreements. Â  Note 5 â€“ Warrant Liability Â 2023 Warrants Â  On January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate of 216,667 shares of the Companyâ€™s common stock (the â€œ2023 Common Warrantsâ€), and placement agent warrants to purchase up to 13,000 shares of the Companyâ€™s common stock (the â€œ2023 Placement Agents Warrantsâ€). Â  The 2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the â€œ2023 Warrantsâ€), provide for a value calculation for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides for a floor on the volatility amount utilized in the value calculation at 100% or greater. The Company has determined this provision introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Companyâ€™s own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability in its consolidated balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is evaluated at the end of each reporting period. Â  The 2023 Warrants were initially recorded at a fair value at $5.8 million at the grant date, and upon the closing of placement, was recorded as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Companyâ€™s unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either exercised or expired. Â  The 2023 Warrant liability is valued using a Binomial pricing model with the following assumptions: Â Schedule of Derivative Liabilities Assumptions Â Â  2023 WarrantsÂ  Â Â  June 30, 2024Â Â  December 31, 2023Â  Â Â  (Unaudited)Â Â  (Unaudited)Â  Stock priceÂ  $2.83Â Â  $7.80Â  Risk-free interest rate 1Â  Â 4.43%Â  Â 4.26% Expected volatility 2Â  Â 116%Â  Â 115% Expected life (in years) 3Â  Â 3.5 - 4.0Â Â  Â 4.25Â  Expected dividend yield 4Â  Â â€”Â Â  Â â€”Â  Fair value of warrantsÂ  $277,000Â Â  $1,050,00Â  Â  1Based on rates established by the Federal Reserve Bank 2Historical volatility of the Companyâ€™s common stock is used to estimate the future volatility of its common stock 3Determined by the remaining contractual life of the derivative instrument 4Based on no dividends paid or expected to be paid Â  13 Â  Â  2020 Warrants Â  The Company issued warrants underlying 58,824 shares of common stock during the year ended December 31, 2020 (the â€œ2020 Warrantsâ€), that contained a fundamental transaction provision that could give rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480, the fair value of the 2020 Warrants is classified as a liability in the Companyâ€™s unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either exercised or expire. Â  The 2020 Warrant liability is valued using a Binomial pricing model with the following assumptions: Â Schedule of Derivative Liabilities Assumptions Â Â  2020 WarrantsÂ Â Â  June 30, 2024Â Â  December 31, 2023Â  Â Â  (Unaudited)Â Â  Â Â  Stock priceÂ  $2.83Â Â  $7.80Â  Risk-free interest rate 1Â  Â 5.09%Â  Â 4.54% Expected volatility 2Â  Â 116%Â  Â 89% Expected life (in years) 3Â  Â 1.0Â Â  Â 1.6Â  Expected dividend yield 4Â  Â â€”Â Â  Â â€”Â  Â Â  Â Â Â Â  Â Â Â  Fair value of warrantsÂ  $â€”Â Â $2,000Â  Â  1Based on rates established by the Federal Reserve Bank 2Historical volatility of the Companyâ€™s common stock is used to estimate the future volatility of its common stock 3Determined by the remaining contractual life of the derivative instrument 4Based on no dividends paid or expected to be paid Â  Warrant Liability Â The details of warrant liability transactions were as follows: Â Schedule of Derivative Liability Transactions Â Â  June 30, 2024Â Â  June 30, 2023Â  Â Â  Six Months EndingÂ  Â Â  June 30, 2024Â Â  June 30, 2023Â  Â Â  (Unaudited)Â Â  (Unaudited)Â  Beginning balanceÂ  $1,052,000Â Â  $â€”Â  Issuance of warrants at fair valueÂ Â â€”Â Â  Â 5,831,000Â  Change in fair valueÂ  Â (775,000)Â  Â (4,311,000) ExtinguishmentÂ  Â â€”Â Â  Â â€”Â  Ending balanceÂ  $277,000Â Â  $1,520,000Â  Â  Note 6 â€“ Stockholdersâ€™ Equity Â  The Companyâ€™s authorized capital as of June 30, 2024 was 250,000,000 shares of common stock, par value $0.001 per share, and 15,000,000 shares of preferred stock, par value $0.01 per share. Â  Common Stock Â  2024 Common Stock Offering Â  On May 23, 2024, the Company received gross proceeds of approximately $3.2 million, before deducting placement agent fees and other offering expenses of $243,000 in relation to a purchase agreement (the â€œPurchase Agreementâ€) signed on May 21, 2024, between the Company and institutional investors (the â€œPurchasersâ€) for the issuance and sale, in a registered direct offering, of 740,000 shares of the Companyâ€™s common stock, par value $0.001 per share (the â€œ2024 Sharesâ€). In a concurrent private placement, the Company issued and sold to the Purchasers warrants to purchase 740,000 shares of the Companyâ€™s common stock (the â€œ2024 Common Warrantsâ€). In addition, the Company issued warrants to the placement agent to purchase 88,800 shares of common stock (the â€œ2024 Placement Agents Warrantsâ€). The 2024 Common Warrants have an exercise price equal to $4.35 per share, and the 2024 Placement Agents Warrants have an exercise price equal to $5.4375 per share, both are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial exercise date. The 2024 Shares and 2024 Common Warrants were sold at an offering price of $4.35 per share. Â  Pursuant to the Purchase Agreement, the Company agreed, with certain exceptions, for a period of 60 days following the closing of the offering not to issue, enter into an agreement to issue or announce the issuance or proposed issuance of the 2024 Shares or any other securities convertible into, or exercisable or exchangeable for, shares of the Companyâ€™s common stock. The Company has also agreed for a period of one year following the closing date of the offering not to (i) issue or agree to issue equity or debt securities convertible into, or exercisable or exchangeable for, shares at a conversion price, exercise price or exchange price which floats with the trading price of the 2024 Shares or which may be adjusted after issuance upon the occurrence of certain events or (ii) enter into any agreement, including an equity line of credit, whereby the Company may issue securities at a future-determined price. Â  The Company determined that under ASC 815-40, the 2024 Common Warrants and the 2024 Placement Agent Warrants do not contain a clause that adjusts the exercise price based on circumstances not considered to be within the Companyâ€™s control and are considered indexed to the Companyâ€™s own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2024 Common Warrants and the 2024 Placement Agent Warrants are classified as equity. Â  14 Â  Â  2023 Private Placement of Common Stock Â  On January 4, 2023, the Company received gross proceeds of $6.5 million, before deducting placement agent fees and other offering expenses of $232,000 in relation to a purchase agreement signed on December 30, 2022, between the Company and an institutional investor for the issuance and sale, in a registered direct offering, of 120,000 shares of the Companyâ€™s common stock, par value $0.001 per share (the â€œ2023 Sharesâ€), pre-funded warrants to purchase up to 96,667 shares of the Companyâ€™s common stock (the â€œPre-Funded Warrantsâ€), warrants to purchase up to an aggregate of 216,667 shares of the Companyâ€™s common stock (the â€œ2023 Common Warrantsâ€) and placement agent warrants to purchase up to 13,000 of the Companyâ€™s common stock (the â€œ2023 Placement Agents Warrantsâ€). The 2023 Common Warrants have an exercise price equal to $30.00 per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The Pre-Funded Warrants had an exercise price of $0.003 per share, are immediately exercisable and could be exercised at any time after their original issuance until such Pre-Funded Warrants were exercised in full. The 2023 Placement Agents Warrants have an exercise price equal to $37.50 per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The 2023 Shares and 2023 Common Warrants were sold at an offering price of $30.00 per share and accompanying 2023 Common Warrant and the Pre-Funded Warrants and 2023 Common Warrants were sold at an offering price of $29.997 per Pre-Funded Warrant and accompanying 2023 Common Warrant. Â  The 2023 Common Warrants and the 2023 Placement Agents Warrants contained a clause not considered to be within the Companyâ€™s control. The Company determined that the provision represented a variable that is not an input to the fair value of a â€œfixed-for-fixedâ€ option as defined under ASC 815-40, and thus the 2023 Common Warrants and the 2023 Placement Agent Warrants are not considered indexed to the Companyâ€™s own stock and not eligible for an exception from derivative accounting. Accordingly, the 2023 Common Warrants and the 2023 Placement Agent Warrants were classified as a warrant liability, and $5.8 million of the initial common stock offering was classified as a warrant liability (see Note 5 â€“ Warrant Liability). Â  Common Stock Issued for Services Â  During the six months ended June 30, 2023, and pursuant to the vesting term of a 2021 agreement, the Company issued 2,449 shares of common stock with a fair value of $315,000 to members of the Companyâ€™s Board of Directors (the â€œBoardâ€), employees, and consultants. The shares were valued at the respective date of the agreements. Â  Preferred Stock Â  Series C Preferred Stock Â  As of June 30, 2024 and December 31, 2023, there were 96,230 shares of series C preferred stock, par value $0.01 per share (the â€œSeries C Preferred Stockâ€) issued and outstanding. Â  As a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the 96,230 shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through June 30, 2024 and 2023, respectively. Â  Series K Preferred Stock Â  On February 16, 2021, the Board designated 115,000 shares of Series K preferred stock, par value $.01 (the â€œSeries K Preferred Stockâ€). Â  Shares of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Companyâ€™s common stock at an effective conversion rate of 100 shares of common stock for each share of Series K Preferred. Shares of the Series K Preferred Stock have the same voting rights as the shares of the Companyâ€™s common stock, with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders of the Companyâ€™s common stock on all matters presented to the Companyâ€™s stockholders. The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the Board) but will participate on an as-converted-to-common-stock basis in any dividends to the holders of the Companyâ€™s common stock. In the event of the Companyâ€™s dissolution, liquidation or winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Companyâ€™s common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Companyâ€™s common stock. Â  As of June 30, 2024 and December 31, 2023, there were no shares of Series K Preferred stock issued and outstanding. Â  15 Â  Â  Note 7 â€“ Common Stock Warrants and Options Â  Common Stock Warrants Â  Stock warrant transactions for the six months ended June 30, 2024 were as follows: Â Schedule of Warrant Activity Â Â  Six Months Ended June 30, 2024Â  Â Â  Number ofÂ Â  Weighted AverageÂ  Â Â  WarrantsÂ Â  Exercise PriceÂ  Warrants outstanding at December 31, 2023Â  Â 304,962Â Â  $63.30Â  GrantedÂ  Â 828,800Â Â  Â 4.47Â  Forfeited/cancelledÂ  Â â€”Â Â  Â â€”Â  ExercisedÂ  Â â€”Â Â  Â â€”Â  Warrants outstanding at June 30, 2024Â  Â 1,133,762Â Â  $20.28Â  Warrants exercisable at June 30, 2024Â  Â 1,133,762Â Â  $20.28Â  Â  As of June 30, 2024, all outstanding warrants are fully vested and had an exercise price greater than the market price of the Companyâ€™s common stock, which resulted in no intrinsic value. Â  Warrants outstanding as of June 30, 2024 are exercisable as follows: Â Schedule of Warrants Outstanding and Exercisable Â Â Â  Warrants Outstanding and Exercisable as of June 30, 2024Â  Range of Exercise PriceÂ Â  Number OutstandingÂ Â  Weighted Average Remaining Contractual Life (Years)Â Â  Weighted Average Exercise PriceÂ  $4.35Â Â  Â 740,000Â Â  Â 4.9Â Â  $4.35Â  Â 5.4375Â Â  Â 88,800Â Â  Â 4.9Â Â  Â 5.4375Â  Â 30.00Â Â  Â 216,666Â Â  Â 4.0Â Â  Â 30.00Â  Â 37.50Â Â  Â 13,000Â Â  Â 3.5Â Â  Â 37.50Â  Â 102.00Â Â  Â 1,867Â Â  Â 1.0Â Â  Â 102.00Â  Â 165.00Â Â  Â 73,429Â Â  Â 1.6Â Â  Â 165.00Â  Â Â Â Â  Â 1,133,762Â Â  Â 4.5Â Â  Â 20.28Â  Â  Common Stock Options Â  In April 2022 the Company established the 2022 Omnibus Incentive Plan (the â€œPlanâ€). The Plan was approved by our Board and stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is 166,667. The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under the Plan. As of June 30, 2024, there were 7,966 shares available for grant under the Plan. Â  The following table summarizes stock option transactions for the six months ended June 30, 2024: Â Schedule of Options Activity Â Â  Six Months Ended June 30, 2024Â  Â Â  Number ofÂ Â  Weighted AverageÂ  Â Â  OptionsÂ Â  Exercise PriceÂ  Options outstanding at December 31, 2023Â  Â 126,265Â Â  $40.15Â  GrantedÂ  Â â€”Â Â  Â â€”Â  Forfeited/cancelledÂ  Â â€”Â Â  Â â€”Â  ExercisedÂ  Â â€”Â Â  Â â€”Â  Options outstanding at June 30, 2024Â  Â 126,265Â Â  $40.15Â  Options exercisable at June 30, 2024Â  Â 126,265Â Â  $40.15Â  Â  The weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of June 30, 2024 was 8.43 years. Furthermore, all options outstanding and all options vested and exercisable as of June 30, 2024 had an exercise price greater than the market price of the Companyâ€™s common stock, which resulted in no intrinsic value. Â  The total fair value of options that vested during the six months ended June 30, 2024 and 2023, was $222,000 and $905,000, respectively, and is included in selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations. As of June 30, 2024, all outstanding stock options were fully vested and exercisable and there was no accompanying unvested compensation expense. Â  16 Â  Â  On May 15, 2023, the Company granted stock options to a member of the Board to purchase 16,666 shares of common stock. The stock options are exercisable at $10.50 per share, expire in 10 years, vest over twelve months and have a fair value of $150,000 on at the date of grant which will be amortized over the vesting period. Â  On January 27, 2023, the Company granted stock options to employees and members of the Board to purchase an aggregate of 66,667 shares of common stock. The stock options are exercisable at $25.50 per share, expire in 10 years, vest over twelve months and have a fair value of $1.4 million at the date of grant which will be amortized over the vesting period. Â  Options outstanding as of June 30, 2024 are exercisable as follows: Â Schedule of Options Outstanding and Options Exercisable Â Â Â  Stock Options Outstanding and Exercisable as of June 30, 2024Â  Range of Exercise PriceÂ Â  Number OutstandingÂ Â  Weighted Average Remaining Contractual Life (Years)Â Â  Weighted Average Exercise PriceÂ  $10.50Â Â  Â 16,666Â Â  Â 8.8Â Â  $10.50Â  Â 25.50Â Â  Â 66,667Â Â  Â 8.6Â Â  Â 25.50Â  Â 74.40Â Â  Â 42,932Â Â  Â 8.0Â Â  Â 74.40Â  Â Â Â Â  Â 126,265Â Â  Â Â Â Â  Â Â Â Â  Note 8 â€“ Commitments and Contingencies Â  Litigation Â  The Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under, and are being handled in, the normal course of business: Â  Ohri Matter Â  On July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer.Â  In the Demand, the Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing that the Company may characterize Mr. Ohriâ€™s termination as â€œfor causeâ€ under his Employment Agreement, and that the Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohriâ€™s breaches.Â  In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohriâ€™s violations, and attorneysâ€™ fees and any forum and arbitration fees. Mr. Ohriâ€™s response to the Companyâ€™s Demand is due August 20, 2024.Â  At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. Â  Berk Matter Â  On November 14, 2023, former interim Chief Executive Officer, Dr. Gregory Berk filed a lawsuit in the US District Court for the District of Massachusetts alleging that the Company discriminated and retaliated against Dr. Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act (â€œSOXâ€). The Parties are proceeding with litigating Dr. Berkâ€™s SOX claim. The Company is vigorously defending this matter and believes it to be without merit. At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. Â  TWF Global Matter Â  On May 24, 2023, TWF Global, LLC (â€œTWFâ€) filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (â€œNotesâ€) and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine if the Companyâ€™s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and will reconsider the motion without further briefing upon the filing of a party affidavit. Z-One has filed a concurrent motion to dismiss of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Companyâ€™s shares of common stock. The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these claims. Â  17 Â  Â  Handelman Matter Â  On May 13, 2022, the Company made an arbitration demand upon Michael Handelman, its former Chief Financial Officer, asserting that he breached his fiduciary duty by misappropriating Company funds and shares of common stock, among other things. The Company seeks among other relief, monetary damages estimated at $470,000; the return of 13,902 shares of our common stock received without authorization; and an award of the Companyâ€™s attorneysâ€™ fees and any forum and arbitration fees. In May 2024, the Arbitrator issued the final award in favor of the Company which awarded the Company its legal fees in the amount of $473,000 plus costs in the amount of $19,000 and the return of the disputed 13,902 shares of common stock, which were returned to the Company in June 2024. Â  Significant Agreements Â  Cytovance Biologics, Inc., a Related Party Â  In October 2020, the Company entered into a Master Services Agreement with Cytovance Biologics, Inc. (â€œCytovanceâ€), to perform biologic development and manufacturing services, and to produce and test compounds used in the Companyâ€™s potential product candidates. The Company subsequently executed numerous Statements of Work (â€œSOWsâ€) for the research and development of products for use in clinical trials. Â  On August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed for future invoices to be settled in in a combination of cash and issuance of the Companyâ€™s common stock. The Agreement also set Cytovanceâ€™s beneficial ownership limitation at 4.9% of the issued and outstanding shares of the Companyâ€™s common stock. Â  On April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovanceâ€™s beneficial ownership limitation to 9.9% of the issued and outstanding shares of the Companyâ€™s common stock. Â  During the six months ended June 30, 2024 and 2023, the Company issued 127,597 and 44,793 shares of common stock to Cytovance to settle accounts payable valued at approximately $810,000 and $1,120,000, respectively. Â  On June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded 5% of the issued and outstanding shares of the Companyâ€™s common stock. Â  As of June 30, 2024 the Companyâ€™s commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance for services that have not yet been rendered as of June 30, 2024, amounted to approximately $1.5 million. Â  University of Minnesota Â  2021 Scientific Research Agreement Â  Effective June 16, 2021, the Company entered into a scientific research agreement with the Regents of the University of Minnesota, expiring on June 30, 2023. Payments totaling approximately $2.1 million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Companyâ€™s TriKEÂ® product development and GMP manufacturing efforts; (2) TriKEÂ® pharmacokinetics optimization in humans; and (3) investigation of the patientâ€™s native NK cell population based on insights obtained from the analysis of the human data generated during our GTB-3550 clinical trial. The major deliverables proposed are: (1) creation of IND enabling data for TriKEÂ® constructs in support of our product development and GMP manufacturing efforts; (2) TriKEÂ® platform drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of changes in the patientâ€™s native NK cell population as a result of TriKEÂ® therapy. Most studies will use TriKEÂ® DNA/amino acid sequences created by the Company under existing licensing terms. Â  The Company recorded an expense classified as research and development of approximately $0 and $192,000, pursuant to the 2021 Scientific Research Agreement, for the six months ended June 30, 2024 and 2023, respectively. Â  As of June 30, 2024 the Companyâ€™s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2021 Scientific Research Agreement for services that have not yet been rendered as of June 30, 2024, amounted to $0. Â  18 Â  Â  2023 Sponsored Research Agreement Â  On May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the â€œ2016 Exclusive Patent License Agreementâ€), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $1.7 million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Companyâ€™s TriKEÂ® product development and commercial GMP manufacturing efforts; (2) TriKEÂ® pharmacokinetics optimization in humans and investigation of effects of altering the route of administration; and (3) research and development of TriKEÂ® platform. The major deliverables proposed are: (1) creation of IND enabling data for TriKEÂ® constructs in support of the Companyâ€™s product development and commercial GMP manufacturing efforts outside of the University of Minnesota; (2) TriKEÂ® platform drug delivery changes to allow transition from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ]) and extended PK in humans and gain an increased understanding of changes in the patientâ€™s native NK cell population as a result of alteration of TriKEÂ® administration; and (3) research and development of TriKEÂ® platform combination with other FDA approved (or soon to be approved) therapeutics and alterations to TriKEÂ® platform through formation of immune complexes. Most studies will use TriKEÂ® DNA/amino acid sequences created by the Company under existing licensing terms. Â  The Company recorded an expense classified as research and development of approximately $863,000 and $0, pursuant to the 2023 Sponsored Research Agreement, for the six months ended June 30, 2024 and 2023, respectively. Â  As of June 30, 2024 the Companyâ€™s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of June 30, 2024, amounted to approximately $862,000. Â  2016 Exclusive Patent License Agreement Â  Effective July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (the â€œ2016 Exclusive Patent License Agreementâ€), to further develop and commercialize cancer therapies using TriKEÂ® technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKEÂ® technology worldwide for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKEÂ® technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $200,000, and license maintenance fees of $200,000 for years 2017 through 2020, and $100,000 per year beginning in year 2021 and each year thereafter. The agreement also includes 4% royalty fees on the net sales of licensed products, not to exceed 6% under subsequent license agreements or amendments to this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 beginning in 2022, $2 million beginning in 2025, and $5 million beginning in 2027 throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products. Â  Effective May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University of Minnesota. The amendment requires an upfront payment of $145,000 and amends the license maintenance fees to $50,000 in 2025, and $100,000 per year beginning in year 2026 and each year thereafter. The amendment also includes 1% to 5% royalty fees on the net sales of licensed products, not to exceed 6% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 in year one, $2 million in years two through five, and $5 million in year six throughout the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products. Â  The Company recorded an expense classified as research and development of $0, pursuant to the 2016 Exclusive Patent License Agreement, for the six months ended June 30, 2024 and 2023. Â  2021 Exclusive License Agreement Â  Effective March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the â€œ2021 Exclusive Patent License Agreementâ€), specific to the B7H3 targeted TriKEÂ®. The agreement requires an upfront payment of $20,000, and license maintenance fees of $5,000 per year beginning in year 2022 and each year thereafter. The agreement also includes 2.5% to 5% royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 in year one though four, and $2 million beginning in year five and throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone. Â  The Company recorded an expense classified as research and development of approximately $145,000 and $0, pursuant to the 2021 Exclusive License Agreement, for the six months ended June 30, 2024 and 2023, respectively. Â  19 Â  Â  Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Â  CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Â  Some of the statements in this Quarterly Report on Form 10-Q are â€œforward-looking statementsâ€ within the meaning of the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our current beliefs, goals and expectations about matters such as our expected financial position and operating results, our business strategy and our financing plans. The forward-looking statements in this report are not based on historical facts, but rather reflect the current expectations of our management concerning future results and events. The forward-looking statements generally can be identified by the use of terms such as â€œbelieve,â€ â€œexpect,â€ â€œanticipate,â€ â€œintend,â€ â€œplan,â€ â€œforesee,â€ â€œmay,â€ â€œguidance,â€ â€œestimate,â€ â€œpotential,â€ â€œoutlook,â€ â€œtarget,â€ â€œforecast,â€ â€œlikelyâ€ or other similar words or phrases. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. We cannot guarantee that our forward-looking statements will turn out to be correct or that our beliefs and goals will not change. Our actual results could be very different from and worse than our expectations for various reasons. You should carefully review all information, including the discussion of risk factors under â€œPart I. Item 1A: Risk Factorsâ€ and â€œPart II. Item 7: Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ of the Form 10-K for the year ended December 31, 2023. Any forward-looking statements in the Form 10-Q are made only as of the date hereof and, except as may be required by law, we do not have any obligation to publicly update any forward-looking statements contained in this Form 10-Q to reflect subsequent events or circumstances. Â  Organization Â  The corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data, Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March 11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc. Â  Overview Â  We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (TriKEÂ®), and Tetra-specific Killer Engager (Dual Targeting TriKEÂ®) fusion protein immune cell engager technology platforms. Our TriKEÂ® and Dual Targeting TriKEÂ® platforms generates proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patientâ€™s own natural killer cells, or NK cells. Once bound to an NK cell, our moieties are designed to enhance the NK cell, and precisely direct it to one or more specifically targeted proteins expressed on a specific type of cancer cell or virus infected cell, resulting in the targeted cellâ€™s death. TriKEÂ®s can be designed to target any number of tumor antigens on hematologic malignancies or solid tumors and do not require patient-specific customization. Â  We are using our TriKEÂ® platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies and solid tumors. The platform is scalable, and we are putting processes in place to be able to produce investigational new drug (IND) ready moieties in a timely manner after a specific TriKEÂ® conceptual design. Specific drug candidates can then be advanced into the clinic on our own or through potential collaborations with partnering companies. We believe our TriKEÂ®s may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies. Â  Our initial work was conducted in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr. Jeffrey Miller, Professor of Medicine, and the Deputy Director at the Center. Dr. Miller is a recognized key opinion leader in the field of NK cell and IL-15 biology and their therapeutic potential. We have exclusive rights to the TriKEÂ® platform and are generating additional intellectual property for specific moieties. Â  20 Â  Â  Our product pipeline as of June 30, 2024 is presented below: Â  Â  GTB-3550 Â  GTB-3550 was our first TriKEÂ® product candidate. It reflected our first-generation TriKEÂ® platform. It is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. We studied this anti-CD16-IL-15-anti-CD33 TriKEÂ® in CD33 positive leukemias, a marker expressed on tumor cells in acute myelogenous leukemia, or AML, and myelodysplastic syndrome, or MDS. CD33 is primarily a myeloid differentiation antigen with endocytic properties broadly expressed on AML blasts and, possibly, some leukemic stem cells. CD33 or Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. The anti-CD33 antibody fragment used for these studies was derived from the M195 humanized anti-CD33 scFv and has been used in multiple human clinical studies. It has been exploited as a target for therapeutic antibodies for many years. We believe the approval of the antibody-drug conjugate gemtuzumab validates this targeted approach. Â  GTB-3550 was replaced by a more potent next-generation camelid nanobody TriKEÂ®, GTB-3650, both targeting CD33 on relapsed/refractory AML and high-risk MDS. The pivot from GTB-3550 to GTB-3650 in our clinical development was based on a solid preclinical foundation that showed markedly enhanced potency of the camelid modification of the first-generation TriKEÂ®. This is illustrated below by better tumor control of AML bearing animals with GTB-3650 (purple dots) compared to GTB-3550 (blue dots). This provided the rationale for pausing further development of GTB-3550 and moving over to solely develop the second-generation TriKEÂ® platform. Â  21 Â  Â  Â  Second Generation TriKEÂ®s Utilize Camelid Nanobody Technology Â  Our goal is to be a leader in immuno-oncology therapies targeting a broad range of indications including hematological malignancies and solid tumors. A key element of our strategy includes introducing a next-generation camelid nanobody platform. Camelid antibodies (often referred as nanobodies) are smaller than human immunoglobulin and consist of two heavy chains. These nanobodies have the potential to have greater affinity to target antigens, potentially resulting in greater potency. We are utilizing this camelid antibody structure for all ofÂ  our new TriKEÂ® product candidates. Â  22 Â  Â  To develop second generation TriKEÂ®s, we designed a new humanized CD16 engager derived from a single-domain antibody. While scFvs consist of a heavy and a light variable chain joined by a linker, single-domain antibodies consist of a single variable heavy chain capable of engaging without the need of a light chain counterpart (see figure below). Â  Â  These single-domain antibodies are thought to have certain attractive features for antibody engineering, including physical stability, ability to bind deep grooves, and increased production yields, amongst others. Pre-clinical studies demonstrated increased NK cell activation against CD33+ targets including enhanced NK cell degranulation (% CD107a+) and IFNg with the single-domain CD16 TriKEÂ® (cam 16-wt15-33; GTB-3650) compared to the original TriKEÂ® (scFv16-m 15-33; GTB-3550) (see figure below). This data was published by Dr. Felices M et al (2020) in Cancer Immunol Res. Â  CD33+ HL60 Targets in Killing Assays Â  The purple line represents the GTB-3650 and the blue line represents GTB-3550. Â  Â  GTB-3650 Â  GTB-3650 is a CD33 targeted TriKEÂ® which targets CD33 on the surface of myeloid leukemias and an agonistic camelid engager to the potent activating receptor on NK cells, CD16. Use of this engager enhances the activity of wild type IL-15 included in GTB-3650, no longer needing the mutant IL-15 included in GTB-3550. The TriKEÂ® approach provides a novel way to specifically target these tumors by leveraging NK cells, which have been shown to mediate relapse protection in this setting, in an anti-CD33-targeted fashion. We are moving GTB-3650 clinically based on pre-clinical data showing a marked increase in potency compared to GTB-3550, which we anticipate could lead to an enhanced efficacy signal in AML and MDS. We have advanced GTB-3650 through preclinical studies and filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in December 2023. In late June 2024, we received clearance from the FDA with respect to our IND Application in relation to GTB 3650. We further anticipate approval to start study enrollment targeting patients with relapsed/refractory AML and high grade MDS in the second half of 2024. This initial study will test GTB-3650 as monotherapy testing administration 2 weeks on and two weeks off (to prevent NK cell exhaustion) for at least 2 cycles of therapy. The design of the trial has been agreed on with the FDA. Â 23 Â  Â  Â  Â  GTB-5550 Â  GTB-5550 is a B7-H3 targeted TriKEÂ® which targets B7-H3 on the surface of advanced solid tumors (figure above). B7-H3 is an exciting target as it displays specific expression on a broad spectrum of solid tumor malignancies, allowing our team to target these malignancies through GTB-5550. Pre-clinical work has shown that this molecule has NK-cell targeted activity against a variety of solid tumor settings, including head and neck cancer squamous cell carcinoma (figure below), prostate cancer, breast cancer, ovarian cancer, glioblastoma, and lung cancer (amongst others). We are advancing GTB-5550 through preclinical studies and initiated a GMP manufacturing campaign in anticipation of filing an IND in the first half of 2025. A pre-IND packet was submitted to the FDA in October 2023 with a written response from the FDA in December 2023. The main question from the FDA was regarding pre-clinical toxicology and a pivot to subcutaneous dosing. The initial trial expected in 2025 is designed as a basket trial for patients with B7-H3+ solid tumors using Monday through Friday dosing (2 weeks on and 2 weeks off to prevent immune exhaustion), and is dependent on manufacturing of clinical materials. Â  Â  Critical Accounting Policies and Estimates Â  The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may differ under different estimates and assumptions. The accounting estimates and assumptions discussed in this section are those that we consider to be the most critical to gain an understanding of our financial statements because they inherently involve significant judgments and uncertainties. Â  Use of Estimates Â  The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include accruals for potential liabilities, assumptions used in deriving the fair value of warrant liabilities, valuation of equity instruments issued for services, and valuation of deferred tax assets. Actual results could differ from those estimates. Â  Warrant Liability Â  We evaluate our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, â€œDerivatives and Hedgingâ€. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Â  24 Â  Â  Our use of derivative financial instruments is generally limited to warrants issued by us that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes. Â  Stock-Based Compensation Â  We periodically issue stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Â  Stock-based payments made to officers, directors, employees, and consultants in exchange for goods and services, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, Compensation-Stock Compensation. Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if we had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods. Â  Results of Operations Â  Comparison of the Three and Six Months Ended June 30, 2024 and 2023 Â  Operating Expenses Â  Â Â  Three Months Ended June 30,Â  Â Â  2024Â Â  2023Â Â  $ ChangeÂ Â  % ChangeÂ  Operating Expenses:Â  Â Â Â Â Â Â Â Â  Â Â Â Â  Â Â Â  Research and developmentÂ  $1,784,000Â Â  $2,095,000Â Â  $(311,000)Â  Â (15)% Selling, general and administrativeÂ  Â 2,002,000Â Â Â 1,128,000Â Â  Â 874,000Â Â  Â 77% Stock compensationÂ  Â 120,000Â Â  Â 398,000Â Â  Â (278,000)Â  Â (70)% Total Operating ExpensesÂ  $3,906,000Â Â $3,621,000Â Â  $285,000Â Â  Â 8% Â  Â Â  Six Months Ended June 30,Â  Â Â  2024Â Â  2023Â Â  $ ChangeÂ Â  % ChangeÂ  Operating Expenses:Â  Â Â Â Â  Â Â Â Â Â Â Â Â  Â Â Â  Research and developmentÂ  $2,561,000Â Â  $3,748,000Â Â  $(1,187,000)Â  Â (32)% Selling, general and administrativeÂ  Â 4,214,000Â Â Â 2,633,000Â Â  Â 1,581,000Â Â  Â 60% Stock compensationÂ  Â 222,000Â Â  Â 905,000Â Â  Â (683,000)Â  Â (75)% Total Operating ExpensesÂ  $6,997,000Â Â $7,286,000Â Â  $(289,000)Â  Â (4)% Â  Research and Development Expenses Â  Research and development expenses decreased by $311,000 and $1.2 million, for the three and six months ended June 30, 2024 and 2023, respectively, primarily due to a decrease in project materials costs, partially offset by an increase in scientific research costs. Â  Research and development expenses relate to our continued development and production of our most advanced TriKEÂ® product candidates GTB-3650 and GTB-5550 along with the progression on other promising candidates. In late June 2024, we received clearance from the FDA with respect to our IND Application in relation to GTB 3650. We anticipate our direct clinical and preclinical expenses to continue to increase in the second half of 2024 as we plan to advance our next generation GTB-3650 camelid nanobody product into the clinic, enroll patients, and perform tests for data collection. We also plan to complete the product development of GTB-5550 and anticipate submission of IND application for GTB-5550 in the first half of 2025. We do not, however, anticipate an increase in related R&D licensing and administrative costs. Â  Selling, General, and Administrative Expenses Â  Selling, general, and administrative expenses increased by $874,000 and $1.6 million, for the three and six months ended June 30, 2024 and 2023, respectively, primarily due to an increase in legal and professional fees. Â  25 Â  Â  Other Income (Expense) Â  Â Â  Three Months Ended June 30,Â  Â Â  2024Â Â  2023Â Â  $ ChangeÂ Â  % ChangeÂ  Other Income (Expense):Â  Â Â Â Â  Â Â Â Â  Â Â Â Â Â Â Â  Interest incomeÂ  $105,000Â Â  $220,000Â Â  $(115,000)Â  Â (52)% Interest expenseÂ  Â â€"Â Â  Â (1,000)Â  Â 1,000Â Â  Â 100% Change in fair value of warrant liabilityÂ  Â 117,000Â Â  Â 1,387,000Â Â  Â (1,270,000)Â  Â (92)% Gain on extinguishment of debtÂ  Â â€"Â Â  Â 14,000Â Â  Â (14,000)Â  Â (100)% Unrealized gain (loss) on marketable securitiesÂ  Â 1,000Â Â  Â 9,000Â Â  Â (8,000)Â  Â (89)% OtherÂ  Â (27,000)Â  Â â€"Â Â  Â (27,000)Â  Â â€"% Total Other Income (Expense)Â $196,000Â Â  $1,629,000Â Â  $(1,433,000)Â  Â (88)% Â  Â Â  Six Months Ended June 30,Â  Â Â  2024Â Â  2023Â Â  $ ChangeÂ Â  % ChangeÂ  Other Income (Expense):Â Â Â Â Â  Â Â Â Â  Â Â Â Â  Â Â Â  Interest incomeÂ  $247,000Â Â  $384,000Â Â  $(137,000)Â  Â (36)% Interest expenseÂ  Â â€"Â Â  Â (213,000)Â  Â 213,000Â Â  Â 100% Change in fair value of warrant liabilityÂ  Â 775,000Â Â  Â 4,311,000Â Â  Â (3,536,000)Â  Â (82)% Gain on extinguishment of debtÂ  Â â€"Â Â  Â 547,000Â Â Â (547,000)Â  Â (100)% Unrealized gain (loss) on marketable securitiesÂ  Â (1,000)Â  Â 38,000Â Â  Â (39,000)Â  Â (103)% OtherÂ  Â â€"Â Â  Â â€"Â Â  Â â€"Â Â  Â â€"% Total Other Income (Expense)Â  $1,021,000Â Â  $5,067,000Â Â  $(4,046,000)Â  Â (80)% Â  Interest Income Â  Interest income decreased by $115,000 and $137,000 for the three and six months ended June 30, 2024 compared to the same prior year periods, respectively, primarily due to lower short term investment balances. Â  Interest Expense Â  Interest expense decreased by $213,000 for the six months ended June 30, 2024 compared to the same prior year periods, respectively. The interest expense for the six months ended June 30, 2023 was due to the financing costs incurred associated with warrants accounted as warrant liability sold during the six months ended June 30, 2023, which did not recur in the current period. Â  Change in Fair Value of Warrant Liability Â  The change in fair value of warrant liability decreased by $1.3 million and $3.5 million for the three and six months ended June 30, 2024 compared to the same prior year periods, respectively, resulting from a reduction in our warrant liability due to the decline in the Companyâ€™s stock price at June 30, 2024 as compared to the prior comparable periods. Â  Gain on Extinguishment of Debt Â  Gain on extinguishment of debt decreased by $14,000 and $547,000 for the three and six months ended June 30, 2024 compared to the same prior year periods, respectively. The gain on extinguishment of debt for the six months ended June 30, 2023 resulted from share settlements of a greater amount of vendor accounts payable than the fair value of the shares on the date of settlement, there were no similar transactions during the current period. Â  Net Loss Â  Â Â  Three Months Ended June 30,Â  Â Â  2024Â Â  2023Â Â  $ ChangeÂ Â  % ChangeÂ  Net LossÂ  $(3,710,000)Â  $(1,992,000)Â  $(1,718,000)Â  Â (86)% Â Â  Â Â Â Â  Â Â Â Â  Â Â Â Â Â Â Â  Â  Â Â  Six Months Ended June 30,Â  Â Â  2024Â Â  2023Â Â  $ ChangeÂ Â  % ChangeÂ  Net LossÂ  $(5,976,000)Â  $(2,219,000)Â  $(3,757,000)Â  Â (169)% Â  26 Â  Â  Net loss increased $1,718,000 for the three months ended June 30, 2024, primarily due to the $1,270,000 decrease in the change in fair value of warrant liability, as described above. Â  Net loss increased $3,757,000 for the six months ended June 30, 2024, primarily due to the $3,536,000 decrease in the change in fair value of warrant liability and the $547,000 decrease in the gain on extinguishment of debt, both as described above. Â  Liquidity and Going Concern Analysis Â  We do not have any product candidates approved for sale and have not generated any revenue from our product sales. We have sustained operating losses since inception, and we expect such losses to continue into the foreseeable future. Historically, we have financed our operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. For the six months ended June 30, 2024, we recorded a net loss of approximately $6.0 million and used cash in operations of $7.7 million. As of June 30, 2024, we had a cash and cash equivalents and short-term investments balance of $9.2 million, working capital of $5.8 million, and stockholdersâ€™ equity of $5.5 million. Â  The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes we will continue as a going concern, and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Â  We have evaluated the significance of the uncertainty regarding our financial condition in relation to our ability to meet our obligations, which has raised doubts about our ability to continue as a going concern. While it is very difficult to estimate our future liquidity requirements we believe if we are unable to obtain additional financing, existing cash resources will not be sufficient to enable us to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed consolidated financial statements are issued. There can be no assurances that we will be able to secure additional financing on acceptable terms. In the event that we do not secure additional financing, we will be forced to delay, reduce, or eliminate some or all of our discretionary spending, which could adversely affect our business prospects, ability to meet long-term liquidity needs and the ability to continue operations. Â  Cash Flows Â  Â Â  Six Months Ended June 30,Â  Â Â  2024Â Â  2023Â  Consolidated Statements of Cash Flow Data:Â  Â Â Â  Â Â  Net cash used in operating activitiesÂ $(7,699,000)Â  $(4,841,000) Net cash provided by (used in) investing activitiesÂ  Â 12,893,000Â Â  Â (4,332,000) Net cash provided by financing activitiesÂ Â 2,976,000Â Â  Â 6,268,000Â  Net increase (decrease) in cash and cash equivalentsÂ  Â 8,170,000Â Â  Â (2,905,000) Cash and cash equivalents, beginning of periodÂ Â 1,079,000Â Â  Â 5,672,000Â  Cash and cash equivalents, end of periodÂ  $9,249,000Â Â  $2,767,000Â  Â  Operating Activities Â  Net cash used in operating activities was $7.7 million for the six months ended June 30, 2024, and was primarily due to a net loss of $6.0 million, a decrease in accounts payable and accrued expenses of $1.2 million, and a decrease in the fair value of warrant liability of $775,000. Â  Net cash used in operating activities was $4.4 million for the six months ended June 30, 2023, and was primarily due to a net loss of $2.2 million, a decrease in the fair value of warrant liability of $4.3 million, and partially offset by stock compensation of $1.2 million and an increase in accounts payable and accrued expenses of $1.1 million. Â  Investing Activities Â  Net cash provided (used) in financing activities for the six months ended June 30, 2024 and 2023, resulted from proceeds from the sale, or (purchase), of short-term investments. Â  Financing Activities Â  Net cash provided by financing activities for the six months ended June 30, 2024 and 2023, resulted from proceeds from the issuance of common stock and warrants. Â  27 Â  Â  Working Capital Â  The following table summarizes total current assets, liabilities, and working capital for the periods ended June 30, 2024 and December 31, 2023: Â  Â Â  As ofÂ Â  Â Â  Â Â  June 30, 2024Â Â  December 31, 2023Â Â  Increase/(Decrease)Â  Current assetsÂ  $9,267,000Â Â  $14,056,000Â Â  $(4,789,000) Current liabilitiesÂ $3,579,000Â Â  $6,633,000Â Â  $(2,874,000) Working capitalÂ  $5,508,000Â Â  $7,423,000Â Â  $(1,915,000) Â  Off-Balance Sheet Arrangements Â  We have no off-balance sheet arrangements as of June 30, 2024. Â  Item 3. Quantitative and Qualitative Disclosures About Market Risk Â  Our Company qualifies as a smaller reporting company, as defined in 17 C.F.R. Â§229.10(f)(1) and is not required to provide information for this Item. Â  Item 4. Controls and Procedures Â  Evaluation of Disclosure Controls and Procedures Â  Our Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer evaluated the effectiveness of our â€œdisclosure controls and proceduresâ€ (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the United States Securities Exchange Act of 1934, as amended), as of June 30, 2024. Based on that evaluation, we have concluded that our disclosure controls and procedures were effective as of June 30, 2024. Â  Managementâ€™s Report on Internal Control Over Financial Reporting Â  Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, a companyâ€™s principal executive and principal accounting officers and effected by a companyâ€™s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with GAAP and includes those policies and procedures that: Â  Â  â— Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets Â  Â  Â  Â  â— Provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and Â  Â  Â  Â  â— Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements. Â  Inherent Limitations on the Effectiveness of Controls Â  Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected. Â  These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Â  Changes in Internal Control Over Financial Reporting Â  No changes in our internal controls over financial reporting were made during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Â  28 Â  Â  PART II. OTHER INFORMATION Â  Item 1. Legal Proceedings Â  Ohri Matter Â  On July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer.Â  In the Demand, the Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing that the Company may characterize Mr. Ohriâ€™s termination as â€œfor causeâ€ under his Employment Agreement, and that the Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohriâ€™s breaches.Â  In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohriâ€™s violations, and attorneysâ€™ fees and any forum and arbitration fees. Mr. Ohriâ€™s response to the Companyâ€™s Demand is due August 20, 2024.Â  At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. Â  Berk Matter Â  On November 14, 2023, former interim Chief Executive Officer, Dr. Gregory Berk filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that the Company discriminated and retaliated against Dr. Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act (â€œSOXâ€). The Parties are proceeding with litigating Dr. Berkâ€™s SOX claim. The Company is vigorously defending this matter and believes it to be without merit. At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any. Â  TWF Global Matter Â  On May 24, 2023, TWF Global, LLC (â€œTWFâ€) filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes (â€œNotesâ€) and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine if the Companyâ€™s shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and will reconsider the motion without further briefing upon the filing of a party affidavit. Z-One has filed a concurrent motion to dismiss of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Companyâ€™s shares of common stock. The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these claims. Â  Handelman Matter Â  On May 13, 2022, the Company made an arbitration demand upon Michael Handelman, our former Chief Financial Officer, asserting that he breached his fiduciary duty by misappropriating Company funds and shares of common stock, among other things. The Company seeks among other relief, monetary damages estimated at $470,000; the return of 13,902 shares of our common stock received without authorization; and an award of the Companyâ€™s attorneysâ€™ fees and any forum and arbitration fees. In May 2024, the Arbitrator issued the final award in favor of the Company which awarded us legal fees in the amount of $473,000 plus costs in the amount of $19,000 and the return of the disputed 13,902 shares of common stock, which were returned to the Company in June 2024. Â  29 Â  Â  Item 6. Exhibits Â  Exhibit Â  Description Â  Filed Herewith Â  Form Â  Number Â  SEC File No. Â  Filing Date Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  3.1 Â  Restated Certificate of Incorporation as filed in Delaware September 10, 1996 and as thereafter amended through March 1, 2002 Â  Â  Â  10-KSB Â  3.A Â  000-08092 Â  4/1/2002 3.2 Â  Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., dated February 9, 2011 Â  Â  Â  10-K Â  3.2 Â  000-08092 Â  3/31/2011 3.3 Â  Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of July 19, 2017 Â  Â  Â  8-K/A Â  3.1 Â  000-08092 Â  3/15/2018 3.4 Â  Certificate of Amendment to the Restated Certificate of Incorporation of GT Biopharma, Inc., effective as of February 10, 2021 Â  Â  Â  8-K Â  3.1 Â  001-40023 Â  2/11/2021 3.5 Â  Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective June 13, 2022 Â  Â  Â  10-K Â  3.5 Â  001-40023 Â  3/30/2023 3.6 Â  Certificate of Amendment to Restated Certificate of Incorporation of the Registrant effective February 1, 2024 Â  Â  Â  8-K Â  3.1 Â  001-40023 Â  2/1/2024 3.7 Â  Amended and Restated Bylaws of GT Biopharma, Inc. effective November 3, 2022 Â  Â  Â  8-K Â  3.1 Â  001-40023 Â  11/9/2022 4.1 Â  Certificate of Designation of Preferences, Rights and Limitations of Series J-1 Preferred Stock of GT Biopharma, Inc., dated April 3, 2019 Â  Â  Â  8-K Â  3.1 Â  000-08092 Â  4/4/2019 4.2 Â  Certificate of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc. dated April 3, 2019 Â  Â  Â  10-K Â  4.2 Â  001-40023 Â  4/16/2021 4.3 Â  Form of Common Warrant Â  Â  Â  8-K Â  4.1 Â  001-40023 Â  5/23/2024 10.1 Â  Amendment No. 1 to Settlement and Investment Agreement, dated as of April 25, 2024, by and between GT Biopharma, Inc. and Cytovance Biologics, Inc. Â  Â  Â  8-K Â  10.1 Â  001-40023 Â  4/30/2024 10.2 Â  Amended and Restated Exclusive Patent License Agreement with the Regents of the University of Minnesota, dated May 13, 2024 Â  X Â  Â  Â  Â  Â  Â  Â  Â  10.3 Â  Sponsored Research Agreement with the Regents of the University of Minnesota dated May 20, 2024 Â  X Â  Â  Â  Â  Â  Â  Â  Â  10.4 Â  Form of Securities Purchase Agreement, dated May 21, 2024 Â  Â  Â  8-K Â  10.1 Â  001-40023 Â  5/23/2024 10.5 Â  Form of Placement Agency Agreement, dated May 21, 2024 Â  Â  Â  8-K Â  10.2 Â  001-40023 Â  5/23/2024 10.6 Â  Employment Agreement between the Company and Alan Urban, dated as of June 7, 2024 Â  Â  Â  8-K Â  10.1 Â  001-40023 Â  6/7/2024 31.1 Â  Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended. Â  X Â  Â  Â  Â  Â  Â  Â  Â  31.2 Â  Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended. Â  X Â  Â  Â  Â  Â  Â  Â  Â  32.1 Â  Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002* Â  X Â  Â  Â  Â  Â  Â  Â  Â  32.2 Â  Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002* Â  X Â  Â  Â  Â  Â  Â  Â  Â  101.INS Â  Inline XBRL Instance Document. Â  X Â  Â  Â  Â  Â  Â  Â  Â  101.SCH Â  Inline XBRL Taxonomy Extension Schema Document. Â  X Â  Â  Â  Â  Â  Â  Â  Â  101.CAL Â  Inline XBRL Taxonomy Extension Calculation Linkbase Â  X Â  Â  Â  Â  Â  Â  Â  Â  101.DEF Â  Inline XBRL Taxonomy Extension Definition Linkbase Â  X Â  Â  Â  Â  Â  Â  Â  Â  101.LAB Â  Inline XBRL Taxonomy Extension Label Linkbase Document. Â  X Â  Â  Â  Â  Â  Â  Â  Â  101.PRE Â  Inline XBRL Taxonomy Extension Presentation Linkbase Â  X Â  Â  Â  Â  Â  Â  Â  Â  104 Â  Cover Page Interactive Data File (embedded within the Inline XBRL document) Â  X Â  Â  Â  Â  Â  Â  Â  Â  * This certification shall not be deemed â€œfiledâ€ for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that Section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act. Â  30 Â  Â  SIGNATURES Â  Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â  Â  GT BIOPHARMA, INC. Â  Â  Â  Dated: August 14, 2024 By: /s/ Michael Breen Â  Â  Michael Breen Â  Â  Interim Chief Executive Officer and Executive Chairman of the Board Â  Â  (Principal Executive Officer) Â  Dated: August 14, 2024 By: /s/ Alan Urban Â  Â  Alan Urban Â  Â  Chief Financial Officer & Secretary Â  Â  (Principal Financial and Accounting Officer) Â  31 Â  EX-10.2 2 ex10-2.htm Â  Exhibit 10.2 Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  EX-10.3 3 ex10-3.htm Â  Exhibit 10.3 Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  EX-31.1 4 ex31-1.htm Â  Exhibit 31.1 Â  CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT Â  I, Michael Breen, certify that: Â  Â  a. I have reviewed this report on Form 10-Q of GT Biopharma, Inc.; Â  Â  Â  Â  b. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â  Â  Â  Â  c. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â  Â  Â  Â  d. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: Â  Â  Â  i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â  Â  Â  Â  Â  Â  ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â  Â  Â  Â  Â  Â  iii) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â  Â  Â  Â  Â  Â  iv) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â  Â  e. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s Board of Directors (or persons performing the equivalent functions): Â  Â  Â  i) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â  Â  Â  Â  Â  Â  ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â  Date: August 14, 2024 By: /s/ Michael Breen Â  Name: Michael Breen Â  Title: Interim Chief Executive Officer and Â  Â  Executive Chairman of the Board Â  Â  (Principal Executive Officer) Â  Â  EX-31.2 5 ex31-2.htm Â  Exhibit 31.2 Â  CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT Â  I, Alan Urban, certify that: Â  Â  a. I have reviewed this report on Form 10-Q of GT Biopharma, Inc.; Â  Â  Â  Â  b. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â  Â  Â  Â  c. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â  Â  Â  Â  d. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have: Â Â Â i) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â Â Â Â Â ii) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â Â Â Â Â iii) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â Â Â Â Â iv) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â Â e. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s Board of Directors (or persons performing the equivalent functions): Â Â Â i) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â Â Â Â Â ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 14, 2024 By: /s/ Alan Urban Â Name: Alan Urban Â Title: Chief Financial Officer & Secretary Â Â (Principal Financial Officer) Â Â Â EX-32.1 6 ex32-1.htm Â Exhibit 32.1 Â CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Pursuant to 18 U.S.C. Â§ 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Michael Breen, Chief Executive Officer of GT Biopharma, Inc. (the â€œCompanyâ€), hereby certify that, to the best of my knowledge: Â (i) the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and Â (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Â Date: August 14, 2024 By: /s/ Michael Breen Â Name: Michael Breen Â Title: Interim Chief Executive Officer and Â Â Executive Chairman of the Board Â Â (Principal Executive Officer) Â Â Â EX-32.2 7 ex32-2.htm Â Exhibit 32.2 Â CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â Pursuant to 18 U.S.C. Â§ 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Alan Urbani, Chief Financial Officer and Principal Accounting Officer of GT Biopharma, Inc. (the â€œCompanyâ€), hereby certify that, to the best of my knowledge: Â (i) the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended June 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and Â (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. Â Date: August 14, 2024 By: /s/ Alan Urban Â Name: Alan Urban Â Title: Chief Financial Officer & Secretary Â Â (Principal Financial Officer) Â Â Â GRAPHIC 8 form10-q_002.jpg begin 644 form10-q_002.jpg

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~~:W K68E0:HN)#()4!,1(S@*QW#W7'>NGN? M&6>6GVE[/:$0RW5S!M)M?18'4G)^8?*6?G+!XEZKDB/Y/HDK[;RM[YQ9WPRZ
M30.+6XV+P;H<4$T(M'1*0:J8>J*+M@^9'S[[@P0U)XE\66"\$*F*^V< 8,/P;[0 G/X%F5T:2+D2"=5I5QLP5S06Y16H*6SA5'-V:O_OWV+E_VH!@J+8O M&KK(D@P4$SK8J6#D(LV@Z40LQ5P6>W>WZ#!$NJD8!DOTJ&GPFEXNJAYKJ5FOA MWBHK\E!%6J:#@[.1X3!3C73M&3T/,:.V[G*L,'Q.UJHKO@K)#;[FF!:P?G@ M;[*$-W%L6S%02[W/L+:]V.Q75LJ\.&EY7+P(/FQ%(CFXL8/;L5$>/EGQ#F6AP1=;?=V9P9[5%Y0OSRE"Y%E)Y+'J'7Y(&Z;A\S_J:F]#E9FL[BAM2:'2XY]
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`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`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`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`R`0OL;]^'9L]M8W0@I6ORA?:]^`!/0@BY2;HWCK$]Z M)@&(&=C'3^X[ZXKPH]ZPI\5OCA5YYN:]J^9N%PU8V7P&_J)(U'3ED\]2E__ M!25:_RF_GH__@J?;6O%BQ1B>\?H^1#G*C)NW(R/@K#C![?M5[_^HQ;]7]'&0D M</^OFHK5WJL!WZB5MA_B[2P2>&4S;K-8:U_A)"_#;JU?@BB0]HBZ+HZY7V8E] M^?_E>/IM22VS]7;F1)KM:5XXC]5R$#U0GZ7Q_.Q9C&<#.6I@_(@[=0?C$5U9D MAOUDY]?GP(^E*Q?>U[S]EUAA(HE6J)GB6B:B]U5G5.[[DS!MN`/_*]#8RG&I

" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** 5** "BBB@ HHHH **** "BBB@#__9 end EX-101.SCH 63 gtbp-20240630.xsd XBRL SCHEMA FILE 00000001 - Document - Coverlink:presentationLinklink:calculationLinklink:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheetslink:presentationLinklink:calculationLinklink:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)link:presentationLinklink:calculationLinklink:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operationslink:presentationLinklink:calculationLinklink:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Operations (Parenthetical)link:presentationLinklink:calculationLinklink:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)link:presentationLinklink:calculationLinklink:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flowslink:presentationLinklink:calculationLinklink:definitionLink 00000008 - Disclosure - Organization and Going Concern Analysislink:presentationLinklink:calculationLinklink:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policieslink:presentationLinklink:calculationLinklink:definitionLink 00000010 - Disclosure - Fair Value of Financial Instrumentslink:presentationLinklink:calculationLinklink:definitionLink 00000011 - Disclosure - Accounts Payable and Accrued Expenses, and Related Partylink:presentationLinklink:calculationLinklink:definitionLink 00000012 - Disclosure - Warrant Liabilitylink:presentationLinklink:calculationLinklink:definitionLink 00000013 - Disclosure - Stockholders' Equitylink:presentationLinklink:calculationLinklink:definitionLink 00000014 - Disclosure - Common Stock Warrants and Optionslink:presentationLinklink:calculationLinklink:definitionLink 00000015 - Disclosure - Commitments and Contingencieslink:presentationLinklink:calculationLinklink:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies)link:presentationLinklink:calculationLinklink:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables)link:presentationLinklink:calculationLinklink:definitionLink 00000018 - Disclosure - Fair Value of Financial Instruments (Tables)link:presentationLinklink:calculationLinklink:definitionLink 00000019 - Disclosure - Accounts Payable and Accrued Expenses, and Related Party (Tables)link:presentationLinklink:calculationLinklink:definitionLink 00000020 - Disclosure - Warrant Liability (Tables)link:presentationLinklink:calculationLinklink:definitionLink 00000021 - Disclosure - Common Stock Warrants and Options (Tables)link:presentationLinklink:calculationLinklink:definitionLink 00000022 - Disclosure - Organization and Going Concern Analysis (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 00000023 - Disclosure - Schedule of Anti-dilutive Securities (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 00000025 - Disclosure - Schedule of Estimated Fair Value of Financial Instrument (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000026 - Disclosure - Schedule of Fair Value Hierarchy Financial Assets (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000027 - Disclosure - Schedule of Accounts Payable (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000028 - Disclosure - Schedule of Accrued Expenses (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000029 - Disclosure - Schedule of Accounts Payable to Related Party (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000030 - Disclosure - Schedule of Derivative Liabilities Assumptions (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000031 - Disclosure - Schedule of Derivative Liability Transactions (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000032 - Disclosure - Warrant Liability (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 00000033 - Disclosure - Stockholders' Equity (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 00000034 - Disclosure - Schedule of Warrant Activity (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000035 - Disclosure - Schedule of Warrants Outstanding and Exercisable

~~***(Details)link:presentationLinklink:calculationLinklink:definitionLink 00000036 - Disclosure - Schedule of Options Activity (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000037 - Disclosure - Schedule of Options Outstanding and Options Exercisable (Details)link:presentationLinklink:calculationLinklink:definitionLink 00000038 - Disclosure - Common Stock Warrants and Options (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 00000039 - Disclosure - Commitments and Contingencies (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink EX-101.CAL 64 gtbp-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 65 gtbp-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 66 gtbp-20240630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series C Preferred Stock [Member] Statement of Income Location, Balance [Axis] Selling, General and Administrative Expenses [Member] Title and Position [Axis] Officers, Employees and Directors [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Statistical Measurement [Axis] Maximum [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Warrant [Member] Financial Instrument [Axis] Short-Term Investments [Member] Investment Type [Axis] Money Market Funds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] US Treasury Securities [Member] US Treasuries [Member] US Government Corporations and Agencies Securities [Member] Related and Nonrelated Parties [Axis] Cytovance Biologics Inc [Member] Common Warrants [Member] Placement Agent Warrant [Member] Purchase Warrant [Member] 2020 Warrants [Member] Debt Instrument [Axis] 2023 Warrants [Member] 2020 Warrants [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Term [Member] Minimum [Member] Measurement Input, Expected Dividend Rate [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Purchase Agreement [Member] 2024 Common Warrants [Member] 2024 Placement Agent Warrant [Member] 2024 Common Shares And 2024 Common Warrants [Member] Prefunded Warrant [Member] 2023 Common Warrants [Member] 2023 Placement Agent Warrant [Member] Class of Warrant or Right [Axis] Pre Funded Warrants [Member] 2023 Common Shares And 2023 Common Warrants [Member] Pre Funded Warrants And 2023 Common Warrants [Member] Common Warrant and Placement Agent Warrant [Member] Board Of Directors Employees And Consultants [Member] Series K Preferred Stocks [Member] Series K Preferred Stock [Member] Warrants [Member] Award Type [Axis] Omnibus Incentive Plan [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Range Six [Member] Investment, Name [Axis] Scientific Research Agreement [Member] Sponsored Research Agreement [Member] 2016 Patent Exclusive License Agreement [Member] Award Date [Axis] 2017 through 2012 [Member] 2022 [Member] 2025 [Member] 2027 [Member] 2021 Patent License Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Short-term investments Prepaid expenses and other current assets Total Current Assets Operating lease right-of-use asset TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable Accrued expenses Current operating lease liability Warrant liability Total Current Liabilities Stockholders' Equity Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively Common stock, par value $0.001, 250,000,000 shares authorized, 2,234,328 and 1,380,633 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Additional paid in capital Accumulated deficit Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Statement [Table] Statement [Line Items] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses: Research and development Selling, general and administrative (including $120,000 and $398,000 from stock compensation granted to officers, directors, and employees during the three months ended June 30, 2024 and 2023, respectively, and $222,000 and $905,000 for the six months ended June 30, 2024 and 2023, respectively) Loss from Operations Other Income (Expense) Interest income Interest expense Change in fair value of warrant liability Gain on extinguishment of debt Unrealized gain (loss) on marketable securities Other Total Other Income Net Loss Net Loss Per Share - Basic Net Loss Per Share - Diluted Weighted average common shares outstanding - basic Weighted average common shares outstanding - diluted Share-based payment arrangement, expense Balance Balance, shares Issuance of common stock and warrants for cash Issuance of common stock and warrants for cash Cancellation of common stock issued to prior CFO Cancellation of common stock issued to prior CFO, shares Issuance of common shares to settle vendor payable Issuance of common shares to settle vendor payable Fair value of vested stock options Net loss Private placement of common stock Issuance of common stock for exercise of prefunded warrants Issuance of common stock for exercise of Prefunded Warrants, shares Initial recognition of fair value of warrant liability Issuance of common shares for services Private placement of common stock, shares Issuance of common shares for services, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation - services Stock based compensation - officers, directors, and employees Change in fair value of warrant liability Gain on extinguishment of share settled debt Change in operating lease right-of-use assets Unrealized loss (gain) on marketable securities Changes in operating assets and liabilities: Decrease in prepaid expenses Increase (Decrease) in accounts payable and accrued expenses (Decrease) in operating lease liability Net Cash Used in Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES Sale (purchase) of investments Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of common stock and warrants, net Net Cash Provided by Financing Activities Net Increase (Decrease) in Cash and Cash Equivalents Cash at Beginning of Period Cash at End of Period SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid during the year for: Interest Income taxes SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES Initial recognition of fair value of warrant liability Fair value of common stock issued to a vendor to settle accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Going Concern Analysis Accounting Policies [Abstract] Summary of Significant Accounting Policies Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Payables and Accruals [Abstract] Accounts Payable and Accrued Expenses, and Related Party Warrant Liability Warrant Liability Equity [Abstract] Stockholders' Equity Common Stock Warrants And Options Common Stock Warrants and Options Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Basis of Presentation and Principles of Consolidation Accounting Estimates Cash Equivalents and Short-Term Investments Fair Value of Financial Instruments Warrant Liability Common Stock (February 2024 Reverse Stock Split) Stock-Based Compensation Research and Development Expenses Leases Net Loss Per Share Concentration Segments Recent Accounting Pronouncements Schedule of Anti-dilutive Securities Schedule of Estimated Fair Value of Financial Instrument Schedule of Fair Value Hierarchy Financial Assets Schedule of Accounts Payable Schedule of Accrued Expenses Schedule of Accounts Payable to Related Party Short-Term Debt [Table] Short-Term Debt [Line Items] Schedule of Derivative Liabilities Assumptions Schedule of Derivative Liability Transactions Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Schedule of Warrant Activity Schedule of Warrants Outstanding and Exercisable Schedule of Options Activity Schedule of Options Outstanding and Options Exercisable Net loss Net cash used in operating activities Cash and cash equivalents, and short-term investments Working capital Stockholders equity Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total anti-dilutive securities Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Cash equivalents Warrant liability Revers stock split ratio Cash, FDIC insured amount Fair Value, off-Balance-Sheet Risk [Table] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Cost Unrealized gains Unrealized losses Fair value Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total financial assets Accounts payable to Cytovance, a related party Other accounts payable Total accounts payable Accrued expenses, University of Minnesota Other accrued expenses Total accrued expenses Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Beginning balance Invoices, net Payments in cash Payments in common stock, at fair value Ending balance Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants measurement input Expected life (in years) Fair value of warrants Schedule Of Derivative Liability Transactions Beginning balance Issuance of warrants at fair value Change in fair value Extinguishment Ending balance Warrants to purchase Volatility amount utilized in the value calculation percentage Warrant fair value Issued warrants of common stock Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Common stock par value Proceeds from private placement Other offering expenses Direct offering Purchase of warrants Warrant exercise price Price per share Shares issued Shares issued, value Preferred stock shares designated Convertible shares issuable Schedule Of Warrant Activity Warrants outstanding, beginning balance Weighted average exercise price, beginning balance Number of warrants, granted Weighted average exercise price, granted Number of warrants, forfeited/cancelled Weighted average exercise price, forfeited/cancelled Number of warrants, exercised Weighted average exercise price, exercised Warrants outstanding, ending balance Weighted average exercise price, ending balance Warrants exercisable, ending balance Weighted average exercise price, exercisable, ending balance Range of exercise price Number of warrants outstanding Warrants outstanding, weighted average remaining contractual life (years) Warrants outstanding, weighted average exercise price Range of exercise price Warrants exercisable, weighted average exercise price Schedule Of Options Activity Number of options outstanding, beginning Weighted-Average Exercise Price, beginning Number of options, granted Weighted-Average Exercise Price, granted Number of options, forfeited/cancelled Weighted-Average Exercise Price, forfeited/cancelled Number of options, exercised Weighted-Average Exercise Price, exercised Number of options outstanding, ending Weighted-Average Exercise Price, ending Number of options outstanding exercisable Weighted-Average Exercise Price,exercisable, ending Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Range of excercise price Options***~~

~~outstanding Options outstanding, weighted average remaining contractual life (years) Options outstanding, weighted average exercise price Options outstanding intrinsic value Awards granted plan Share-based compensation arrangement by share-based payment award, options, exercisable, weighted average remaining contractual term Selling, general and administrative expense Purchase an aggregate Exercise price Stock options expire Fair value Purchase an aggregate Loss Contingencies [Table] Loss Contingencies [Line Items] Loss Contingency, Damages Sought, Value Treasury Stock, Common, Shares Legal fee Shares return, value Shares return Equity method investment, ownership percentage Accounts payable, current Beneficial ownership percentage Stock issued during period, value, issued for services Aggregate research and development expense Research and development expense Unbilled and unaccrued amounts Proceeds from upfront amount Maintenance fee Net sales percentage Annual royalty payments Performance milestone payments Sales milestone payments Gross sales Sales revenue Cumulative gross sales [custom:RoyaltyExpenseYearOne] [custom:RoyaltyExpenseYearTwoThroughFive] [custom:RoyaltyExpenseYearAfterSix] Upfront license fee License maintenance fee, receivable Warrant liability non-current. Working capital. Warrant liabilities noncurrent. Warrant Liability Policy [Text Block] Officers, Employees and Directors [Member] Stock based compensation common shares for services. Stock based compensation officers employees and board of directors. Cash paid during the year for [Abstract] US Treasuries [Member] Stock issued during period value cancellation of cmmon stock previously issued. Stock issued during period shares cancellation of cmmon stock previously issued. Stock issued during period shares common shares to settle vendor payable. Stock issued during period value issuance of common stock and warrants for cash. Stock issued during period value issuance of common stock for exercise of prefunded warrants Stock issued during period share issuance of common stock for exercise of prefunded warrants Accrued liabilities. Schedule of Accounts Payable and Related Party [Table Text Block] Cytovance Biologics Inc [Member] Repayments of related party common stock. Warrant Liability [Text Block] Common Warrants [Member] Placement Agent Warrant [Member] Purchase Warrant [Member] 2023 Warrants [Member] 2020 Warrants [Member] 2020 Warrants [Member] Warrant liabilities current. Extinguishment of warrant. Purchase Agreement [Member] Common Shares and Common Warrants [Member] Prefunded Warrant [Member] Pre Funded Warrants [Member] Pre-Funded Warrants and Common Warrants [Member] Common Warrant and Placement Agent Warrant [Member] Board Of Directors Employees And Consultants [Member] Series K Preferred Stocks [Member] Series K Preferred Stock [Member] Common Stock Warrants and Options [Text Block] Share Based Compensation Arrangements By Share Based Payment Award Non Options Equity Instruments Exercisable. Share based compensation arrangements by share based payment award non options outstanding weighted average exercise price. Share based compensation arrangement by share based payment award non options granted weighted average exercise price. Share based compensation arrangement by share based payment award non options forfeitures and expirations weighted average exercise price. Share based compensation arrangement by share based payment award non options exercised weighted average exercise price. Share Based Compensation Arrangement By ShareBased Payment Award Non Options Exercisable Weighted Average Exercise Price. Schedule of warrants oustanding and exercisable [Table Text Block] Warrants [Member] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Range Six [Member] Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price. Share based compensation arrangement by share based payment award non options equity instruments exercisable weighted average exercise price. Omnibus Incentive Plan [Member] Share based compensation shares authorized under stock option plans exercise price. Upfront license fee. 2021 Patent License Agreement [Member] License maintenance fee, receivable. Royalty fee percentage. Performance milestone payments. Sales milestone payments. Gross sales. Sales revenue. Cummulative gross sales. Equity method investment beneficial ownership percentage. Scientific Research Agreement [Member] Sponsored Research Agreement [Member] Received upfront payment. 2016 Patent License Agreement [Member] 2017 through 2012 [Member] 2022 [Member] 2025 [Member] 2027 [Member] Royalty expense year one. Royalty expense year two through five. Royalty expense year after six. Stock issued during period value common shares to settle vendor payable. Stock issued during period share issuance of common stock and warrants for cash. Common Stock Reverse Stock Split [Policy Text Block] 2024 Common Warrants [Member] 2024 Placement Agent Warrant [Member] 2024 Common Shares And 2024 Common Warrants [Member] 2023 Common Warrants [Member] 2023 Placement Agent Warrant [Member] 2023 Common Shares And 2023 Common Warrants [Member] Pre Funded Warrants And 2023 Common Warrants [Member] 2020 Warrants [Member] [Default Label] Assets, Current Assets Liabilities, Current Liabilities and Equity Operating Income (Loss) Interest Expense, Nonoperating Nonoperating Income (Expense) Shares, Outstanding StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable Adjustments to Additional Paid in Capital, Warrant Issued Debt Securities, Unrealized Gain (Loss) Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Payments for (Proceeds from) Investments Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents WarrantLiabilityTextBlock Equity [Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] WarrantLiabilityPolicyTextBlock WarrantLiabilitiesNoncurrent Debt Securities, Available-for-Sale, Unrealized Loss Repayments of Related Party Debt WarrantLiabilitiesCurrent Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture EX-101.PRE 67 gtbp-20240630_pre.xml XBRL PRESENTATION FILE XML 69 R1.htm IDEA: XBRL DOCUMENT~~

~~Cover - shares~~ ~~6 Months Ended~~
~~Jun. 30, 2024~~
~~Aug. 10, 2024~~

~~Cover [Abstract] Document Type 10-Q Amendment Flag false Document Quarterly Report true Document Transition Report false Document Period End Date Jun. 30, 2024 Document Fiscal Period Focus Q2 Document Fiscal Year Focus 2024 Current Fiscal Year End Date --12-31 Entity File Number 001-40023 Entity Registrant Name GT BIOPHARMA, INC. Entity Central Index Key 0000109657 Entity Tax Identification Number 94-1620407 Entity Incorporation, State or Country Code DE Entity Address, Address Line One 315 Montgomery Street Entity Address, Address Line Two 10th Floor Entity Address, City or Town San Francisco Entity Address, State or Province CA Entity Address, Postal Zip Code 94104 City Area Code 415 Local Phone Number 919-4040 Title of 12(b) Security Common Stock, $0.001 par value per share Trading Symbol GTBP Security Exchange Name NASDAQ Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Non-accelerated Filer Entity Small Business true Entity Emerging Growth Company false Entity Shell Company false Entity Common Stock, Shares Outstanding 2,234,328~~

~~- Definition~~

~~Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration~~

~~- Definition~~

~~Area code of city~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration~~

~~- Definition~~

~~Cover page.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration~~

~~- Definition~~

~~End date of current fiscal year in the format --MM-DD.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_CurrentFiscalYearEndDate Namespace Prefix:dei_ Data Type:xbrli:gMonthDayItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_DocumentFiscalPeriodFocus Namespace Prefix:dei_ Data Type:dei:fiscalPeriodItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_DocumentFiscalYearFocus Namespace Prefix:dei_ Data Type:xbrli:gYearItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_DocumentPeriodEndDate Namespace Prefix:dei_ Data Type:xbrli:dateItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Boolean flag that is true only for a form used as an quarterly report.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a~~

~~+ Details~~
~~Name:dei_DocumentQuarterlyReport Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Boolean flag that is true only for a form used as a transition report.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1~~

~~+ Details~~
~~Name:dei_DocumentTransitionReport Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_DocumentType Namespace Prefix:dei_ Data Type:dei:submissionTypeItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Address Line 1 such as Attn, Building Name, Street Name~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityAddressAddressLine1 Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Address Line 2 such as Street or Suite number~~

~~+ References~~

~~No definition available.~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityAddressAddressLine2 Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Name of the City or Town~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityAddressCityOrTown Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Code for the postal or zip code~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityAddressPostalZipCode Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Name of the state or province.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityAddressStateOrProvince Namespace Prefix:dei_ Data Type:dei:stateOrProvinceItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2~~

~~+ Details~~
~~Name:dei_EntityCentralIndexKey Namespace Prefix:dei_ Data Type:dei:centralIndexKeyItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityCommonStockSharesOutstanding Namespace Prefix:dei_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

~~- Definition~~

~~Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityCurrentReportingStatus Namespace Prefix:dei_ Data Type:dei:yesNoItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Indicate if registrant meets the emerging growth company criteria.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2~~

~~+ Details~~
~~Name:dei_EntityEmergingGrowthCompany Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityFileNumber Namespace Prefix:dei_ Data Type:dei:fileNumberItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2~~

~~+ Details~~
~~Name:dei_EntityFilerCategory Namespace Prefix:dei_ Data Type:dei:filerCategoryItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Two-character EDGAR code representing the state or country of incorporation.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:dei_EntityIncorporationStateCountryCode Namespace Prefix:dei_ Data Type:dei:edgarStateCountryItemType Balance Type:na Period Type: duration~~

~~- Definition~~

~~Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405~~

~~+ Details~~
~~Name:dei_EntityInteractiveDataCurrent Namespace Prefix:dei_ Data Type:dei:yesNoItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2~~

~~+ Details~~
~~Name:dei_EntityRegistrantName Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2~~

~~+ Details~~
~~Name:dei_EntityShellCompany Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Indicates that the company is a Smaller Reporting Company (SRC).~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2~~

~~+ Details~~

~~Name:dei_EntitySmallBusiness Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2~~

~~+ Details~~

~~Name:dei_EntityTaxIdentificationNumber Namespace Prefix:dei_ Data Type:dei:employerIdItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Local phone number for entity.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_LocalPhoneNumber Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Title of a 12(b) registered security.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b~~

~~+ Details~~

~~Name:dei_Security12bTitle Namespace Prefix:dei_ Data Type:dei:securityTitleItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Name of the Exchange on which a security is registered.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1~~

~~+ Details~~

~~Name:dei_SecurityExchangeName Namespace Prefix:dei_ Data Type:dei:edgarExchangeCodeItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Trading symbol of an instrument as listed on an exchange.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_TradingSymbol Namespace Prefix:dei_ Data Type:dei:tradingSymbolItemType Balance Type:na Period Type:duration XML 70 R2.htm IDEA: XBRL DOCUMENT~~

~~Condensed Consolidated Balance Sheets - USD ($)Jun. 30, 2024Dec. 31, 2023Current assets Cash and cash equivalents$ 9,249,000$ 1,079,000Short-term investments12,893,000Prepaid expenses and other current assets18,00084,000Total Current Assets9,267,00014,056,000Operating lease right-of-use asset53,000TOTAL ASSETS9,267,00014,109,000Current liabilities Accounts payable1,717,0004,328,000Accrued expenses1,765,0001,195,000 Current operating lease liability58,000Warrant liability277,0001,052,000Total Current Liabilities3,759,0006,633,000Stockholders’ Equity Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively1,0001,000Common stock, par value $0.001, 250,000,000 shares authorized, 2,234,328 and 1,380,633 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively2,0001,000Additional paid in capital693,546,000689,539,000Accumulated deficit(688,041,000)(682,065,000)Total Stockholders’ Equity5,508,0007,476,000TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 9,267,000$ 14,109,000~~

~~- Definition~~

~~Warrant liability non-current.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_WarrantLiabilityNonCurrent Namespace Prefix:GTBP_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- Definition~~

~~Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10~~

~~+ Details~~

~~Name:us-gaap_AccountsPayableCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- Definition~~

~~Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~

~~Name:us-gaap_AccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- Definition~~

~~Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~

~~Name:us-gaap_AdditionalPaidInCapital Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- Definition~~

~~Amount of asset recognized for present right to economic benefit.~~

~~***+ References***~~

~~***Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1***~~

~~***+ Details***~~

~~***Name:us-gaap_Assets Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant***~~

~~***- Definition***~~

~~***Amount of asset recognized for present right to economic benefit, classified as current.***~~

~~***+ References***~~

~~***Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20:***~~

***http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7***

~~+ Details~~
~~Name:us-gaap_AssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- References~~

~~No definition available.~~

~~+ Details~~
~~Name:us-gaap_AssetsCurrentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4~~

~~+ Details~~
~~Name:us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- Definition~~

~~Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1~~

~~+ Details~~

~~Name:us-gaap_CommonStockValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- Definition~~

~~Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~

~~Name:us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: instant~~

~~- Definition~~

***~~Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.~~***

***~~+ References~~***

***~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7~~***

~~***+ Details***~~
~~***Name:us-gaap_LiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant***~~

~~***- References***~~

~~***No definition available.***~~

~~***+ Details***~~
~~***Name:us-gaap_LiabilitiesCurrentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.***~~

~~***+ References***~~

~~***Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1***~~

~~***+ Details***~~
~~***Name:us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant***~~

~~***- Definition***~~

~~***Amount of lessee's right to use underlying asset under operating lease.***~~

~~***+ References***~~

~~***Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1***~~

~~*+ Details*~~

~~*Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant*~~

~~*- Definition*~~

~~*Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.*~~

~~*+ References*~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1*~~

~~*+ Details*~~

~~*Name:us-gaap_PreferredStockValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant*~~

~~*- Definition*~~

~~*Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.*~~

~~*+ References*~~

~~*Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1*~~

~~*+ Details*~~

~~*Name:us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant*~~

~~*- Definition*~~

~~*Amount of accumulated undistributed earnings (deficit).*~~

~~*+ References*~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1*~~

~~*+ Details*~~

~~*Name:us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: instant*~~

~~*- Definition*~~

~~*Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.*~~

~~*+ References*~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1*~~

~~***+ Details***~~

~~***Name:us-gaap_ShortTermInvestments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant***~~

~~***- Definition***~~

~~***Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2***~~

~~+ Details~~

~~Name:us-gaap_StockholdersEquity~~ ~~Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- References~~

~~No definition available.~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_StockholdersEquityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 71 R3.htm IDEA: XBRL DOCUMENT~~

~~Condensed Consolidated Balance Sheets (Parenthetical) - $ / sharesJun. 30, 2024Dec. 31, 2023Preferred stock, par value$ 0.01$ 0.01Preferred stock, shares authorized15,000,00015,000,000Preferred stock, shares issued 96,230Preferred stock, shares outstanding 96,230Common stock, par value $ 0.001$ 0.001Common stock, shares authorized250,000,000250,000,000Common stock, shares issued2,234,3281,380,633Common stock, shares outstanding2,234,3281,380,633Series C Preferred Stock [Member] Preferred stock, par value$ 0.01$ 0.01Preferred stock, shares issued96,23096,230 Preferred stock, shares outstanding96,23096,230~~

~~- Definition~~

~~Face amount or stated value per share of common stock.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~

~~Name:us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant~~

~~- Definition~~

~~The maximum number of common shares permitted to be issued by an entity's charter and bylaws.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1~~

~~+ Details~~

~~Name:us-gaap_CommonStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

~~- Definition~~

~~Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~

~~Name:us-gaap_CommonStockSharesIssued Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

~~- Definition~~

~~Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name~~

~~***https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3***~~

~~***+ Details***~~

~~***Name:us-gaap_CommonStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant***~~

~~***- Definition***~~

~~***Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13***~~

~~***+ Details***~~

~~***Name:us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period***~~

~~Type:instant~~

~~- Definition~~

~~The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1~~

~~+ Details~~

~~Name:us-gaap_PreferredStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

~~- Definition~~

~~Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13~~

~~+ Details~~

~~Name:us-gaap_PreferredStockSharesIssued Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

~~- Definition~~

~~Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3~~

~~+ Details~~

~~Name:us-gaap_PreferredStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

~~- Details~~

~~Name:us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 72 R4.htm IDEA: XBRL DOCUMENT~~

~~Condensed Consolidated Statements of Operations - USD ($)3 Months Ended6 Months Ended~~

~~Jun. 30, 2024~~

~~Jun. 30, 2023~~

~~Jun. 30, 2024~~

~~Jun. 30, 2023~~

~~Operating Expenses:    Research and development$ 1,784,000$ 2,095,000$ 2,561,000$ 3,745,000Selling, general and administrative (including $120,000 and $398,000 from stock compensation granted to officers, directors, and employees during the three months ended June 30, 2024 and 2023, respectively, and $222,000 and $905,000 for the six months ended June 30, 2024 and 2023, respectively)2,122,0001,526,0004,436,0003,541,000Loss from Operations(3,906,000)(3,621,000)(6,997,000)(7,286,000)Other Income (Expense)    Interest income105,000220,000247,000384,000Interest expense(1,000)(213,000)Change in fair value of warrant liability117,0001,387,000775,0004,311,000Gain on extinguishment of debt14,000547,000 Unrealized gain (loss) on marketable securities1,0009,000(1,000)38,000Other(27,000) Total Other Income196,0001,629,0001,021,0005,067,000Net Loss$ (3,710,000)$ (1,992,000)$ (5,976,000)$ (2,219,000)Net Loss Per Share - Basic$ (2.17)$ (1.49)$ (3.86)$ (1.68)Net Loss Per Share - Diluted$ (2.17)$ (1.49)$ (3.86)$ (1.68)Weighted average common shares outstanding - basic1,711,9551,339,0871,546,2941,321,069Weighted average common shares outstanding - diluted1,711,9551,339,0871,546,2941,321,069~~

~~- Definition~~

~~The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7~~

***~~+ Details~~***

***~~Name:us-gaap_EarningsPerShareBasic Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration~~***

***~~- Definition~~***

***~~The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.~~***

*+ References*

~~*Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7*~~

~~+ Details~~

~~Name:us-gaap_EarningsPerShareDiluted Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~*Amount of expense (income) related to adjustment to fair value of warrant liability.*~~

~~+ References~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13*~~

~~+ Details~~

~~Name:us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration~~

~~- Definition~~

~~*Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.*~~

~~+ References~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4*~~

~~+ Details~~

~~Name:us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration~~

~~- Definition~~

~~Amount of interest expense classified as nonoperating.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2~~

~~+ Details~~

~~Name:us-gaap_InterestExpenseNonoperating Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Amount of interest income earned from interest bearing assets classified as other.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_InterestIncomeOther Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Amount of unrealized gain (loss) on investment in marketable security.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2~~

~~+ Details~~

~~Name:us-gaap_MarketableSecuritiesUnrealizedGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI~~

***SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1***

~~***+ Details***~~

~~*Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration*~~

~~*- Definition*~~

~~*The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).*~~

~~*+ References*~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2*~~

~~*+ Details*~~

~~*Name:us-gaap_NonoperatingIncomeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration*~~

~~*- References*~~

~~*No definition available.*~~

~~*+ Details*~~

~~*Name:us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration*~~

~~*- References*~~

~~*No definition available.*~~

~~*+ Details*~~

~~*Name:us-gaap_OperatingExpensesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration*~~

~~*- Definition*~~

~~*The net result for the period of deducting operating expenses from operating revenues.*~~

~~*+ References*~~

~~*Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31*~~

***~~+ Details~~***

***~~Name:us-gaap_OperatingIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~***

***~~- Definition~~***

***~~Amount of income (expense) related to nonoperating activities, classified as other.~~***

***~~+ References~~***

***~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2~~***

***~~+ Details~~***

***~~Name:us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration~~***

***~~- Definition~~***

***~~Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.~~***

***~~+ References~~***

***~~Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1~~***

~~+ Details~~

~~Name:us-gaap_ResearchAndDevelopmentExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration~~

~~- Definition~~

~~The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2~~

~~+ Details~~

~~Name:us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16~~

~~+ Details~~

~~Name:us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10~~

~~+ Details~~

~~Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration XML 73 R5.htm IDEA: XBRL DOCUMENT~~

~~Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)3 Months Ended6 Months Ended~~
~~Jun. 30, 2024~~
~~Jun. 30, 2023~~
~~Jun. 30, 2024~~
~~Jun. 30, 2023~~
~~Selling, General and Administrative Expenses [Member] | Officers, Employees and Directors [Member]  Share-based payment arrangement, expense~~
~~$ 120,000$ 398,000$ 222,000$ 905,000~~

~~- Definition~~

~~Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2~~

~~+ Details~~
~~Name:us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Details~~
~~Name:us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~
~~- Details~~
~~Name:srt_TitleOfIndividualAxis=GTBP_OfficersEmployeesAndDirectorsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 74~~
~~R6.htm IDEA: XBRL DOCUMENT~~
~~Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total~~
~~Balance at Dec. 31, 2022$ 1,000$ 1,000$ 686,200,000$ (674,467,000)$ 11,734,000Balance, shares at Dec. 31, 202296,2301,090,748  Issuance of common shares to settle vendor payable591,000591,000Issuance of common shares to settle vendor payable 44,793  Fair value of vested stock options 905,000905,000Net loss (2,219,000)(2,219,000)Private placement of common stock6,268,0006,268,000Issuance of common stock for exercise of prefunded warrants Issuance of common stock for exercise of Prefunded Warrants, shares 96,666  Initial recognition of fair value of warrant liability (5,831,000)(5,831,000)Issuance of common shares for services315,000315,000Private placement of common stock, shares 120,000  Issuance of common shares for services, shares 2,449  Balance at Jun. 30, 2023$ 1,000$ 1,000688,448,000(676,687,000)11,763,000Balance, shares at Jun. 30, 2023 96,2301,354,656  Balance at Mar. 31, 2023$ 1,000$ 1,000687,746,000(682,065,000)13,053,000Balance, shares at Mar. 31, 202396,2301,229,424  Issuance of common shares to settle vendor payable304,000304,000Issuance of common shares to settle vendor payable 28,566  Fair value of vested stock options398,000398,000Net loss (1,992,000)(1,992,000)Private placement of common stock Issuance of common stock for exercise of prefunded warrants Issuance of common stock for exercise of Prefunded Warrants, shares 96,666  Initial recognition of fair value of warrant liability Issuance of common shares for services Balance at Jun. 30, 2023$ 1,000$ 1,000688,448,000(676,687,000)11,763,000Balance, shares at Jun. 30, 202396,230 1,354,656  Balance at Dec. 31, 2023$ 1,000$ 1,000689,539,000(682,065,000)7,476,000Balance, shares at Dec. 31, 202396,2301,380,633  Issuance of common stock and warrants for cash$ 1,0002,975,0002,976,000Issuance of common stock and warrants for cash 740,000  Cancellation of common stock issued to prior CFO Cancellation of common stock issued to prior CFO, shares (13,902)  Issuance of common shares to settle vendor payable 810,000810,000Issuance of common shares to settle vendor payable 127,597  Fair value of vested stock options222,000222,000Net loss (5,976,000) (5,976,000)Issuance of common shares for services  1,500,000Balance at Jun. 30, 2024$ 1,000$ 2,000693,546,000(688,041,000)5,508,000Balance, shares at Jun. 30, 202496,2302,234,328  Balance at Mar. 31, 2024$ 1,000$ 1,000689,641,000(684,331,000)5,312,000Balance, shares at Mar. 31, 2024 96,2301,380,633  Issuance of common stock and warrants for cash$ 1,0002,975,0002,976,000Issuance of common stock and warrants for cash 740,000  Cancellation of common stock issued to prior CFO Cancellation of common stock issued to prior CFO, shares (13,902)  Issuance of common shares to settle vendor payable810,000810,000Issuance of common shares to settle vendor payable 127,597  Fair value of vested stock options120,000120,000 Net loss (3,710,000)(3,710,000)Balance at Jun. 30, 2024$ 1,000$ 2,000$ 693,546,000$ (688,041,000)$ 5,508,000Balance, shares at Jun. 30, 202496,230 2,234,328~~
~~- Definition~~

~~Stock issued during period share issuance of common stock and warrants for cash.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockAndWarrantsForCash Namespace Prefix:GTBP_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Stock issued during period share issuance of common stock for exercise of prefunded warrants~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:GTBP_StockIssuedDuringPeriodShareIssuanceOfCommonStockForExerciseOfPrefundedWarrants Namespace Prefix:GTBP_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Stock issued during period shares cancellation of cmmon stock previously issued.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_StockIssuedDuringPeriodSharesCancellationOfCommonStockPreviouslyIssued Namespace Prefix:GTBP_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Stock issued during period shares common shares to settle vendor payable.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_StockIssuedDuringPeriodSharesCommonSharesToSettleVendorPayable Namespace Prefix:GTBP_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Stock issued during period value cancellation of cmmon stock previously issued.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_StockIssuedDuringPeriodValueCancellationOfCommonStockPreviouslyIssued Namespace Prefix:GTBP_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Stock issued during period value common shares to settle vendor payable.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_StockIssuedDuringPeriodValueCommonSharesToSettleVendorPayable Namespace Prefix:GTBP_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Stock issued during period value issuance of common stock and warrants for cash.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsForCash Namespace Prefix:GTBP_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Stock issued during period value issuance of common stock for exercise of prefunded warrants~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_StockIssuedDuringPeriodValueIssuanceOfCommonStockForExerciseOfPrefundedWarrants Namespace Prefix:GTBP_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2~~

~~+ Details~~

~~Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type: credit Period Type:duration~~

~~- Definition~~

~~The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1~~

~~***+ Details***~~

~~***Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration***~~

~~***- Definition***~~

~~***Number of shares issued which are neither cancelled nor held in the treasury.***~~

~~***+ References***~~

~~***No definition available.***~~

~~***+ Details***~~

~~***Name:us-gaap_SharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant***~~

~~***- Definition***~~

~~***Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.***~~

~~***+ References***~~

~~***No definition available.***~~

~~***+ Details***~~

~~***Name:us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***Number of new stock issued during the period.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -***~~

~~*http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1*~~

~~*+ Details*~~

~~*Name:us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration*~~

~~*- Definition*~~

~~*Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.*~~

~~*+ References*~~

~~*No definition available.*~~

~~*+ Details*~~

~~*Name:us-gaap_StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration*~~

~~*- Definition*~~

~~*Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.*~~

~~*+ References*~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI*~~

~~https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1~~

~~+ Details~~

~~Name:us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-~~

***gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2***

~~+ Details~~

~~Name:us-gaap_StockholdersEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant XML 75~~

~~R7.htm IDEA: XBRL DOCUMENT~~

~~Condensed Consolidated Statements of Cash Flows - USD ($)3 Months Ended6 Months Ended12 Months Ended~~
~~Jun. 30, 2024~~
~~Jun. 30, 2023~~
~~Jun. 30, 2024~~
~~Jun. 30, 2023~~
~~Dec. 31, 2023~~

~~CASH FLOWS FROM OPERATING ACTIVITIES Net loss$ (3,710,000)$ (1,992,000)$ (5,976,000)$ (2,219,000) Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation - services 315,000 Stock based compensation - officers, directors, and employees 222,000905,000 Change in fair value of warrant liability(117,000)(1,387,000)(775,000)(4,311,000) Gain on extinguishment of share settled debt (14,000)(547,000) Change in operating lease right-of-use assets 53,00051,000 Unrealized loss (gain) on marketable securities (1,000)(38,000) Changes in operating assets and liabilities: Decrease in prepaid expenses 67,0005,000 Increase (Decrease) in accounts payable and accrued expenses (1,231,000)1,052,000 (Decrease) in operating lease liability (58,000)(54,000) Net Cash Used in Operating Activities (7,699,000)(4,841,000) CASH FLOWS FROM INVESTING ACTIVITIES Sale (purchase) of investments 12,893,000(4,332,000) Net Cash Provided by (Used in) Investing Activities 12,893,000(4,332,000) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from issuance of common stock and warrants, net 2,976,0006,268,000 Net Cash Provided by Financing Activities 2,976,0006,268,000 Net Increase (Decrease) in Cash and Cash Equivalents 8,170,000(2,905,000) Cash at Beginning of Period 1,079,0005,672,000$ 5,672,000Cash at End of Period$ 9,249,000$ 2,767,0009,249,0002,767,000$ 1,079,000SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Interest Income taxes SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES Initial recognition of fair value of warrant liability 5,831,000 Fair value of common stock issued to a vendor to settle accounts payable $ 810,000$ 591,000~~

~~- Definition~~

~~Stock based compensation common shares for services.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_StockBasedCompensationCommonSharesForServices Namespace Prefix:GTBP_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Stock based compensation officers employees and board of directors.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:GTBP_StockBasedCompensationOfficersEmployeesAndBoardOfDirectors Namespace Prefix:GTBP_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~
~~Name:us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4~~

~~+ Details~~
~~Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- Definition~~

~~Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1~~

~~+ Details~~
~~Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair~~

~~income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1~~

~~+ Details~~

~~Name:us-gaap_DebtSecuritiesUnrealizedGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration~~

~~- Definition~~

~~Amount of expense (income) related to adjustment to fair value of warrant liability.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13~~

~~+ Details~~

~~Name:us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration~~

~~- Definition~~

~~Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4~~

~~+ Details~~

~~Name:us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration~~

~~- Definition~~

~~Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2~~

~~+ Details~~

~~Name:us-gaap_IncomeTaxesPaidNet Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration~~

~~- Definition~~

~~Amount of increase (decrease) in obligation for operating lease.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4~~

~~+ Details~~

~~Name:us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28~~

~~+ Details~~

~~Name:us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28~~

~~+ Details~~

~~Name:us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration~~

~~- Definition~~

~~Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2~~

~~+ Details~~

~~Name:us-gaap_InterestPaid Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~The fair value of liabilities assumed in noncash investing or financing activities.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5~~

~~+ Details~~
~~Name:us-gaap_LiabilitiesAssumed1 Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24~~

~~+ Details~~
~~Name:us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~
~~Name:us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24~~

~~+ Details~~
~~Name:us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~
~~Name:us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25~~

~~+ Details~~

~~Name:us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:na Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI~~

~~***https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1***~~

~~***+ Details***~~

~~***Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration***~~

~~***- References***~~

~~***No definition available.***~~

~~***+ Details***~~

~~***Name:us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration***~~

~~***- Definition***~~

~~***Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.***~~

~~***+ References***~~

~~***Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28***~~

~~***+ Details***~~

~~Name:us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_PaymentsForProceedsFromInvestments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type: duration~~

~~- Definition~~

~~The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3~~

~~+ Details~~

~~Name:us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration~~

~~- Definition~~

~~The fair value of stock issued in noncash financing activities.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5~~

~~+ Details~~

~~Name:us-gaap_StockIssued1 Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration XML 76 R8.htm IDEA: XBRL DOCUMENT~~

~~Organization and Going Concern Analysis6 Months Ended~~

~~Jun. 30, 2024~~

~~Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Going Concern Analysis~~

## ~~*Note 1 – Organization and Going Concern Analysis*~~

### ~~*Organization*~~

~~*The corporate predecessor of GT Biopharma, Inc, Diagnostic Data, Inc., was incorporated in the state of California in 1965. Diagnostic Data, Inc. changed its incorporation to the state of Delaware on December 21, 1972 and changed its name to DDI Pharmaceuticals, Inc. on March 11, 1985. On September 7, 1994, DDI Pharmaceuticals, Inc. merged with International BioClinical, Inc. and Bioxytech S.A. and changed its name to OXIS International, Inc. On July 17, 2017, OXIS International, Inc. changed its name to GT Biopharma, Inc.*~~

~~*Throughout this Quarterly Report on Form 10-Q, the terms "GTBP," "we," "us," "our," "the Company" and "our Company" refer to GT Biopharma, Inc.*~~

~~*The GT Biopharma logo, TriKE®, and other trademarks or service marks of GT Biopharma, Inc. appearing in this quarterly report are the property of the Company. This quarterly report on Form 10-Q also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders.*~~

~~*The Company is a clinical stage biopharmaceutical company focused on the development and commercialization of novel immune-oncology products based on our proprietary Tri-specific Killer Engager (TriKE®), and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms. The Company's TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer cells (NK cells).*~~

### ~~*Going Concern Analysis*~~

~~*The Company does not have any product candidates approved for sale and have not generated any revenue from its product sales. The Company has sustained operating losses since inception, and expects such losses to continue into the foreseeable future. Historically, the Company has financed its operations through public and private sales of common stock, issuance of preferred and common stock, issuance of convertible debt instruments, and strategic collaborations. For the six months ended June 30, 2024, the Company recorded a net loss of approximately $ million and used cash in operations of $ million. As of June 30, 2024, the Company had a cash and cash equivalents and short-term investments balance of $ million, working capital of $ million, and stockholders' equity of $ million.6.07.79.25.85.5*~~

~~*The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.*~~

~~*The Company has evaluated the significance of the uncertainty regarding the Company's financial condition in relation to its ability to meet its obligations, which has raised doubts about the Company's ability to continue as a going concern. While it is very difficult to estimate the Company's future liquidity requirements, the Company believes if it is unable to obtain additional financing, existing cash resources will not be sufficient to enable it to fund the anticipated level of operations through one year from the date the accompanying unaudited condensed consolidated financial statements are issued. There can be no assurances that the Company will be able to secure additional financing on acceptable terms. In the event the Company does not secure additional financing, the Company will be forced to delay, reduce, or eliminate some or all of its discretionary spending, which could adversely affect the Company's business prospects, ability to meet long-term liquidity needs and the ability to continue operations.*~~

~~*- References*~~

~~*No definition available.*~~

~~*+ Details*~~

~~*Name:us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration*~~

~~*- Definition*~~

~~*The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.*~~

~~*+ References*~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent*~~

~~*+ Details*~~

~~*Name:us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 77 R9.htm IDEA: XBRL DOCUMENT*~~
~~*Summary of Significant Accounting Policies6 Months Ended*~~
~~*Jun. 30, 2024*~~
~~*Accounting Policies [Abstract] Summary of Significant Accounting Policies*~~

## ~~*Note 2 – Summary of Significant Accounting Policies*~~

### ~~*Basis of Presentation and Principles of Consolidation*~~

~~*The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.*~~

~~*The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the "2023 Annual Report"). The consolidated balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.*~~

~~*In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.*~~

## ~~*Accounting Estimates*~~

~~*The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include management's estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets.*~~

## ~~*Cash Equivalents and Short-Term Investments*~~

~~*The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed consolidated financial statements. At June 30, 2024 total cash equivalents which consist of money market funds and US treasuries, amounted to approximately $ million. At December 31, 2023 total cash equivalents which consist of money market funds, amounted to approximately $.7.6443,000*~~

~~*Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying unaudited condensed consolidated statements of operations. At June 30, 2024 and December 31, 2023, total short-term investments which consist of US treasuries and US government agencies, amounted to approximately $ and $ million, respectively.012.9*~~

## ~~*Fair Value of Financial Instruments*~~

~~*Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.*~~

~~*The three levels of the fair value hierarchy are as follows:*~~

~~*Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.*~~

~~*Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.*~~

~~*Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.*~~

~~*The carrying amounts of the Company's other financial assets and liabilities, such as cash and cash equivalents, short term investments, prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity of these instruments.*~~

~~*The carrying amount of the Company's warrant liability of $ and $million at June 30, 2024 and December 31, 2023, respectively, was based on Level 3 measurements.277,0001.1*~~

## ~~*Warrant Liability*~~

~~*The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, "" ("ASC 815"). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.Derivatives and Hedging*~~

~~*The Company's use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.*~~

## ~~*Common Stock (February 2024 Reverse Stock Split)*~~

~~*On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company's common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol "GTBP."*~~

~~*As a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the reverse stock-split from shares to shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized shares of common stock remains unchanged at shares.41,419,0001,380,633250,000,000*~~

~~*Proportionate adjustments have been made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options and warrants for the Company's common stock, and to the number of shares of common stock reserved for future issuance pursuant to the Company's 2022 Omnibus Incentive Plan.*~~

~~*All share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented.*~~

## ~~*Stock-Based Compensation*~~

~~*The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.*~~

~~*Stock-based payments to officers, directors, employees, and consultants goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, . Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.in exchange for Compensation-Stock Compensation*~~

## ~~*Research and Development Expenses*~~

~~*Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company's products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed.*~~

## ~~*Leases*~~

~~*The Company accounts for its lease in accordance with the guidance of ASC 842, . The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset during the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.Leases*~~

~~*In June 2024, the Company's lease expired and was not renewed.*~~

## ~~*Net Loss Per Share*~~

~~*Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.*~~

~~*The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:*~~

|  | ~~June 30, 2024 (Unaudited)~~ | ~~June 30, 2023 (Unaudited)~~ |
|---|---|---|
| ~~Options to purchase common stock~~ | ~~126,265~~ | ~~124,599~~ |
| ~~Warrants to purchase common stock~~ | ~~1,133,762~~ | ~~304,962~~ |
| ~~Total anti-dilutive securities~~ | ~~1,260,027~~ | ~~429,561~~ |

~~***Concentration***~~

~~*Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation ("FDIC") insurance limits of up to $. 250,000Management believes that the financial institutions that hold the Company's cash are financially sound and, accordingly, minimal credit risk exists.*~~

~~*The Company has a significant concentration of expenses incurred from and accounts payable and accrued expenses to Cytovance, a related party, and the University of Minnesota, see Note 4 – Accounts Payable and Related Party.*~~

~~***Segments***~~

~~*The Company determined its reporting units in accordance with "" ("ASC 280"). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.Segment Reporting*~~

~~*Management has determined that the Company has one consolidated operating segment. The Company's reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company's reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments.*~~

~~***Recent Accounting Pronouncements***~~

~~*In November 2023, the FASB issued ASU No. 2023-07, "" ("ASU 2023-07"), which introduces new reportable segment disclosure requirements related to significant segment expenses and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable segment's profits and losses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are in the process of evaluating the impact that ASU 2023-07 will have on our segment related disclosures.Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*~~

~~*The Company's management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company's financial position and results of operations.*~~

~~***- References***~~

~~***No definition available.***~~

~~***+ Details***~~

~~***Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***The entire disclosure for all significant accounting policies of the reporting entity.***~~

~~***+ References***~~

~~***Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent***~~

~~***+ Details***~~

~~***Name:us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 78 R10.htm IDEA: XBRL DOCUMENT***~~

~~***Fair Value of Financial Instruments6 Months Ended***~~
~~***Jun. 30, 2024***~~

~~***Fair Value Disclosures [Abstract] Fair Value of Financial Instruments***~~

~~***Note 3 – Fair Value of Financial Instruments***~~

~~***Financial Assets***~~

~~*The following table represents the estimated fair values of the Company's financial instruments:*~~

~~***June 30, 2024 (Unaudited) Unrealized Unrealized Fair Cost Gains Losses Value*** *Short-term investments* $ — $ — $ — $ — *Total* $— $ — $— $—~~

|  | ~~December 31, 2023~~ |  |  |  |
|---|---|---|---|---|
|  | ~~Cost~~ | ~~Unrealized Gains~~ | ~~Unrealized Losses~~ | ~~Fair Value~~ |
| ~~Short-term investments~~ | ~~$ 12,845,000~~ | ~~$ 48,000~~ | ~~$ —~~ | ~~$ 12,893,000~~ |
| ~~Total~~ | ~~$ 12,845,000~~ | ~~$ 48,000~~ | ~~$ —~~ | ~~$12,893,000~~ |

~~*The following table represents the Company's fair value hierarchy for its financial assets (cash equivalents and investments):*~~

|  | ~~Fair Value~~ | ~~Level 1~~ | ~~Level 2~~ | ~~Level 3~~ |
|---|---|---|---|---|
|  | ~~June 30, 2024 (Unaudited)~~ |  |  |  |
|  | ~~Fair Value~~ | ~~Level 1~~ | ~~Level 2~~ | ~~Level 3~~ |
| ~~Cash equivalents:~~ |  |  |  |  |
| ~~Money market funds~~ | ~~$ 1,037,000~~ | ~~$ 1,037,000~~ | ~~$ —~~ | ~~$~~ |

| | | | | |
|---|---|---|---|---|
| ~~US treasuries~~ | ~~6,570,000~~ | ~~—~~ | ~~6,570,000~~ | ~~—~~ |
| ~~Short-term investments:~~ | | | | |
| ~~US treasuries~~ | | | | |
| ~~Total financial assets~~ | ~~$7,607,000~~ | ~~$1,037,000~~ | ~~$6,570,000~~ | ~~$ —~~ |

| | ~~Fair Value~~ | ~~Level 1~~ | ~~Level 2~~ | ~~Level 3~~ |
|---|---|---|---|---|
| | ~~December 31, 2023~~ | | | |
| | ~~Fair Value~~ | ~~Level 1~~ | ~~Level 2~~ | ~~Level 3~~ |
| ~~Cash equivalents:~~ | | | | |
| ~~Money market funds~~ | ~~$ 443,000~~ | ~~$ 443,000~~ | ~~$ —~~ | ~~$ —~~ |
| ~~Short-term investments:~~ | | | | |
| ~~US treasuries and US gov't. agencies~~ | ~~12,893,000~~ | ~~—~~ | ~~12,893,000~~ | ~~—~~ |
| ~~Total financial assets~~ | ~~$13,336,000~~ | ~~$443,000~~ | ~~$12,893,000~~ | ~~$ —~~ |

~~*Warrant Liability*~~

~~*For the details of warrant liability transactions see Note 5 – Warrant Liability.*~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_FairValueDisclosuresAbstract~~ ~~Namespace Prefix:us-gaap_~~ ~~Data Type:xbrli:stringItemType~~ ~~Balance Type:na~~ ~~Period Type:duration~~

~~- Definition~~

~~The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1~~

~~+ Details~~

~~Name:us-gaap_FairValueDisclosuresTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type: duration XML 79 R11.htm IDEA: XBRL DOCUMENT~~

~~Accounts Payable and Accrued Expenses, and Related Party6 Months Ended~~
~~Jun. 30, 2024~~

~~Payables and Accruals [Abstract] Accounts Payable and Accrued Expenses, and Related Party~~
~~Note 4 – Accounts Payable and Accrued Expenses, and Related Party~~

~~Accounts payable consists of the following:~~

| | ~~As of June 30, 2024~~ | ~~As of December 31, 2023~~ |
|---|---|---|
| | ~~(Unaudited)~~ | |
| ~~Accounts payable to Cytovance, a related party~~[1] | ~~$ 842,000~~ | ~~$ 3,515,000~~ |
| ~~Other accounts payable~~ | ~~875,000~~ | ~~813,000~~ |
| ~~Total accounts payable~~ | ~~$ 1,717,000~~ | ~~$ 4,328,000~~ |

~~[1] Accounts Payable to Cytovance Biologics, Inc., a Related Party~~

~~Accrued Expenses consists of the following:~~

| | ~~As of June 30, 2024~~ | ~~As of December 31, 2023~~ |
|---|---|---|
| | ~~(Unaudited)~~ | |
| ~~Accrued expenses, University of Minnesota~~ | ~~$ 862,000~~ | ~~$ 192,000~~ |
| ~~Other accrued expenses~~ | ~~903,000~~ | ~~1,003,000~~ |
| ~~Total accrued expenses~~ | ~~$ 1,765,000~~ | ~~$ 1,195,000~~ |

~~Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock~~[1]

~~See Note 8 – Commitments and Contingencies, Significant Agreements.~~

~~The details of the Company’s accounts payable to Cytovance Biologics, Inc., were as follows:~~

| | ~~June 30, 2024~~ | ~~June 30, 2023~~ |
|---|---|---|
| | ~~Six Months Ending~~ | |
| | ~~June 30, 2024~~ | ~~June 30, 2023~~ |
| | ~~(Unaudited)~~ | ~~(Unaudited)~~ |
| ~~Beginning balance~~ | ~~$ 3,515,000~~ | ~~$ 2,283,000~~ |
| ~~Invoices, net~~ | ~~778,000~~ | ~~2,877,000~~ |
| ~~Payments in cash~~ | ~~(2,641,000)~~ | ~~(1,130,000)~~ |
| ~~Payments in common stock, at fair value~~ | ~~(810,000)~~ | ~~(1,120,000)~~ |
| ~~Ending balance~~ | ~~$ 842,000~~ | ~~$ 2,910,000~~ |

~~University of Minnesota~~

~~See Note 8 – Commitments and Contingencies, Significant Agreements.~~

~~- Definition~~

~~The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~

~~Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock~~ ~~Namespace Prefix: us-gaap_~~ ~~Data Type: dtr-types:textBlockItemType~~ ~~Balance~~

~~Type:na Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_PayablesAndAccrualsAbstract~~ ~~Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 80~~

~~R12.htm IDEA: XBRL DOCUMENT~~

| ~~Warrant Liability~~ | ~~6 Months Ended~~ |
|---|---|
| | ~~Jun. 30, 2024~~ |

~~Warrant Liability~~ ~~Warrant Liability~~

~~Note 5 – Warrant Liability~~

~~2023 Warrants~~

~~On January 4, 2023, as part of the private placement offering, the Company issued common stock, warrants to purchase up to an aggregate of shares of the Company's common stock (the "2023 Common Warrants"), and placement agent warrants to purchase up to shares of the Company's common stock (the "2023 Placement Agents Warrants").~~216,66713,000

~~The 2023 Common Warrants and the 2023 Placement Agents Warrants (collectively the "2023 Warrants"), provide for a value calculation for the warrants using the Black Scholes model in the event of certain fundamental transactions. The fair value calculation provides for a floor on the volatility amount utilized in the value calculation at % or greater. The Company has determined this provision introduces leverage to the holders that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company's own equity shares. Therefore, pursuant to ASC 815, the Company has classified the 2023 Warrants as a liability in its consolidated balance sheet. The classification of the 2023 Warrants, including whether they should be recorded as liability or as equity, is evaluated at the end of each reporting period.~~100

~~The 2023 Warrants were initially recorded at a fair value at $ million at the grant date, and upon the closing of placement, was recorded as a cost of capital. The fair value of the 2023 Warrants classified as a liability in the Company's unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either exercised or expired.~~5.8

~~The 2023 Warrant liability is valued using a Binomial pricing model with the following assumptions:~~

| | ~~2023 Warrants~~ | |
|---|---|---|
| | ~~June 30, 2024~~ ~~(Unaudited)~~ | ~~December 31, 2023~~ ~~(Unaudited)~~ |
| ~~Stock price~~ | ~~$ 2.83~~ | ~~$ 7.80~~ |
| ~~Risk-free interest rate~~ [1] | ~~4.43%~~ | ~~4.26%~~ |
| ~~Expected volatility~~ [2] | ~~116%~~ | ~~115%~~ |
| ~~Expected life (in years)~~ [3] | ~~3.54.0~~ | ~~4.25~~ |
| ~~Expected dividend yield~~ [4] | ~~—~~ | ~~—~~ |
| ~~Fair value of warrants~~ | ~~$277,000~~ | ~~$1,050,00~~ |

[1] ~~Based on rates established by the Federal Reserve Bank~~

[2] ~~Historical volatility of the Company's common stock is used to estimate the future volatility of its common stock~~

[3] ~~Determined by the remaining contractual life of the derivative instrument~~

[4] ~~Based on no dividends paid or expected to be paid~~

~~2020 Warrants~~

~~The Company issued warrants underlying shares of common stock during the year ended December 31, 2020 (the "2020 Warrants"), that contained a fundamental transaction provision that could give rise to an obligation to pay cash to the warrant holder upon occurrence of certain change in control type events. In accordance with ASC 480, the fair value of the 2020 Warrants is classified as a liability in the Company's unaudited condensed consolidated balance sheets and will be re-measured at the end of every reporting period with the change in value reported in the unaudited condensed consolidated statements of operations until they are either exercised or expire.~~58,824

~~The 2020 Warrant liability is valued using a Binomial pricing model with the following assumptions:~~

| | ~~2020 Warrants~~ | |
|---|---|---|
| | ~~June 30, 2024~~ ~~(Unaudited)~~ | ~~December 31, 2023~~ |
| ~~Stock price~~ | ~~$ 2.83~~ | ~~$ 7.80~~ |
| ~~Risk-free interest rate~~ [1] | ~~5.09%~~ | ~~4.54%~~ |
| ~~Expected volatility~~ [2] | ~~116%~~ | ~~89%~~ |
| ~~Expected life (in years)~~ [3] | ~~1.0~~ | ~~1.6~~ |
| ~~Expected dividend yield~~ [4] | ~~—~~ | ~~—~~ |
| ~~Fair value of warrants~~ | ~~$ —~~ | ~~$2,000~~ |

[1] ~~Based on rates established by the Federal Reserve Bank~~ [2] ~~Historical volatility of the Company's common stock is used to estimate the future volatility of its common stock~~ [3] ~~Determined by the remaining contractual life of the derivative instrument~~ [4] ~~Based on no dividends paid or expected to be paid~~

~~Warrant Liability~~

~~The details of warrant liability transactions were as follows:~~

| | ~~Six Months Ending~~ | |
|---|---|---|
| | ~~June 30, 2024~~ ~~(Unaudited)~~ | ~~June 30, 2023~~ ~~(Unaudited)~~ |
| ~~Beginning balance~~ | ~~$ 1,052,000~~ | ~~$~~ |
| ~~Issuance of warrants at fair value~~ | ~~—~~ | ~~5,831,000~~ |
| ~~Change in fair value~~ | ~~(775,000)~~ | ~~(4,311,000)~~ |
| ~~Extinguishment~~ | ~~—~~ | ~~—~~ |
| ~~Ending balance~~ | ~~$277,000~~ | ~~$1,520,000~~ |

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_DisclosureWarrantLiabilityAbstract~~ ~~Namespace Prefix:GTBP_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Warrant Liability [Text Block]~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_WarrantLiabilityTextBlock Namespace Prefix:GTBP_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 81 R13.htm IDEA: XBRL DOCUMENT~~

~~Stockholders' Equity~~ ~~6 Months Ended~~
~~Jun. 30, 2024~~

~~Equity [Abstract]~~ ~~Stockholders' Equity~~

## ~~Note 6 – Stockholders' Equity~~

~~The Company's authorized capital as of June 30, 2024 was shares of common stock, par value $ per share, and shares of preferred stock, par value $ per share.250,000,0000.00115,000,0000.01~~

### ~~Common Stock~~

### ~~2024 Common Stock Offering~~

~~On May 23, 2024, the Company received gross proceeds of approximately $ million, before deducting placement agent fees and other offering expenses of $ in relation to a purchase agreement signed on May 21, 2024, between the Company and institutional investors (the "Purchasers") for the issuance and sale, in a registered direct offering, of shares of the Company's common stock, par value $ per share (the "2024 Shares"). In a concurrent private placement, the Company issued and sold to the Purchasers warrants to purchase shares of the Company's common stock (the "2024 Common Warrants"). In addition, the Company issued warrants to the placement agent to purchase shares of common stock (the "2024 Placement Agents Warrants"). The 2024 Common Warrants have an exercise price equal to $ per share, and the 2024 Placement Agents Warrants have an exercise price equal to $ per share, both are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial exercise date. The 2024 Shares and 2024 Common Warrants were sold at an offering price of $ per share.3.2243,000(the "Purchase Agreement") 740,0000.001740,00088,8004.355.43754.35~~

~~Pursuant to the Purchase Agreement, the Company agreed, with certain exceptions, for a period of 60 days following the closing of the offering not to issue, enter into an agreement to issue or announce the issuance or proposed issuance of the 2024 Shares or any other securities convertible into, or exercisable or exchangeable for, shares of the Company's common stock. The Company has also agreed for a period of one year following the closing date of the offering not to (i) issue or agree to issue equity or debt securities convertible into, or exercisable or exchangeable for, shares at a conversion price, exercise price or exchange price which floats with the trading price of the 2024 Shares or which may be adjusted after issuance upon the occurrence of certain events or (ii) enter into any agreement, including an equity line of credit, whereby the Company may issue securities at a future-determined price.~~

~~The Company determined that under ASC 815-40, the 2024 Common Warrants and the 2024 Placement Agent Warrants do not contain a clause that adjusts the exercise price based on circumstances not considered to be within the Company's control and are considered indexed to the Company's own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2024 Common Warrants and the 2024 Placement Agent Warrants are classified as equity.~~

### ~~2023 Private Placement of Common Stock~~

~~On January 4, 2023, the Company received gross proceeds of $ million, before deducting placement agent fees and other offering expenses of $ in relation to a purchase agreement signed on December 30, 2022, between the Company and an institutional investor for the issuance and sale, in a registered direct offering, of shares of the Company's common stock, par value $ per share (the "2023 Shares"), pre-funded warrants to purchase up to shares of the Company's common stock (the "Pre-Funded Warrants"), warrants to purchase up to an aggregate of shares of the Company's common stock (the "2023 Common Warrants") and placement agent warrants to purchase up to of the Company's common stock (the "2023 Placement Agents Warrants"). The 2023 Common Warrants have an exercise price equal to $ per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The Pre-Funded Warrants had an exercise price of $ per share, are immediately exercisable and could be exercised at any time after their original issuance until such Pre-Funded Warrants were exercised in full. The 2023 Placement Agents Warrants have an exercise price equal to $ per share, are exercisable commencing six months following issuance, and have a term of exercise equal to five years following the initial issuance date. The 2023 Shares and 2023 Common Warrants were sold at an offering price of $ per share and accompanying 2023 Common Warrant and the Pre-Funded Warrants and 2023 Common Warrants were sold at an offering price of $per Pre-Funded Warrant and accompanying 2023 Common Warrant.6.5232,000120,0000.00196,667216,66713,00030.000.00337.5030.0029.997~~

~~The 2023 Common Warrants and the 2023 Placement Agents Warrants contained a clause not considered to be within the Company's control. The Company determined that the provision represented a variable that is not an input to the fair value of a "fixed-for-fixed" option as defined under ASC 815-40, and thus the 2023 Common Warrants and the 2023 Placement Agent Warrants are not considered indexed to the Company's own stock and not eligible for an exception from derivative accounting. Accordingly, the 2023 Common Warrants and the 2023 Placement Agent Warrants were classified as a warrant liability, and $ million of the initial common stock offering was classified as a warrant liability (see Note 5 - Warrant Liability).5.8~~

### ~~Common Stock Issued for Services~~

~~During the six months ended June 30, 2023, and pursuant to the vesting term of a 2021 agreement, the Company issued shares of common stock with a fair value of $to members of the Company's Board of Directors (the "Board"), employees, and consultants. The shares were valued at the respective date of the agreements.2,449315,000~~

### ~~Preferred Stock~~

### ~~Series C Preferred Stock~~

~~As of June 30, 2024 and December 31, 2023, there were shares of series C preferred stock, par value $ per share (the "Series C Preferred Stock") issued and outstanding.96,2300.01~~

~~As a result of reverse stock splits in previous years and the agreement terms for adjusting the rights of the related shares, the shares of Series C Preferred Stock are not currently convertible, have no voting rights, and in the event of liquidation, the holders of the Series C Preferred Stock would not participate in any distribution of the assets or surplus funds of the Company. The holders of Series C Preferred Stock also are not currently entitled to any dividends if and when declared by the Board. No dividends to holders of the Series C Preferred Stock were declared or unpaid through June 30, 2024 and 2023, respectively.96,230~~

### ~~Series K Preferred Stock~~

~~On February 16, 2021, the Board designated shares of Series K preferred stock, par value $ (the "Series K Preferred Stock").115,000.01~~

~~Shares of the Series K Preferred Stock are convertible at any time, at the option of the holders, into shares of the Company's common stock at an effective conversion rate of shares of common stock for each share of Series K Preferred. Shares of the Series K Preferred Stock have the same voting rights as the shares of the Company's common stock, with the holders of the Series K Preferred Stock entitled to vote on an as-converted-to-common stock basis, subject to the beneficial ownership limitation, together with the holders of the Company's common stock on all matters presented to the Company's stockholders. The Series K Preferred Stock are not entitled to any dividends (unless specifically declared by the Board) but will participate on an as-converted-to-common-stock basis in any dividends to the holders of the Company's common stock. In the event of the Company's dissolution, liquidation or winding up, the holders of the Series K Preferred Stock will be on parity with the holders of the Company's common stock and will participate, on a on an as-converted-to-common stock basis, in any distribution to holders of the Company's common stock.100~~

~~As of June 30, 2024 and December 31, 2023, there were shares of Series K Preferred stock issued and outstanding.no~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_EquityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The entire disclosure for equity.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -~~

~~***Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18***~~

~~+ Details~~

~~Name:us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 82 R14.htm IDEA: XBRL DOCUMENT~~

~~Common Stock Warrants and Options~~ ~~6 Months Ended~~
~~Jun. 30, 2024~~

~~Common Stock Warrants And Options~~ ~~Common Stock Warrants and Options~~

## ~~Note 7 – Common Stock Warrants and Options~~

### ~~Common Stock Warrants~~

~~Stock warrant transactions for the six months ended June 30, 2024 were as follows:~~

| | ~~Six Months Ended June 30, 2024~~ | |
|---|---|---|
| | ~~Number of Warrants~~ | ~~Weighted Average Exercise Price~~ |
| ~~Warrants outstanding at December 31, 2023~~ | ~~304,962~~ | ~~$ 63.30~~ |
| ~~Granted~~ | ~~828,800~~ | ~~4.47~~ |
| ~~Forfeited/cancelled~~ | ~~—~~ | ~~—~~ |
| ~~Exercised~~ | ~~—~~ | ~~—~~ |
| ~~Warrants outstanding at June 30, 2024~~ | ~~1,133,762~~ | ~~$20.28~~ |
| ~~Warrants exercisable at June 30, 2024~~ | ~~1,133,762~~ | ~~$20.28~~ |

~~As of June 30, 2024, all outstanding warrants are fully vested and had an exercise price greater than the market price of the Company's common stock, which resulted in intrinsic value.~~no

~~Warrants outstanding as of June 30, 2024 are exercisable as follows:~~

| ~~Warrants Outstanding and Exercisable as of June 30, 2024~~ | | | |
|---|---|---|---|
| ~~Range of Exercise Price~~ | ~~Number Outstanding~~ | ~~Weighted Average Remaining Contractual Life (Years)~~ | ~~Weighted Average Exercise Price~~ |
| ~~$ 4.35~~ | ~~740,000~~ | ~~4.9~~ | ~~$ 4.35~~ |
| ~~5.4375~~ | ~~88,800~~ | ~~4.9~~ | ~~5.4375~~ |
| ~~30.00~~ | ~~216,666~~ | ~~4.0~~ | ~~30.00~~ |
| ~~37.50~~ | ~~13,000~~ | ~~3.5~~ | ~~37.50~~ |
| ~~102.00~~ | ~~1,867~~ | ~~1.0~~ | ~~102.00~~ |
| ~~165.00~~ | ~~73,429~~ | ~~1.6~~ | ~~165.00~~ |
| | ~~1,133,762~~ | ~~4.5~~ | ~~20.28~~ |

### ~~Common Stock Options~~

~~In April 2022 the Company established the 2022 Omnibus Incentive Plan (the "Plan"). The Plan was approved by our Board and stockholders. The purpose of the Plan is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors, and key consultants. The maximum number of shares of common stock that may be issued pursuant to awards granted under the Plan is . The shares of our common stock underlying cancelled and forfeited awards issued under the Plan may again become available for grant under the Plan. As of June 30, 2024, there were shares available for grant under the Plan.~~166,6677,966

~~The following table summarizes stock option transactions for the six months ended June 30, 2024:~~

| | ~~Six Months Ended June 30, 2024~~ | |
|---|---|---|
| | ~~Number of Options~~ | ~~Weighted Average Exercise Price~~ |
| ~~Options outstanding at December 31, 2023~~ | ~~126,265~~ | ~~$ 40.15~~ |
| ~~Granted~~ | ~~—~~ | ~~—~~ |
| ~~Forfeited/cancelled~~ | ~~—~~ | ~~—~~ |
| ~~Exercised~~ | ~~—~~ | ~~—~~ |
| ~~Options outstanding at June 30, 2024~~ | ~~126,265~~ | ~~$40.15~~ |
| ~~Options exercisable at June 30, 2024~~ | ~~126,265~~ | ~~$40.15~~ |

~~The weighted average remaining contractual life of all options outstanding, and all options vested and exercisable as of June 30, 2024 was years. Furthermore, all options outstanding and all options vested and exercisable as of June 30, 2024 had an exercise price greater than the market price of the Company's common stock, which resulted in no intrinsic value.~~8.43

~~The total fair value of options that vested during the six months ended June 30, 2024 and 2023, was $ and $, respectively, and is included in selling, general and administrative expense in the accompanying unaudited condensed consolidated statements of operations. As of June 30, 2024, all outstanding stock options were fully vested and exercisable and there was no accompanying unvested compensation expense.~~222,000905,000

~~On May 15, 2023, the Company granted stock options to a member of the Board to purchase shares of common stock. The stock options are exercisable at $ per share, expire in years, vest over twelve months and have a fair value of $ on at the date of grant~~ 16,66610.5010150,000~~which will be amortized over the vesting period.~~

~~On January 27, 2023, the Company granted stock options to employees and members of the Board to purchase an aggregate of shares of common stock. The stock options are exercisable at $ per share, expire in years, vest over twelve months and have a fair value of $ million at the date of grant which will be amortized over the vesting period.~~66,66725.50101.4

~~Options outstanding as of June 30, 2024 are exercisable as follows:~~

| ~~Stock Options Outstanding and Exercisable as of June 30, 2024~~ | | | |
|---|---|---|---|
| ~~Range of Exercise Price~~ | ~~Number Outstanding~~ | ~~Weighted Average Remaining Contractual Life (Years)~~ | ~~Weighted Average Exercise Price~~ |
| ~~$ 10.50~~ | ~~16,666~~ | ~~8.8~~ | ~~$ 10.50~~ |
| ~~25.50~~ | ~~66,667~~ | ~~8.6~~ | ~~25.50~~ |
| ~~74.40~~ | ~~42,932~~ | ~~8.0~~ | ~~74.40~~ |
| | ~~126,265~~ | | |

~~- Definition~~

~~Common Stock Warrants and Options [Text Block]~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_CommonStockWarrantsAndOptionsTextBlock Namespace Prefix:GTBP_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_DisclosureCommonStockWarrantsAndOptionsAbstract Namespace Prefix:GTBP_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 83 R15.htm IDEA: XBRL DOCUMENT~~

| ~~Commitments and Contingencies~~ | ~~6 Months Ended~~ |
|---|---|
| | ~~Jun. 30, 2024~~ |
| ~~Commitments and Contingencies Disclosure [Abstract]~~ | |
| ~~Commitments and Contingencies~~ | |

~~Note 8 – Commitments and Contingencies~~

~~Litigation~~

~~The Company is involved in certain legal proceedings that arise from time to time in the ordinary course of our business. Except for income tax contingencies, we record accruals for contingencies to the extent that our management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. There is no current or pending litigation of any significance with the exception of the matters identified below that have arisen under, and are being handled in, the normal course of business:~~

~~Ohri Matter~~

~~On July 22, 2024, the Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer. In the Demand, the Company asserts claims against Mr. Ohri for breach of his fiduciary duties and breach of contract and seeks a declaratory judgment providing that the Company may characterize Mr. Ohri's termination as "for cause" under his Employment Agreement, and that the Company may revoke the Separation Agreement entered into between the Company and Mr. Ohri prior to the Company learning of Mr. Ohri's breaches. In addition to the declaratory judgment, the Company seeks damages arising from Mr. Ohri's violations, and attorneys' fees and any forum and arbitration fees. Mr. Ohri's response to the Company's Demand is due August 20, 2024. At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any.~~

~~Berk Matter~~

~~On November 14, 2023, former interim Chief Executive Officer, Dr. Gregory Berk filed a lawsuit in the US District Court for the Di alleging that the Company discriminated and retaliated against Dr. Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act ("SOX"). The Parties are proceeding with litigating Dr. Berk's SOX claim. The Company is vigorously defending this matter and believes it to be without merit. At this early stage in the proceedings the Company is not able to determine the probability of the outcome of this matter or a range of reasonably expected losses, if any.strict of Massachusetts~~

~~TWF Global Matter~~

~~On May 24, 2023, TWF Global, LLC ("TWF") filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant. The Complaint alleges that TWF is the holder of two Convertible Promissory Notes ("Notes") and that the Company did not deliver shares of common stock due on conversion in February 2021. TWF was seeking per diem liquidated damages based on the terms of alleged Notes. On July 14, 2023, the Company filed a motion to dismiss for improper forum because the terms of the Notes, as alleged, require disputes to be filed in New York state and federal courts. TWF voluntarily dismissed its Complaint before the California Superior Court of Los Angeles without prejudice. The Company subsequently filed a Summons and Complaint for Interpleader against TWF and Z-One LLC before the Supreme Court of the State of New York County of New York, asking the Supreme Court to determine if the Company's shares of common stock are properly registered to TWF or Z-One LLC, as both of these entities have made conflicting demands for registration of the shares of common stock. On February 5, 2024, the Company filed a motion for entry of default against TWF, seeking an order directing the Company to register the shares of common stock in the name of Z-One and that the Company be released from all associated liability and claims. The Court denied the motion without prejudice and will reconsider the motion without further briefing upon the filing of a party affidavit. Z-One has filed a concurrent motion to dismiss of the action, representing that Z-One and TWF have settled their dispute over the entitlement to the Company's shares of common stock. The Company believes that any claims related to the Notes are without merit and will continue to defend vigorously against these claims.~~

~~Handelman Matter~~

~~On May 13, 2022, the Company made an arbitration demand upon Michael Handelman, its former Chief Financial Officer, asserting that he breached his fiduciary duty by misappropriating Company funds and shares of common stock, among other things. The Company seeks among other relief, monetary damages estimated at $; the return of shares of our common stock received without authorization; and an award of the Company's attorneys' fees and any forum and arbitration fees. In May 2024, the Arbitrator issued the final award in favor of the Company which awarded the Company its legal fees in the amount of $ plus costs in the amount of $ and the return of the disputed shares of common stock, which were returned to the Company in June 2024.~~470,00013,902473,00019,00013,902

~~Significant Agreements~~

~~Cytovance Biologics, Inc., a Related Party~~

~~In October 2020, the Company entered into a Master Services Agreement with Cytovance Biologics, Inc. ("Cytovance"), to perform biologic development and manufacturing services, and to produce and test compounds used in the Company's potential product candidates. The Company subsequently executed numerous Statements of Work ("SOWs") for the research and development of products for use in clinical trials.~~

~~On August 24, 2022, the Company entered into a Settlement and Investment Agreement with Cytovance that amended existing SOWs and allowed for future invoices to be settled in in a combination of cash and issuance of the Company's common stock. The Agreement also set Cytovance's beneficial ownership limitation at % of the issued and outstanding shares of the Company's common stock.~~4.9

~~On April 25, 2024, the Company entered into an Amendment to the Settlement and Investment Agreement with Cytovance that increased Cytovance's beneficial ownership limitation to % of the issued and outstanding shares of the Company's common stock.~~9.9

~~During the six months ended June 30, 2024 and 2023, the Company issued and shares of common stock to Cytovance to settle accounts payable valued at approximately $ and $, respectively.~~127,59744,793810,0001,120,000

~~On June 30, 2024, Cytovance became a related party as their beneficial ownership exceeded % of the issued and outstanding shares of the Company's common stock.~~5

~~As of June 30, 2024 the Company's commitments in relation to unbilled and unaccrued SOWs and any related Change Orders from Cytovance for services that have not yet been rendered as of June 30, 2024, amounted to approximately $ million.~~1.5

~~University of Minnesota~~

~~2021 Scientific Research Agreement~~

~~Effective June 16, 2021, the Company entered into a scientific research agreement with the Regents of the University of Minnesota, expiring on June 30, 2023. Payments totaling approximately $ million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Company's TriKE® product development and GMP manufacturing efforts; (2) TriKE® pharmacokinetics optimization in humans; and (3) investigation of the patient's native NK cell population based on insights obtained from the analysis of the human data generated during our GTB-3550 clinical trial. The major deliverables proposed are: (1) creation of IND enabling data for TriKE® constructs in support of our product development and GMP manufacturing efforts; (2) TriKE® platform drug delivery changes to allow transition to alternative drug delivery means and extended PK in humans; and (3) gain an increased understanding of changes in the patient's native NK cell population as a result of TriKE® therapy. Most studies will use TriKE® DNA/amino acid sequences created by the Company under existing licensing terms.~~2.1

~~The Company recorded an expense classified as research and development of approximately $ and $, pursuant to the 2021 Scientific Research Agreement, for the six months ended June 30, 2024 and 2023, respectively.~~0192,000

~~As of June 30, 2024 the Company’s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2021 Scientific Research Agreement for services that have not yet been rendered as of June 30, 2024, amounted to $.0~~

### ~~2023 Sponsored Research Agreement~~

~~On May 20, 2024, the Company entered into a sponsored research agreement with the Regents of the University of Minnesota (the “2016 Exclusive Patent License Agreement”), effective July 1, 2023, and expiring on July 1, 2025. Payments totaling approximately $ million are due over the life of the agreement. The purpose of the agreement is for the Regents of the University of Minnesota to continue work with the Company with three major goals in mind: (1) support the Company’s TriKE® product development and commercial GMP manufacturing efforts; (2) TriKE® pharmacokinetics optimization in humans and investigation of effects of altering the route of administration; and (3) research and development of TriKE® platform. The major deliverables proposed are: (1) creation of IND enabling data for TriKE® constructs in support of the Company’s product development and commercial GMP manufacturing efforts outside of the University of Minnesota; (2) TriKE® platform drug delivery changes to allow transition from intravenous (IV) continuous infusion to alternative drug delivery administration (IV bolus, intraperitoneal [IP], subcutaneous [SQ]) and extended PK in humans and gain an increased understanding of changes in the patient’s native NK cell population as a result of alteration of TriKE® administration; and (3) research and development of TriKE® platform combination with other FDA approved (or soon to be approved) therapeutics and alterations to TriKE® platform through formation of immune complexes. Most studies will use TriKE® DNA/amino acid sequences created by the Company under existing licensing terms.1.7~~

~~The Company recorded an expense classified as research and development of approximately $ and $, pursuant to the 2023 Sponsored Research Agreement, for the six months ended June 30, 2024 and 2023, respectively.863,0000~~

~~As of June 30, 2024 the Company’s commitments in relation to unbilled and unaccrued amounts from the University of Minnesota pursuant to the 2023 Sponsored Research Agreement for services that have not yet been rendered as of June 30, 2024, amounted to approximately $.862,000~~

### ~~2016 Exclusive Patent License Agreement~~

~~Effective July 18, 2016, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (the “2016 Exclusive Patent License Agreement”), to further develop and commercialize cancer therapies using TriKE® technology developed by researchers at the University of Minnesota to target NK cells to cancer. Under the terms of the agreement, the Company receives exclusive rights to conduct research and to develop, make, use, sell, and import TriKE® technology worldwide for the treatment of any disease, state, or condition in humans. The Company is responsible for obtaining all permits, licenses, authorizations, registrations, and regulatory approvals required or granted by any governmental authority anywhere in the world that is responsible for the regulation of products such as the TriKE® technology, including without limitation the FDA and the European Agency for the Evaluation of Medicinal Products in the European Union. The agreement requires an upfront payment of $, and license maintenance fees of $ for years 2017 through 2020, and $ per year beginning in year 2021 and each year thereafter. The agreement also includes % royalty fees on the net sales of licensed products, not to exceed % under subsequent license agreements or amendments to this agreement, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $ beginning in 2022, $ million beginning in 2025, and $ million beginning in 2027 throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $ million, and one-time sales milestone payments of $ million upon reaching $ million in cumulative gross sales, and $ million upon reaching $ million in cumulative gross sales of licensed products.200,000200,000100,00046250,000253.112505500~~

~~Effective May 13, 2024, the Company entered into an amended and restated exclusive patent license agreement with the Regents of the University of Minnesota. The amendment requires an upfront payment of $145,000 and amends the license maintenance fees to $50,000 in 2025, and $100,000 per year beginning in year 2026 and each year thereafter. The amendment also includes 1% to 5% royalty fees on the net sales of licensed products, not to exceed 6% under subsequent license agreements or amendments, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $250,000 in year one, $2 million in years two through five, and $5 million in year six throughout the remainder of the term. The amendment also includes numerous performance milestone payments including clinical development milestone payments totaling $3.1 million, and one-time sales milestone, and one-time sales milestone payments of $1 million upon reaching $250 million in cumulative gross sales, and $5 million upon reaching $500 million in cumulative gross sales of licensed products.~~

~~The Company recorded an expense classified as research and development of $, pursuant to the 2016 Exclusive Patent License Agreement, for the six months ended June 30, 2024 and 2023.0~~

### ~~2021 Exclusive License Agreement~~

~~Effective March 26, 2021, the Company entered into an exclusive license agreement with the Regents of the University of Minnesota (the “2021 Exclusive Patent License Agreement”), specific to the B7H3 targeted TriKE®. The agreement requires an upfront payment of $, and license maintenance fees of $ per year beginning in year 2022 and each year thereafter. The agreement also includes % to % royalty fees on the net sales of licensed products, and minimum royalty payments due upon the commencement of commercial sales of licensed product is $ in year one though four, and $ million beginning in year five and throughout the remainder of the term. The agreement also includes numerous performance milestone payments including clinical development milestone payments totaling $ million, and one-time sales milestone payments of $ million upon reaching $ million in cumulative gross sales, and $ million upon reaching $ million in cumulative gross sales of licensed products. There is no double payment intended; if one of the milestone payments has been paid under the 2016 restated exclusive patent license agreement no further payment is due for the corresponding milestone.20,0005,0002.55250,00023.112505500~~

~~The Company recorded an expense classified as research and development of approximately $145,000 and $0, pursuant to the 2021 Exclusive License Agreement, for the six months ended June 30, 2024 and 2023, respectively.~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The entire disclosure for commitments and contingencies.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent~~

~~+ Details~~

~~Name:us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 84 R16.htm IDEA: XBRL DOCUMENT~~

~~Summary of Significant Accounting Policies (Policies)6 Months Ended~~
~~Jun. 30, 2024~~

~~Accounting Policies [Abstract] Basis of Presentation and Principles of Consolidation~~

## ~~Basis of Presentation and Principles of Consolidation~~

~~The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oxis Biotech, Inc. and Georgetown Translational Pharmaceuticals, Inc. All intercompany transactions and balances have been eliminated in consolidation.~~

~~The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 26, 2024 (the “2023 Annual Report”). The consolidated balance sheet as of December 31, 2023 included herein, was derived from the audited consolidated financial statements as of that date.~~

~~In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.~~

~~Accounting Estimates~~

## ~~Accounting Estimates~~

~~The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include management’s estimates for continued liquidity, accruals for potential liabilities, assumptions used in deriving the fair value of derivative liabilities, valuation of equity instruments issued for debt and services and realization of deferred tax assets.~~

~~Cash Equivalents and Short-Term Investments~~

## ~~Cash Equivalents and Short-Term Investments~~

~~The Company considers highly liquid investments with maturities of three months or less at the date of acquisition as cash equivalents in the accompanying unaudited condensed consolidated financial statements. At June 30, 2024 total cash equivalents which consist of money market funds and US treasuries, amounted to approximately $ million. At December 31, 2023 total cash equivalents which consist of money market funds, amounted to approximately $.7.6443,000~~

~~Management generally determines the appropriate classification of its investments at the time of purchase. We classify these investments as short-term investments, as part of current assets, based upon our ability and intent to use any and all of these investments as necessary to satisfy liquidity requirements that may arise from our business. Investments are carried at fair value with the unrealized holding gains and losses reported in the accompanying unaudited condensed consolidated statements of operations. At June 30, 2024 and December 31, 2023, total short-term investments which consist of US treasuries and US government agencies, amounted to approximately $ and $ million, respectively.012.9~~

~~Fair Value of Financial Instruments~~

## ~~Fair Value of Financial Instruments~~

~~Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.~~

~~The three levels of the fair value hierarchy are as follows:~~

~~Level 1 Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access.~~

~~Level 2 Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.~~

~~Level 3 Valuations based on inputs that are unobservable, supported by little or no market activity and that are significant to the fair value of the assets or liabilities.~~

~~The carrying amounts of the Company’s other financial assets and liabilities, such as cash and cash equivalents, short term investments, prepaid expenses and other current assets, accounts payable, accrued expenses, approximate their fair values because of the short maturity of these instruments.~~

~~The carrying amount of the Company’s warrant liability of $ and $million at June 30, 2024 and December 31, 2023, respectively, was based on Level 3 measurements.277,0001.1~~

~~Warrant Liability~~

## ~~Warrant Liability~~

~~The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “” (“ASC 815”). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations.Derivatives and Hedging~~

~~The Company’s use of derivative financial instruments is generally limited to warrants issued by the Company that do not meet the criteria for equity treatment and are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.~~

~~Common Stock (February 2024 Reverse Stock Split)~~

## ~~Common Stock (February 2024 Reverse Stock Split)~~

~~On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company’s common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol “GTBP.”~~

~~As a result of the reverse stock-split, every thirty (30) shares of issued and outstanding common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split. Stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive their pro-rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock-split (reduced by any customary brokerage fees, commission and other expenses). The reverse stock split reduced the number of shares of common stock outstanding on the effective date of the reverse stock-split from shares to shares, subject to minor adjustments due to the treatment of fractional shares. The number of authorized~~

~~shares of common stock remains unchanged at shares.41,419,0001,380,633250,000,000~~

~~Proportionate adjustments have been made to the per share exercise price and the number of shares of common stock that may be purchased upon exercise of outstanding stock options and warrants for the Company’s common stock, and to the number of shares of common stock reserved for future issuance pursuant to the Company’s 2022 Omnibus Incentive Plan.~~

~~All share and per share information within this report have been adjusted to retroactively reflect the reverse stock-split as of the earliest period presented.~~

~~-Stock-Based Compensation~~

### ~~Stock-Based Compensation~~

~~The Company periodically issues stock-based compensation to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.~~

~~Stock-based payments to officers, directors, employees, and consultants goods and services, which include grants of employee stock options, are recognized in the financial statements based on their grant date fair values in accordance with ASC 718, . Stock based payments to officers, directors, employees, and consultants, which are generally time vested, are measured at the grant date fair value and depending on the conditions associated with the vesting of the award, compensation cost is recognized on a straight-line or graded basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life, and future dividends. The assumptions used in the Black-Scholes option pricing model could materially affect compensation expense recorded in future periods.in exchange for Compensation-Stock Compensation~~

~~-Research and Development Expenses~~

### ~~Research and Development Expenses~~

~~Costs incurred for research and development are expensed as incurred. The salaries, benefits, and overhead costs of personnel conducting research and development of the Company’s products are included in research and development expenses. Purchased materials that do not have an alternative future use are also expensed.~~

~~-Leases~~

### ~~Leases~~

~~The Company accounts for its lease in accordance with the guidance of ASC 842, . The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments.Leases~~

~~In June 2024, the Company’s lease expired and was not renewed.~~

~~-Net Loss Per Share~~

### ~~Net Loss Per Share~~

~~Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed using the weighted-average number of common shares and the dilutive effect of contingent shares outstanding during the period. Potentially dilutive contingent shares, which primarily consist of stock issuable upon exercise of stock options and warrants have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.~~

~~The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:~~

| | ~~June 30, 2024 (Unaudited)~~ | ~~June 30, 2023 (Unaudited)~~ |
|---|---|---|
| ~~Options to purchase common stock~~ | ~~126,265~~ | ~~124,599~~ |
| ~~Warrants to purchase common stock~~ | ~~1,133,762~~ | ~~304,962~~ |
| ~~Total anti-dilutive securities~~ | ~~1,260,027~~ | ~~429,561~~ |

~~-Concentration~~

### ~~Concentration~~

~~Cash is deposited in one financial institution. The balances held at this financial institution at times may be in excess of Federal Deposit Insurance Corporation (“FDIC”) insurance limits of up to $. 250,000Management believes that the financial institutions that hold the Company’s cash are financially sound and, accordingly, minimal credit risk exists.~~

~~The Company has a significant concentration of expenses incurred from and accounts payable and accrued expenses to Cytovance, a related party, and the University of Minnesota, see Note 4 – Accounts Payable and Related Party.~~

~~-Segments~~

### ~~Segments~~

~~The Company determined its reporting units in accordance with “” (“ASC 280”). Management evaluates a reporting unit by first identifying its operating segments under ASC 280. The Company then evaluates each operating segment to determine if it includes one or more components that constitute a business. If there are components within an operating segment that meet the definition of a business, the Company evaluates those components to determine if they must be aggregated into one or more reporting units. If applicable, when determining if it is appropriate to aggregate different operating segments, the Company determines if the segments are economically similar and, if so, the operating segments are aggregated.Segment Reporting~~

~~Management has determined that the Company has one consolidated operating segment. The Company’s reporting segment reflects the manner in which its chief operating decision maker reviews results and allocates resources. The Company’s reporting segment meets the definition of an operating segment and does not include the aggregation of multiple operating segments.~~

~~-Recent Accounting Pronouncements~~

### ~~Recent Accounting Pronouncements~~

~~In November 2023, the FASB issued ASU No. 2023-07, “” (“ASU 2023-07”), which introduces new reportable segment disclosure requirements related to significant segment expenses and also expands reportable segment disclosure requirements for interim reporting. The amendment will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and are included within each reportable segment’s profits and losses. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. We are in the process of evaluating the impact that ASU 2023-07 will have on our segment related disclosures.Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures~~

~~The Company’s management has evaluated all the recently issued, but not yet effective, accounting standards and guidance that have been issued or proposed by the FASB or other standards-setting bodies through the filing date of these financial statements and does not believe the future adoption of any such pronouncements will have a material effect on the Company’s financial position and results of operations.~~

~~- Definition~~

~~Common Stock Reverse Stock Split [Policy Text Block]~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_CommonStockReverseStockSplitPolicyTextBlock Namespace Prefix:GTBP_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Warrant Liability Policy [Text Block]~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_WarrantLiabilityPolicyTextBlock Namespace Prefix:GTBP_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- References~~

~~No definition available.~~

~~***+ Details***~~
~~***Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent***~~

~~***+ Details***~~
~~***Name:us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1***~~

~~***+ Details***~~
~~***Name:us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2***~~

~~***+ Details***~~
~~***Name:us-gaap_CompensationRelatedCostsPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***Disclosure of accounting policy for credit risk.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1***~~

~~+ Details~~
~~Name:us-gaap_ConcentrationRiskCreditRisk Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2~~

~~+ Details~~
~~Name:us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type: duration~~

~~- Definition~~

~~Disclosure of accounting policy for determining the fair value of financial instruments.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1~~

~~+ Details~~
~~Name:us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type: duration~~

~~- Definition~~

~~Disclosure of accounting policy for leasing arrangement entered into by lessee.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1~~

~~+ Details~~

~~Name:us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type: na Period Type:duration~~

~~- Definition~~

~~Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1~~

~~+ Details~~

~~Name:us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Disclosure of accounting policy for segment reporting.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29~~

~~***+ Details***~~

~~***Name:us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting***~~

~~Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8~~

~~+ Details~~

~~Name:us-gaap_UseOfEstimates Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 85~~

~~R17.htm IDEA: XBRL DOCUMENT~~

~~Summary of Significant Accounting Policies (Tables)6 Months Ended~~
~~Jun. 30, 2024~~

~~Accounting Policies [Abstract] Schedule of Anti-dilutive Securities~~

~~The following common stock equivalents were excluded in the computation of the net loss per share because their effect is anti-dilutive:~~

| | ~~June 30, 2024 (Unaudited)~~ | ~~June 30, 2023 (Unaudited)~~ |
|---|---|---|
| ~~Options to purchase common stock~~ | ~~126,265~~ | ~~124,599~~ |
| ~~Warrants to purchase common stock~~ | ~~1,133,762~~ | ~~304,962~~ |
| ~~Total anti-dilutive securities~~ | ~~1,260,027~~ | ~~429,561~~ |

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per~~

~~Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 86 R18.htm IDEA: XBRL DOCUMENT~~

~~Fair Value of Financial Instruments (Tables)6 Months Ended~~

~~Jun. 30, 2024~~

~~Fair Value Disclosures [Abstract]~~ ~~Schedule of Estimated Fair Value of Financial Instrument~~

~~The following table represents the estimated fair values of the Company's financial instruments:~~

| | ~~June 30, 2024 (Unaudited)~~ | | | |
|---|---|---|---|---|
| | ~~Cost~~ | ~~Unrealized Gains~~ | ~~Unrealized Losses~~ | ~~Fair Value~~ |
| ~~Short-term investments~~ | ~~$ —~~ | ~~$ —~~ | ~~$ —~~ | ~~$ —~~ |
| ~~Total~~ | ~~$—~~ | ~~$ —~~ | ~~$—~~ | ~~$—~~ |

| | ~~December 31, 2023~~ | | | |
|---|---|---|---|---|
| | ~~Cost~~ | ~~Unrealized Gains~~ | ~~Unrealized Losses~~ | ~~Fair Value~~ |
| ~~Short-term investments~~ | ~~$ 12,845,000~~ | ~~$ 48,000~~ | ~~$ —~~ | ~~$ 12,893,000~~ |
| ~~Total~~ | ~~$ 12,845,000~~ | ~~$ 48,000~~ | ~~$ —~~ | ~~$12,893,000~~ |

~~Schedule of Fair Value Hierarchy Financial Assets~~

~~The following table represents the Company's fair value hierarchy for its financial assets (cash equivalents and investments):~~

| | ~~Fair Value~~ | ~~Level 1~~ | ~~Level 2~~ | ~~Level 3~~ |
|---|---|---|---|---|
| | ~~June 30, 2024 (Unaudited)~~ | | | |
| | ~~Fair Value~~ | ~~Level 1~~ | ~~Level 2~~ | ~~Level 3~~ |
| ~~Cash equivalents:~~ | | | | |
| ~~Money market funds~~ | ~~$ 1,037,000~~ | ~~$ 1,037,000~~ | ~~$ —~~ | ~~$ —~~ |
| ~~US treasuries~~ | ~~6,570,000~~ | ~~—~~ | ~~6,570,000~~ | ~~—~~ |
| ~~Short-term investments:~~ | | | | |
| ~~US treasuries~~ | ~~—~~ | ~~—~~ | ~~—~~ | ~~—~~ |
| ~~Total financial assets~~ | ~~$7,607,000~~ | ~~$1,037,000~~ | ~~$6,570,000~~ | ~~$ —~~ |

| | ~~Fair Value~~ | ~~Level 1~~ | ~~Level 2~~ | ~~Level 3~~ |
|---|---|---|---|---|
| | ~~December 31, 2023~~ | | | |
| | ~~Fair Value~~ | ~~Level 1~~ | ~~Level 2~~ | ~~Level 3~~ |
| ~~Cash equivalents:~~ | | | | |
| ~~Money market funds~~ | ~~$ 443,000~~ | ~~$ 443,000~~ | ~~$ —~~ | ~~$ —~~ |
| ~~Short-term investments:~~ | | | | |
| ~~US treasuries and US gov't. agencies~~ | ~~12,893,000~~ | ~~—~~ | ~~12,893,000~~ | ~~—~~ |
| ~~Total financial assets~~ | ~~$13,336,000~~ | ~~$443,000~~ | ~~$12,893,000~~ | ~~$ —~~ |

~~- Definition~~

~~Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3~~

~~+ Details~~

~~Name:us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3~~

~~+ Details~~

~~Name:us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 87 R19.htm IDEA: XBRL DOCUMENT~~

~~Accounts Payable and Accrued Expenses, and Related Party (Tables)6 Months Ended~~
~~Jun. 30, 2024~~

~~Payables and Accruals [Abstract] Schedule of Accounts Payable~~

~~Accounts payable consists of the following:~~

| | ~~As of June 30, 2024~~ | ~~As of December 31, 2023~~ |
|---|---|---|
| | | ~~(Unaudited)~~ |
| ~~Accounts payable to Cytovance, a related party~~ [1] | | |

| | | |
|---|---|---|
| | ~~$ 842,000~~ | ~~$ 3,515,000~~ |
| ~~Other accounts payable~~ | ~~875,000~~ | ~~813,000~~ |
| ~~Total accounts payable~~ | ~~$ 1,717,000~~ | ~~$ 4,328,000~~ |

~~Schedule of Accrued Expenses~~

~~Accrued Expenses consists of the following:~~

| | ~~As of June 30, 2024~~ | ~~As of December 31, 2023~~ |
|---|---|---|
| | ~~(Unaudited)~~ | |
| ~~Accrued expenses, University of Minnesota~~ | ~~$ 862,000~~ | ~~$ 192,000~~ |
| ~~Other accrued expenses~~ | ~~903,000~~ | ~~1,003,000~~ |
| ~~Total accrued expenses~~ | ~~$ 1,765,000~~ | ~~$ 1,195,000~~ |

~~Schedule of Accounts~~

~~Payable to Related Party~~

~~The details of the Company's accounts payable to Cytovance Biologics, Inc., were as follows:~~

| | ~~June 30, 2024~~ | ~~June 30, 2023~~ |
|---|---|---|
| | ~~Six Months Ending~~ | |
| | ~~June 30, 2024~~ | ~~June 30, 2023~~ |
| | ~~(Unaudited)~~ | ~~(Unaudited)~~ |
| ~~Beginning balance~~ | ~~$ 3,515,000~~ | ~~$ 2,283,000~~ |
| ~~Invoices, net~~ | ~~778,000~~ | ~~2,877,000~~ |
| ~~Payments in cash~~ | ~~(2,641,000)~~ | ~~(1,130,000)~~ |
| ~~Payments in common stock, at fair value~~ | ~~(810,000)~~ | ~~(1,120,000)~~ |
| ~~Ending balance~~ | ~~$ 842,000~~ | ~~$ 2,910,000~~ |

~~- Definition~~

~~Schedule of Accounts Payable and Related Party [Table Text Block]~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_ScheduleOfAccountsPayableAndRelatedPartyTableTextBlock Namespace Prefix:GTBP_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_PayablesAndAccrualsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure of the components of accrued liabilities.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 88 R20.htm IDEA: XBRL DOCUMENT~~

~~Warrant Liability (Tables)6 Months Ended~~
~~Jun. 30, 2024~~

~~Short-Term Debt [Line Items]~~ ~~Schedule of Derivative Liability Transactions~~

~~The details of warrant liability transactions were as follows:~~

| | ~~June 30, 2024~~ | ~~June 30, 2023~~ |
|---|---|---|
| | ~~Six Months Ending~~ | |
| | ~~June 30, 2024~~ | ~~June 30, 2023~~ |
| | ~~(Unaudited)~~ | ~~(Unaudited)~~ |
| ~~Beginning balance~~ | ~~$ 1,052,000~~ | ~~$~~ |
| ~~Issuance of warrants at fair value~~ | ~~—~~ | ~~5,831,000~~ |
| ~~Change in fair value~~ | ~~(775,000)~~ | ~~(4,311,000)~~ |
| ~~Extinguishment~~ | ~~—~~ | |
| ~~Ending balance~~ | ~~$277,000~~ | ~~$1,520,000~~ |

~~2023 Warrants [Member]~~ ~~Short-Term Debt [Line Items]~~

~~Schedule of Derivative Liabilities Assumptions~~

~~The 2023 Warrant liability is valued using a Binomial pricing model with the following assumptions:~~

| | ~~2023 Warrants~~ | |
|---|---|---|
| | ~~June 30, 2024~~ | ~~December 31, 2023~~ |
| | ~~(Unaudited)~~ | ~~(Unaudited)~~ |
| ~~Stock price~~ | ~~$ 2.83~~ | ~~$ 7.80~~ |
| ~~Risk-free interest rate~~ [1] | | |

~~4.43% 4.26%Expected volatility~~ [2] ~~116% 115%Expected life (in years)~~ [3] ~~3.54.0 4.25 Expected dividend yield~~ [4] ~~— —~~

~~Fair value of warrants $277,000 $1,050,00~~

[1] ~~Based on rates established by the Federal Reserve Bank~~

[2] ~~Historical volatility of the Company's common stock is used to estimate the future volatility of its common stock~~

[3] ~~Determined by the remaining contractual life of the derivative instrument~~

[4] ~~Based on no dividends paid or expected to be paid~~ ~~2020 Warrants [Member]~~ ~~Short-Term Debt [Line Items]~~ ~~Schedule of Derivative Liabilities Assumptions~~

~~The 2020 Warrant liability is valued using a Binomial pricing model with the following assumptions:~~

| | ~~2020 Warrants~~ | |
|---|---|---|
| | ~~June 30, 2024~~<br>~~(Unaudited)~~ | ~~December 31, 2023~~ |
| ~~Stock price~~ | ~~$ 2.83~~ | ~~$ 7.80~~ |

~~Risk-free interest rate~~ [1]

~~5.09% 4.54%Expected volatility~~ [2] ~~116% 89%Expected life (in years)~~ [3] ~~1.0 1.6 Expected dividend yield~~ [4] ~~— —~~

~~— $2,000~~

~~Fair value of warrants $~~

[1] ~~Based on rates established by the Federal Reserve Bank~~ [2] ~~Historical volatility of the Company's common stock is used to estimate the future volatility of its common stock~~ [3] ~~Determined by the remaining contractual life of the derivative instrument~~ [4] ~~Based on no dividends paid or expected to be paid~~

~~- Definition~~

~~Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2~~

~~+ Details~~

~~Name:us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure of derivative liabilities at fair value.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_ShortTermDebtLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Details~~

~~Name:us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyThreeWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~- Details~~

~~Name:us-gaap_DebtInstrumentAxis=GTBP_TwoThousandTwentyWarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 89~~

~~R21.htm IDEA: XBRL DOCUMENT~~

~~Common Stock Warrants and Options (Tables)6 Months Ended~~

~~Jun. 30, 2024~~

~~Class of Warrant or Right [Line Items]~~ ~~Schedule of Warrant Activity~~

~~Stock warrant transactions for the six months ended June 30, 2024 were as follows:~~

| | ~~Six Months Ended June 30, 2024~~ | |
|---|---|---|
| | ~~Number of Warrants~~ | ~~Weighted Average Exercise Price~~ |
| ~~Warrants outstanding at December 31, 2023~~ | ~~304,962~~ | ~~$ 63.30~~ |
| ~~Granted~~ | ~~828,800~~ | ~~4.47~~ |
| ~~Forfeited/cancelled~~ | ~~—~~ | ~~—~~ |
| ~~Exercised~~ | ~~—~~ | ~~—~~ |
| ~~Warrants outstanding at June 30, 2024~~ | ~~1,133,762~~ | ~~$20.28~~ |
| ~~Warrants exercisable at June 30, 2024~~ | ~~1,133,762~~ | ~~$20.28~~ |

~~Schedule of Options Activity~~

~~The following table summarizes stock option transactions for the six months ended June 30, 2024:~~

| | ~~Six Months Ended June 30, 2024~~ | |
|---|---|---|
| | ~~Number of Options~~ | ~~Weighted Average Exercise Price~~ |
| ~~Options outstanding at December 31, 2023~~ | ~~126,265~~ | ~~$ 40.15~~ |
| ~~Granted~~ | ~~—~~ | ~~—~~ |
| ~~Forfeited/cancelled~~ | ~~—~~ | ~~—~~ |
| ~~Exercised~~ | ~~—~~ | ~~—~~ |
| ~~Options outstanding at June 30, 2024~~ | ~~126,265~~ | ~~$40.15~~ |
| ~~Options exercisable at June 30, 2024~~ | ~~126,265~~ | ~~$40.15~~ |

~~Schedule of Options Outstanding and Options Exercisable~~

~~Options outstanding as of June 30, 2024 are exercisable as follows:~~

~~Stock Options Outstanding and Exercisable as of June 30, 2024~~

| ~~Range of Exercise Price~~ | ~~Number Outstanding~~ | ~~Weighted Average Remaining Contractual Life (Years)~~ | ~~Weighted Average Exercise Price~~ |
|---|---|---|---|
| ~~$ 10.50~~ | ~~16,666~~ | ~~8.8~~ | ~~$ 10.50~~ |
| ~~25.50~~ | ~~66,667~~ | ~~8.6~~ | ~~25.50~~ |
| ~~74.40~~ | ~~42,932~~ | ~~8.0~~ | ~~74.40~~ |
| | ~~126,265~~ | | |

~~Warrants [Member]~~

~~Class of Warrant or Right [Line Items]~~ ~~Schedule of Warrants Outstanding and Exercisable~~

~~Warrants outstanding as of June 30, 2024 are exercisable as follows:~~

~~Warrants Outstanding and Exercisable as of June 30, 2024~~

| ~~Range of Exercise Price~~ | ~~Number Outstanding~~ | ~~Weighted Average Remaining Contractual Life (Years)~~ | ~~Weighted Average Exercise Price~~ |
|---|---|---|---|
| ~~$ 4.35~~ | ~~740,000~~ | ~~4.9~~ | ~~$ 4.35~~ |
| ~~5.4375~~ | ~~88,800~~ | ~~4.9~~ | ~~5.4375~~ |
| ~~30.00~~ | ~~216,666~~ | ~~4.0~~ | ~~30.00~~ |
| ~~37.50~~ | ~~13,000~~ | ~~3.5~~ | ~~37.50~~ |
| ~~102.00~~ | ~~1,867~~ | ~~1.0~~ | ~~102.00~~ |
| ~~165.00~~ | ~~73,429~~ | ~~1.6~~ | ~~165.00~~ |
| | ~~1,133,762~~ | ~~4.5~~ | ~~20.28~~ |

~~- Definition~~

~~Schedule of warrants oustanding and exercisable [Table Text Block]~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:GTBP_ScheduleOfWarrantsOustandingAndExercisableTableTextBlock Namespace Prefix:GTBP_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock Namespace Prefix: us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~- Details~~

~~Name:us-gaap_ClassOfWarrantOrRightAxis=GTBP_WarrantsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 90 R22.htm~~
~~IDEA: XBRL DOCUMENT~~
~~Organization and Going Concern Analysis (Details Narrative) - USD ($) 3 Months Ended6 Months Ended~~
~~Jun. 30, 2024~~
~~Jun. 30, 2023~~
~~Jun. 30, 2024~~
~~Jun. 30, 2023~~
~~Mar. 31, 2024~~
~~Dec. 31, 2023~~
~~Mar. 31, 2023~~
~~Dec. 31, 2022~~
~~Organization, Consolidation and Presentation of Financial Statements [Abstract] Net loss$ 3,710,000$ 1,992,000$ 5,976,000$ 2,219,000 Net cash used in operating activities 7,699,0004,841,000 Cash and cash equivalents, and short-term investments9,200,000 9,200,000 Working capital 5,800,000 5,800,000 Stockholders equity$ 5,508,000$ 11,763,000$ 5,508,000$ 11,763,000$ 5,312,000$ 7,476,000$ 13,053,000$ 11,734,000~~
~~- Definition~~

~~Working capital.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:GTBP_WorkingCapital Namespace Prefix:GTBP_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- Definition~~

~~Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~
~~Name:us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- Definition~~

~~Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25~~

~~+ Details~~
~~Name:us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-~~

~~***50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1***~~

~~***+ Details***~~

~~***Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration***~~

~~***- References***~~

~~***No definition available.***~~

~~***+ Details***~~

~~***Name:us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration***~~

~~***- Definition***~~

~~***Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.***~~

~~***+ References***~~

~~***Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2***~~

~~+ Details~~
~~Name:us-gaap_StockholdersEquity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant XML 91 R23.htm IDEA: XBRL DOCUMENT~~
~~Schedule of Anti-dilutive Securities (Details) - shares6 Months Ended~~
~~Jun. 30, 2024~~
~~Jun. 30, 2023~~
~~Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total anti-dilutive securities1,260,027429,561Share-Based Payment Arrangement, Option [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total anti-dilutive securities126,265124,599Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total anti-dilutive securities1,133,762304,962~~

~~- Definition~~

~~Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1~~

~~+ Details~~
~~Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Details~~
~~Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~
~~- Details~~
~~Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 92 R24.htm IDEA: XBRL DOCUMENT~~
~~Summary of Significant Accounting Policies (Details Narrative) - USD ($) 6 Months Ended~~
~~Jun. 30, 2024~~
~~Feb. 05, 2024~~
~~Feb. 02, 2024~~
~~Dec. 31, 2023~~
~~Property, Plant and Equipment [Line Items] Cash equivalents$ 7,600,000 $ 443,000Short-term investments 12,893,000Warrant liability$ 277,000 $ 1,100,000Revers stock split ratio~~
~~On February 2, 2024, the Company effectuated a reverse stock-split of its common stock, par value $0.001 per share, at a ratio of 1 for 30. The Company's common stock began trading on a reverse stock-split-adjusted basis on The Nasdaq Capital Market on February 5, 2024 under the existing trading symbol "GTBP."~~
~~Common stock, shares outstanding2,234,328 1,380,633Common stock, shares authorized250,000,000 250,000,000Maximum [Member] Property, Plant and Equipment [Line Items] Cash, FDIC insured amount$ 250,000 Common Stock [Member] Property, Plant and Equipment [Line Items] Common stock, shares outstanding 1,380,63341,419,000~~
~~- Definition~~

~~Warrant liabilities noncurrent.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:GTBP_WarrantLiabilitiesNoncurrent Namespace Prefix:GTBP_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- Definition~~

~~Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~

~~Name:us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: instant~~

~~- Definition~~

~~The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_CashFDICInsuredAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- Definition~~

~~The maximum number of common shares permitted to be issued by an entity's charter and bylaws.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1~~

~~+ Details~~

~~Name:us-gaap_CommonStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

~~- Definition~~

~~Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3~~

~~*+ Details*~~

~~*Name:us-gaap_CommonStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant*~~

~~*- Definition*~~

~~*Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.*~~

~~*+ References*~~

~~*Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A*~~

~~*+ Details*~~

~~*Name:us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration*~~

~~*- Definition*~~

~~*Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.*~~

~~*+ References*~~

~~*Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1*~~

~~+ Details~~

~~Name:us-gaap_ShortTermInvestments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- Definition~~

~~Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4~~

~~+ Details~~

~~Name:us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type: duration~~

~~- Details~~

~~Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~- Details~~

~~Name:us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 93~~
~~R25.htm IDEA: XBRL DOCUMENT~~
~~Schedule of Estimated Fair Value of Financial Instrument (Details) - USD ($)6 Months Ended12 Months Ended~~
~~Jun. 30, 2024~~
~~Dec. 31, 2023~~
~~Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Cost$ 12,845,000Unrealized gains48,000Unrealized losses Fair value 12,893,000Short-Term Investments [Member] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Cost12,845,000Unrealized gains48,000Unrealized losses Fair value$ 12,893,000~~

~~- Definition~~

~~Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1~~

~~+ Details~~

~~Name:us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- Definition~~

~~Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2~~

~~+ Details~~

~~Name:us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9~~

~~+ Details~~

~~Name:us-gaap_DebtSecuritiesAvailableForSaleRealizedGain Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2~~

~~+ Details~~

~~Name:us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Details~~

~~Name:us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 94 R26.htm IDEA: XBRL DOCUMENT~~

~~DB\M/MDEF\IN=C1NA9 M&8IM/R"1=I(.>X4BDE\'POKL^J1:IJ$'VORS>VL3IY-T47:"P*DKD [2,@ M&ELO"$%AK%Q>V^I:@+6XN6NWTXNI@\YN2X^7"X*)!~~
~~(P ;>VT?1-,75;YX-&NTNK9I!'N^0$* MC80 J S=LG/6G?\ ""P>3:QG4[H_9]7?5U.U.9F+$J>/NY=N.O(YXH B;QM( MU_"D.FK):S:M)I"R&Y(D69~~
~~U+519WME80QK+>WF\ MPQN^Q=J %V+8)P,J. >6';)'#6VF:TFOW-W9Q:E#JLEXSL]Y:6C6_DF3.#.% M\QD\O"J VX8 P I ['Q!X:AUZ2QN!>75C?~~
~~6,C/;7=J5$D>X89?F!!4CJ".PH M QH/&6JW&M6^D#PS+%?-9BZG2:\10B^=Y3!2 =_=E)V[ACIFI8?',+LMU)87 M::-)9R7B:DL,I18T7>3)F,!,#G %5=-~~
~~\!V&G6LVGF^OKK27CDBBTZXD5H8$D!#!2%#XPS M*,L< F@#)@U#4+OX@Z3?2V#PI/H5S-# MX9-_P"\A*AE.$1\-@D9'/WB%!J'~~
~~MPUXDE9_#,%A9V]CH$^C37@BDN7>2-4:,U '*'Q;;:5<^*;^YT66UO;&&Q:[S<^8)6D4A1Q\J*I." MP[9)'%4/&_B"\O?#NOV,MF]I #M0'*L05;H<=1@UL^( M?~~
~~#,MO#K^H64NHW%QJPMEGAMA#N6.)@#Y8<8;Y"P*MG=G'M6?9>%;K6--NM'E MEO;70YA%*OG6=O;SB>.0.-~~
~~JQJ!L^1<[ER<#!QF@"35_&NL1WESIUMI]O;WEI MJMA;RE[DNLD-Q(NTJ0G#$;E8$';U!;-;D?BHR^*Y= 6VB$\+*) ]SMD*-%O\ MU$*_/&&PF0<[LY R8;~~
~~[P);WU_J5\VIWD5Q>S6D^^-8_W,EN221@JHH&223P !W-25D^*98H?"6L231P21+93;DGSY;# M8>'QSM/?VS0!#9^+=(OKEK>*XE658!W>&&/ND G(~~
~~!R,X.J># M]9OKS5KR)M/66358=0LXYRTD4H2 0-',I3@,H)R-V"1Z5:A\-ZHMYH5VMEH] MH;74);RZ@LR8T :!H0$_=CS&PVXE@O3'3!H~~
~~V4\7Z))=6ML+S$MRZ1Q[H9 N M]X_,5&8KA7*LUY!NM_%L.F?+;CFV9X05&2<'YS\QR> MN,<8MZMX6\1:CKD=VTNG2Q6NLPW]JSRR(1"L10QE A~~
~~8$D[\DOP#M $9\(: MXMMJ"A; O<>)8M80&X< 1(T;%2?+^\?+^GS=>* .H3Q3I/9;[3;Z":U,>W5(8BKC[3 V(=Q!^5QN;(//[I,@8%:?B'2+R_F MTN]T^2(7>FW?~~
~~VE$GR(Y08WC=21DJ=KG#8."!P: (Y/"A^.RM[H[_"7%T;.- M/)D\PS@D&(Q[=X?C[I /3U%:+ZYIT>A#6I+CR[ QB422(RG!Z?*1NW$D +C) M)QC/%#M4N-~~
~~0M]0B^QK^[F,,:%I5 8R $H0>0V#@@'!Z4 7K7Q1I=Y)>112RB2S8 M+<1R6TL;(3C:,,H)+9&T#ELC&:BD\9:%"D)FOA$TUW]B2.6-T<3==C(5W*<8 M(R~~
~~""#T()XF/3[KQ"FK6ELNG2:O*UM?-J*W@O;:9H7 2&?;%'M! .%53P6/7 MKKW'A35KB/2)4L=$LIK;6(K^XALRR1[$1DP&\L%W(;J0H ';) .EL?$VEZC M8-~~